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Resumé 
 
Le long bio-polymère d'ADN est condensé à l’intérieur du noyau des cellules eukaryotes 
à l'aide de petites protéines appelées histones. En plus de leurs fonctions condensatrices, 
ces histones sont également la cible de nombreuses modifications post-traductionnelles 
(MPT), particulièrement au niveau de leur section N-terminale.  Ces modifications 
réversibles font partie d’un code d’histones épi-génétique transmissible qui orchestre et 
module dynamiquement certains événements impliquant la chromatine, tels l’activation et 
la désactivation de gènes ainsi que la duplication et la réparation d’ADN. Ces 
modifications sont impliquées subséquemment dans la signalisation et la progression de 
cancers, tels que la leucémie. En conséquence, l'élucidation des modifications d’histones 
est importante pour comprendre leurs fonctions biologiques. 
 
Une méthodologie analytique a été mise au point en laboratoire pour isoler, détecter, et 
quantifier les MPT d’histones en utilisant une approche rapide à deux volets à l’aide 
d’outils bioinformatiques spécialisés. La méthodologie développée en laboratoire a été 
validée en utilisant des histones de souche sauvage ainsi que deux types d’histones 
mutants déficients en enzymes acétyltransferase. Des trois sources d’histones utilisées, la 
seule MPT qui a démontré un changement significatif est l’acétylation de l’histone H3 à 
lysine 56 (H3K56ac). L’expression et la stœchiométrie de cette MPT, issue de cellules de 
souche sauvage et de cellules mutantes, ont été déterminées avec précision et comparées. 
 
Les fonctions de balayage polyvalentes d'un instrument à trappe ionique quadrupôle 
linéaire hybride ont été utilisées pour améliorer la détection de protéines intactes. Le 
mode de balayage « enhanced multiply charged » (EMC) a été modifié pour contenir et 
détecter les ions de protéines intactes situées dans la trappe ionique linéaire. Ce mode de 
balayage nommé « targeted EMC » (tEMC) a permis de quadrupler le niveau de 
sensibilité (signal/interférence), et quintupler la résolution du mode de balayage 
conventionnel. De plus, la capacité de séparation des charges du tEMC a réduit de façon 
significative les effets de « space charge » dans la trappe ionique linéaire. La résolution 
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supérieure du mode tEMC a permis de différencier plusieurs isoformes modifiées, 
particulièrement pour l’histone H3. L’analyse des peptides d’histones trypsiques à l’aide 
du mode de balayage « MRM » a permis le séquençage et la quantification de MPT avec 
un haut degré de précision. La seule MPT qui était sous-exprimée entre l’histone de 
souche sauvage et le mutant DOT1L fut la méthylation de l’histone H3 lysine 79 
(H3K79me1). 
 
Les effets de deux inhibiteurs d’enzymes HDAC (HDACi) sur l’expression de MPT 
d’histone ont été évalués en utilisant la méthodologie analytique mentionnée. Les 
histones extraites de cellules normales et cancéreuses ont été exposées à du Vorinostat 
(SAHA) ou du Entinostat (MS-275) pour une période de 24 à 72 heures. Deux histones 
furent principalement affectées, soit H3 et H4. Étonnamment, les mêmes effets n'ont pas 
été détectés lorsque les cellules normales ont été traitées avec le HDACi pour une période 
de 48 à 72 heures. Une méthode absolue de quantification avec une courbe d’étalonnage 
a été développée pour le peptide H3K56ac. Contrairement à certaines publications, nos 
résultats démontrent que cette MPT est présente dans les cellules mammifères avec une 
stœchiométrie très basse (< 0,1%) et n'est pas surexprimée de façon significative après le 
traitement au HDACi. 
 
 
Mots Clés: Histones,  modifications post-traductionnelles,  spectrométrie de masse, 
nanoLC-MS/MS, trappe ionique linéaire, protéomique quantitative.
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Summary 
 
In eukaryotic cells, the lengthy DNA biopolymer is condensed into the cell nucleus with 
the aid of small packaging proteins called histones. In addition to their packing functions, 
histones are also targets of numerous post translational modifications (PTMs),  especially 
on their N-terminus. These reversible modifications are believed to be constituents of a 
heritable epigenetic “histone code” that dynamically orchestrate and modulate chromatin-
based events such as gene activation and silencing, DNA replication and repair, and are 
also involved in the downstream signaling and progression of cancers, such as leukemia. 
Thus, the elucidation of histone PTMs is important in understanding their biological 
function. 
 
An analytical workflow was designed and set-up in the laboratory to isolate, detect, and 
quantitate histone PTM, using a two-pronged, unbiased, and rapid approach with 
specialized bioinformatic tools. The workflow was validated using histones from wild-
type, and 2 mutants deficient in acetyltransferase activity. Between the three histone 
sources, the only PTM that demonstrated any change was acetylation at histone H3 lysine 
56 (H3K56ac). The down-regulation and stoichiometry of this PTM was accurately 
assessed between wild-type and mutant cells. 
 
The versatile scan functions of a hybrid quadrupole-linear ion trap instrument were 
exploited to enhance the detection of intact histone proteins. The enhanced multiply 
charged (EMC) scan was modified in order to contain and detect intact protein ions 
within the linear ion trap. This targeted EMC (or tEMC) resulted in not only a 4-fold 
increase in signal-to-noise, but also a 5-fold increase in resolution. Furthermore, the 
charge separation capability of the tEMC dramatically reduced space charge effects 
within the linear ion trap. The superior resolution of the tEMC mode allowed for the 
discimination of many modified histone isoforms, especially for histone H3. Using the 
bottom-up strategy with multiple reaction monitoring (MRM), histone peptides were 
quantified and sequenced with a high degree of precision. The only PTM that was down-
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regulated between wild-type and DOT1L mutant histones was methylation at histone H3 
lysine 79 (H3K79me1).  
 
The effects of two clinically relevant small molecule HDAC inhibitors (HDACi) on 
histone PTMs patterns were assessed using the analytical workflow developed. Histones 
derived from both normal and cancer cells were exposed to either Vorinostat (SAHA) or 
Entinostat (MS-275) over a 24- to 72 hour period. The two core histones primarily 
affected were H3 and H4.  Surprisingly, the same effects were not observed when normal 
cells were treated with three doses of SAHA at 24-hour intervals over a 72-hour period. 
An absolute quantitation method using a calibration curve was developed for H3K56ac. 
In opposition to other published litterature, our findings demonstrate that this PTM is 
present in very low stoichiometry (< 0.1%) in mammalian cells, and exhibits no 
significant up-regulation in different cell lines treated with several types of HDACi. 
 
 
Keywords:  Histones, post-translational modifications, mass spectrometry, nanoLC-
MS/MS, linear ion trap, quantitative proteomics. 
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1.1 DNA structure and properties 
 
The organizational and biological blueprint of an organism’s genetic information 
is contained in its DNA sequence. At the most basic structural level, DNA consists of a 
constant deoxyribose sugar moiety, and four variable and alternating nucleotide bases [1]: 
adenine (A), thymine (T), cytosine (C), and guanine (G), (see Figure 1.1). Antiparallel 
polynucleotide chains can form hydrogen bonds with each other, joining A-T and C-G 
base pairs (bp). X-ray diffraction studies using DNA fibers by Watson and Crick [2] 
enabled the elucidation of the DNA structure, and the formulation of the classical “B-
form” model. According to their pioneering work, DNA is a repeating right-handed 
double helix, requiring 10 base residues to complete a full turn, with a precise 36 degree 
rotation angle between subsequent bp. The majority of DNA molecules adopt this B-form 
in vivo, while being stabilized by “high water activity” and along a spine of hydration [3]. 
Biophysical studies have shed a great deal of insight about the hydration dynamics [4] 
and conformational stabilization [5] of B-DNA in solution using short synthetic 
oligomers. DNA can also adopt two other well-characterized conformations, notably the 
A- and Z-forms [6]; these depend on the chemical environment and DNA sequence. The 
A-form arises when DNA becomes dehydrated, resulting in a more compact double helix, 
with 11 bp per turn. The Z-confirmation can form in solutions of high ionic strength, with 
alternating CG-CG and CA-TG sequences [7], resulting in a left-handed helix. The 
classical model was amended primarily by the work of Dickerson and co-workers [8]. 
Using x-ray diffraction analysis of DNA dodecamer crystals, they concluded that the bp 
bond rotation had a slightly different range (28 to 42 degrees). Furthermore, the bp were 
not co-planar, but rather could rotate in opposite directions; this “propeller twisting” [9] 
enabled a high degree of bp stacking. One of the most important topological properties of 
DNA is its ability to be supercoiled [10, 11] and twisted periodically into multiple 
superhelices without physical damage, enabling the macromolecule to be highly 
compacted. 
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(a) (b) 
       
Figure 1.1: The helical structure of DNA, with its four nucleotide base pairs (a). 
Chemical structure of DNA, with negatively charged phosphate groups (b). From 
references [12] and [13].  
 
1.2 Histones: the packaging proteins of DNA 
 
All essential proteins necessary for the biological functioning of an organism are 
encoded in its DNA sequence, forming a very long biopolymer that twists onto itself to 
generate a thermodynamically stable helical structure. Almost 3 billion bp make up the 
human genome [14] (6 billion bp per diploid cell), and the entire DNA sequence from a 
cell would easily span a linear distance of roughly two meters when annealed and 
unwrapped. This very lengthy sequence of nucleotides cannot occupy the limited size of 
the cell nucleus (about 10-5 m in diameter) without some form of packaging. As a result, 
nature has evolved an elegant solution to accommodate and package DNA in a highly 
ordered manner. The key proteins involved in this packaging process in eukaryotic 
organisms are called histones [15]. These proteins are relatively small (10 to 20 kDa), and 
highly basic; their entire amino acid sequence contains over 20% lysine and arginine 
residues. Together, DNA and histones form chromatin fibers (see Figure 1.2), which are 
the physiologically relevant substrate for important cellular activities such as DNA 
transcription, replication, and repair. At the first level of organization, 147 bp of DNA are 
wrapped in roughly 1 ¾ turn around an octamer of histone proteins, forming a 
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nucleosome, or nucleosome core particle (NCP). At first, DNA was believed to reside in 
“uniform supercoils”, however, the existence of NCPs was demonstrated by several 
groups including Clark [16], Hewish [17], and Noll [18] in chromatin digestion studies 
using micrococcal nuclease and DNase I. Unlike DNA strands, chromatin digestion was 
incomplete and did not form small oligonucleotides; this result led to the conclusion that 
the protein component was not evenly distributed along the DNA strands, suggesting the 
presence of a “subunit”. Although these experiments were simplistic in design, the same 
results and observations by different research groups were convincing enough and led to 
further investigation by emerging instrumental techniques such as electron microscopy 
and high resolution x-ray crystallography. Chromatin extracted from eukaryotic cells was 
found to be present in a linear array of repeating spheres (“beads on a string”) by Olins 
[19]; this further corroborated the coiling of DNA to form the NCP. Finally, Luger [20] 
and Davey [21] provided concrete evidence at the atomic level using crystallized human 
α-satellite DNA and recombinant histone proteins. Their studies showed that 147 bp of 
DNA underwent excessive curvature to coil around a histone protein core forming a 
superhelix, whose folding was dependant on electrostatic interactions between the 
histones and DNA.  
 
 
 
Figure 1.2: Histone proteins aid in the packaging of DNA into the cell nucleus. 
From reference [22]. 
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A closer inspection of the NCP reveals an octameric histone complex. The protein 
complex is made up of four different types of core histones, namely, H2A, H2B, H3, and 
H4 (see Figure 1.3). The association of the four core histones is also ordered and specific: 
two pairs of H2A and H2B molecules assemble into two H2A-H2B dimers, forming a 
tetramer, while H3 and H4 form an (H3-H4)2 tetramer [23, 24]. All four core histones 
share common structural motifs, including a hydrophobic core, referred to as the histone-
fold or globular domain, comprising three α-helices, and hydrophilic extremities, i.e., 
conformationally flexible N-termini or N-terminal “tails”, as well as short C-terminal 
ends. The histone-fold domain is primarily involved in maintaining structural integrity of 
the NCP, while the more basic histone tails, rich in lysine and arginine residues, protrude 
outside of the NCP structure. The core of the histone-fold domains from two different 
histones associate interfaces together in a head-to-tail fashion that results in inter-
molecular, six α-helix bundles, forming a “handshake motif” by the two forms of 
heterodimers: H2A-H2B and H3-H4 [25]. Both the α-helices and the “paired-element 
motifs” of the helix/loop-and-strand/helix (HSH) structures contribute to form grooves in 
the histone-fold octamer [26], which serve as “docking pads” for DNA. Moreover, 
specific arginine residues [27] in the globular domain provide DNA anchoring points for 
negatively charged phosphate groups by electrostatic and hydrogen bonding.  
 
 
 
Figure 1.3: Formation of the octameric complex by the four core histones. From 
reference [28] 
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As Arents points out [26], an important and well-conserved lysine-arginine pair 
for DNA interaction exists in the HSH2 loop between helix II and strand B. The core 
histones bind to the DNA backbone at precise locations [20], namely the L1L2 loops, and 
four α1α1 helices in the globular domain. 
 
1.2.1 Higher order chromatin architecture 
 
Repeating units of nucleosomes are compacted further into a helical coil of 
nucleosomes. This is achieved by additional structural components and chromatin 
associated proteins to form the “30 nm fiber” [29]. This constitutes the secondary level of 
DNA-histone organization. Chromatin fibers are stabilized and maintained in a higher 
order structure by another type of histone, referred to as linker histone H1 [30].  In 
mammals, there are six different types of histone H1 variants (H1.0 to H1.5), each 
possessing different biological properties, and named according to their chromatographic 
behavior [31]. Histone H1 is structurally and functionally different from the four core 
histones comprising the nucleosome. Compared to the histones present in the NCP, 
histone H1 is longer and heavier (about 23 kDa), with three distinct structural domains 
[32]. These are characterized by an 80 residue long globular domain, attached to a short 
N-terminal and a long C-terminal extension, both of which are highly basic [33].  
 
The globular domain of H1 also contains two surfaces lined with positively 
charged amino acids that provide two additional DNA binding regions in NCPs.  A short 
sequence of DNA resides outside of the nucleosome, and varies in length depending on 
species and tissue. This linker DNA provides contact points for the N- and C-terminal 
extensions of histone H1. Linker histone H1 helps to stabilize and maintain the higher 
ordered chromatin fiber by neutralizing the negative electrostatic charges on the DNA 
molecule, and also by interacting with NCPs. Biophysical studies have shown that 
although linker histone H1 helps maintain chromatin stability, it is not totally essential. 
For example, Carruthers and colleagues [34] have shown that nucleosomal arrays from 
histone octamers depleted of histone H1 and twelve 208 bp tandem repeats of Lytechinus 
5S rDNA were able to fold in salt solutions of varying concentrations. Although unstable 
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in solution, the arrays showed a high degree of folding. The extensive basic N- and C- 
terminal extensions of linker histone H1 provide the driving force to stabilize and 
maintain the higher order chromatin structure.  Tertiary structure formation involves 
further packaging of chromatin into thick and condensed fibers. Two models (shown in 
Figure 1.4) have been proposed to describe this higher order architecture: the solenoid 
and “zig-zag” models [35]. Due to its highly compacted nature, the spatial arrangement 
and localization of individual nucleosomes within the 30 nm fiber is not resolvable. 
Although it is very difficult to determine with absolute certainty which model holds true 
in vivo, experimental evidence points to the “zig-zag” model as being the most plausible 
one [36-38]. In this model, nucleosomes become “interacting partners”, imparting more 
stabilization. 
 
 
 
Figure 1.4: Two models of chromatin structures, i.e., the solenoid (left) and “zig-zag” 
models. From reference [39]. 
 
Further folding of the chromatin fiber into a metaphase chromosome necessitates 
the formation of radial and helical loops of 50 to 100 kbp. Construction of this highly 
organized chromosomal configuration is aided by the support of a nuclear “matrix” or 
“scaffold” [6]. One of the major components of this scaffolding is topoisomerase II (topo 
II).  A study conducted by Takeyasu demonstrated that topo II was an integral component 
necessary for the condensation of mitotic chromosomes and had the ability to join two 
DNA strands together. Moreover, this process required histone H1-bound chromatin for 
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the formation of higher order structures in an ATP-independent manner [40]. Other 
chromatin-associated proteins are involved in this higher order packing [41]; these 
include MeCP2, which binds to methylated DNA and stabilizes loops, MENT, a serpin 
family protein that aids in oligomerization, and Polycomb, a large protein complex 
involved in gene silencing and can also attach to nucleosomes. In addition, inner nuclear 
membrane proteins such as the lamins [42] provide binding sites for chromatin within the 
cell nucleus. All of these structural components work together in concert to ultimately 
achieve the final packaged state of the chromosome.  
                          
1.2.2 Histone modifications  
 
 The preceding sections have described histone proteins solely as packaging agents 
of chromatin, resulting in nucleosomes with a rather rigid globular domain, and flexible 
N-terminal tails. Histones have a number of amino acids, including basic lysine and 
arginine residues, spread over the length of both the globular domain and the flexible N-
terminal tails that can be covalently modified. These post-translational modifications 
(PTMs) of histones have been known for many years; for example, acetylation was first 
reported in 1963 by Phillips in histones isolated from calf thymus extracts [43]. To date, 
there are over 60 PTM sites on histones that have been identified by techniques such as 
Edman sequencing and mass spectrometry [44]; this list continues to grow as research 
intensifies. The most common and well-characterized histone PTMs include acetylation, 
methylation, and phosphorylation. Some of these PTMs are shown in Figure 1.5. A great 
number of lysine residues can be modified by acetylation and methylation (in mono-, di-, 
and trimethyl forms). Arginine residues can be methylated (mono- and dimethyl forms), 
while serine and threonine can be phosphorylated. Other less commonly observed PTMs 
include conjugation of histone lysine residues to small proteins such as Ubiquitin and 
Sumo, as well as ADP-ribosylation of histone arginine, aspartic and glutamic acid side 
chains. The majority of these PTMs occur on the N- and C-terminal tails of histones, yet 
a small number of important modifications have also been detected in the globular 
domain, e.g. histone H3 lysine 79 methylation. The multitude of these PTMs leads to an 
ever increasing complexity and combinatorial “explosion” of possibilities. 
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 The fact that histone proteins show a high degree of sequence conservation 
between different species, and their modifications often have similar functions in various 
biological systems suggests that these PTMs are important and possess evolutionarily 
conserved roles in cell biology. The modification of histones is dictated by both internal 
and external cellular stimuli, and ultimately leads to changes in the structure and function 
of chromatin, mediating important biological processes such as gene transcription, DNA 
replication, and damage repair [45]. These alterations in chromatin can be achieved by 
three known mechanisms: (a) disrupting DNA-histone electrostatic interactions (“cis” 
effects), and (b) recruitment of enzymes and chromatin remodeling complexes (“trans” 
effects), and (c) replacement of canonical histones by histone variants, e.g., H3.1 by 
replacement H3.3, and H2A by H2A.Z.   
 
 
 
 
Figure 1.5: A partial list of known histone PTMs that occur on the N-terminal tails and 
globular domains of the core histones. From reference [46]. 
 
One of the best known and most studied cis-effects of chromatin remodeling is 
the acetylation of lysine residues on core histones. The incorporation of an acetyl group 
removes the positive charge on the lysine side chain, thus negating the electrostatic 
contact with the DNA backbone. This PTM favours the unraveling of a specific region of 
chromatin, making DNA more accessible, and allowing gene transcription to proceed. In 
the yeast S. cerevisiae, lysine 14 on the H3 N-terminal tail can be acetylated by the 
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enzyme Gcn5, which activates gene transcription [47]. As demonstrated by Cairns [48], 
H3K14ac is an active mark for transcription recognized by the bromo domain of the RSC 
complex, an ATP-dependent nucleosome remodelling enzyme that promotes gene 
activation by disrupting histone-DNA interactions. Thus, histone modifications can also 
serve as a “docking site” for larger enzyme complexes and remodeling machinery. These 
trans-effect chromatin marks direct the engagement of other binding proteins, which can 
signal downstream cellular processes. Another example of such a trans (but opposing) 
effect is the methylation of lysine 9 on histone H3 [49]. This modification can be 
generated by the Suv39h methyltransferase, providing an anchoring point for the chromo 
domain heterochromatin binding protein 1 (HP1). Once bound to chromatin that contains 
K9-methylated H3 molecules, HP1 can mediate the formation of heterochromatic 
regions, forcing DNA to be inaccessible, and promoting gene silencing. The third 
mechanism involves the substitution of core histones by sequence variants in 
nucleosomes. These histone variants are utilized to establish chromatin states with 
specialized functions. In mammalian cells, one such histone variant is H3.3, which 
resembles the canonical H3 histone, but differs only in four amino acid residues.  
 
In the fruit fly D. melanogaster and human cells, this H3 variant can be deposited 
into chromatin in a replication-independent manner, and directed into sites of 
transcriptionally active genes [50]. These small differences in amino acids are crucial for 
the deposition of H3.3 into specific regions, and its function after incorporation into 
chromatin [51]. One of these differences is at position 31; in H3.1, this residue is an 
alanine, while in H3.3, the alanine is replaced by a serine or threonine. Unlike the alanine 
residue in the canonical histone H3, serine and threonine can be phosphorylated, 
triggering important downstream cellular events. Allis and colleagues [52] have 
demonstrated that Ser-31 phosphorylation occurs only in metaphase, and is localized in 
specific areas adjoining centromeres. Suggested functions for this residue difference and 
PTM include protection of euchromatin, and substitution of H3.3 by the canonical H3. 
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1.3 Epigenetics: Going beyond the DNA sequence 
 
A recent study performed by Fraga [53] examined phenotypic differences in 
monozygous (MZ) twins. Although genetically identical at birth, these MZ twins 
developed significant differences over time, e.g., risk of disease progression.  This begs 
the following question: what mechanism(s) is responsible for these alterations over time? 
One major finding in the study was that older twins showed drastic changes in their DNA 
methylation and histone acetylation profiles. Hence, the answer could lie beyond the 
genetic information encoded in the DNA sequence. The regulation of phenotypes by non-
DNA related mechanisms brings us to the concept of epigenetics. The idea that 
phenotypic changes can be caused by non-genotypic changes is not entirely new. 
Originally coined by Conrad Waddington in 1942 (see Figure 1.6), epigenetics was the 
term used to “describe events that could not be explained by genetic principles” [54]. A 
more recent definition by Allis would describe epigenetics as the collection of 
modifications to chromatin producing different states of gene expression from the same 
genome [46].  In multicellular organisms, most cells have the same genotype, yet become 
differentiated and organized to fulfill many distinct roles.  
 
 
Figure 1.6: The classical epigenetic “landscape” by Waddington. In this figure, a cell is 
represented by a ball at the top of the hill. A number of slopes are present, representing a 
limited number of pathways that the cell can take, leading to different cellular fates. From 
reference [54] 
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There are two main epigenetic mechanisms in mammalian cells: (1) DNA 
methylation and (2) histone modifications [55].  The vast majority of DNA methylation 
occurs on cytosine residues in 5’-CpG-3’ dinucleotides. In regions where CpG 
dinucleotides occur frequently (known as CpG “islands”), methylation of cytosine is a 
mark of gene silencing [56].  
 
The second mechanism is the modification of specific amino acid residues of 
histone proteins.  As described the previous section, the diverse types of histone PTM can 
modulate when and how genes are expressed, using chromatin as a template for 
synchronizing cellular events. These modifications usually do not occur as single events 
on chromatin, but rather in combination with each other at precise residues and defined 
times within the cell cycle, causing spatio-temporal changes in chromatin structure that 
lead to gene transcription or repression. An example of histone PTMs working in concert 
to modulate chromatin remodelling is shown in Figure 1.7. 
 
        
 
Figure 1.7: Histone PTMs are a series of synchronized events working synergistically or 
antagonistically to generate active (left) or repressed (right) chromatin states. From 
reference [46]. 
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The combinatorial nature and phenotypic changes of these modifications lead to 
the formulation of the “histone code” hypothesis by Allis, Strahl and Jenuwein [57, 58]. 
According to them, these PTMs form an “epigenetic language” that is reversible and 
heritable, without necessitating changes in the DNA sequence. The multiple sites of 
modification present on the small segments of the N-terminal tails makes them “hotspots” 
for enzymatic activity. Addition of a modification on a specific residue of an N-terminal 
tail can affect the binding and the catalytic rate of another enzyme, either inductively or 
antagonistically. Some research groups have provided evidence that supports the 
existence of this histone code by modification “switches”. For example, Lo and 
colleagues have shown that H3 serine-10 phosphorylation up-regulates the acetylation of 
H3 lys-14 by several HATs, including Gcn5, PCAF, and p300 [59]. This modification 
sequence is linked to transcriptional activation.  
 
Epigenetics can be viewed as a double edged sword. On one hand, epigenetic 
mechanisms are involved in regulating important DNA metabolic processes such as gene 
transcription and DNA repair, which help maintain a high degree of genomic integrity 
and stability [60]. This regulation is maintained by a multitude of “feedback 
mechanisms”, and interplay between different enzymes, such as DNA methyltransferases 
and chromatin modifying complexes. However, epigenetic mechanisms are often 
disrupted in diseases such as cancer. Essentially, cancer is genetic disease in which gene 
expression has become abnormal and cellular homeostasis is unbalanced. Some common 
attributes of different types of cancers include unregulated cell proliferation, point 
mutations, loss or silencing of genes, tumor growth, invasion, and metastasis [61]. 
However, the molecular complexity of this disease is further expanded by dysfunctional 
epigenetic regulation, such as defects in DNA cytosine methylation and histone 
modifications.  
 
Both genetic and epigenetic factors can work in tandem to interfere with normal 
cellular activity, producing two types of aberrations in gene expression that contribute to 
cancer: (1) induction of oncogenes, and (2) silencing of tumor suppressor genes [46]. One 
example is the oncogenic activation of the ras gene [62]. This occurs by a genetic point 
  
 
14
 
mutations that cause single amino acid substitutions in the Ras protein, and high 
spontaneous mutation rates, especially in pancreatic cancers [63]. The presence of the 
positive K-ras mutation in patients with lung adenocarcinomas is associated with poor 
prognosis and low survival rates. The second mechanism by which cancer may be 
induced is by epigenetic repression of genes that are important to regulate and maintain 
healthy cellular functions. One key epigenetic mechanism involved in tumorigenesis is 
CpG island promoter hypermethylation [64].  In bladder cancers, the CDK inhibitor and 
tumor suppressor p16INK4a becomes silenced by extended hypermethylation of the DNA 
region encoding the gene [65]. This allows malignant cells to bypass senescence and 
proliferate without constraint. Histone modifications can also contribute to abnormal 
gene silencing during carcinogenesis. Baylin and colleagues demonstrated that, in cancer 
cells, the silenced promoter of tumor suppressor gene hMLH1 resides in an area whereby 
histones are de-acetylated and subsequently methylated at H3K9 [66].  In mixed lineage 
leukemia (MLL), a chromosome translocation aberrantly fuses the AF10 and MLL genes 
(see Figure 1.8). The AF10-MLL oncogenic fusion protein aberrantly recruits the histone 
methyltransferase hDOT1L, resulting in abrogation of the H3K4me mark characteristic 
of active chromatin, and induces H3K79 hypermethylation, leading to the overexpression 
of the HoxA9 gene and leukemogenesis [67].  
 
 
 
Figure 1.8: Normal myeloid differentiation mediated by histone modifications 
characteristic of healthy cells (top). Fusion proteins (MLL-AF10) cause aberrant H3K79 
methylation and transcription of the Hoxa9 gene, leading to leukemia (bottom). From 
reference [67]. 
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1.3.1 Epigenetic drug therapy: a promising avenue for cancer treatment 
 
Biochemical processes often require strict regulation by opposite sets of enzymes. 
In diseases such as cancer, these processes become dysregulated, leading to the silencing 
of genes that are involved in tumor suppression. The realization that abnormal epigenetic 
gene inactivation can be reversed led to an interest in studying the enzymes that 
propagate epigenetic marks as potential therapeutic drug targets. As discussed in the 
previous section, an important epigenetic process that is often dysregulated in cancer 
cells is DNA methylation. When CpG islands become hypermethylated by DNA 
methyltransferases (DNMTs), this can lead to inappropriate inactivation of tumor 
suppressor genes. Studies of DNA methylation during the 1960s led to the discovery of 
methylation inhibitors, such as 5-azacytidine [68]. This small molecule has anti-
proliferative properties and inhibits tumor growth. Further optimization resulted in the 
development of structural analogues such as 5-aza-2’-deoxycytidine [69] that have less 
toxicity and side effects. This research also prompted studies of other enzyme inhibitors 
as potential epigenetic therapies. These inhibitors exert their pharmacological effects [70] 
by administration as prodrugs, metabolic activation via phosphorylation, and 
incorporation into DNA as a modified nucleosides that subsequently interfere with DNA 
methylation. Continued research into DNMT inhibitors has led to their use as epigenetic 
chemotherapies that reverse the aberrant gene silencing that occurs in cancer cells. For 
example, in myelodysplastic syndrome (MDS), the genes encoding the CDK inhibitors 
p15 and p16 become hypermethylated. Upon treatment with the DNMT inhibitor 5-aza-2-
deoxycytidine (decitabine), the hypermethylated state of these genes was reversed in 
responsive patients, restoring gene function and controlling the proliferation of malignant 
cells [71]. Clinical studies led to the approval by the US food and drug administration of 
5-azacytidine for the treatment of all subtypes of MDS [72], while several other structural 
analogues are in different phases of drug development. 
 
Histone modifications such as acetylation are also a highly regulated. This 
regulation is mediated by the reversible actions of both histone acetyltransferases (HATs) 
and deacetylases (HDACs). In cancers such as acute promyelocytic leukemia (APL) [73], 
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HDAC enzymes contribute to epigenetic gene silencing through aberrant recruitment by 
fusion proteins to specific loci, forming a complex with other enzymes, and remodeling 
chromatin into a condensed state. This deacetylation effect is amplified in cancer, since 
HDACs can undergo overexpression in certain malignancies such as colon cancer [74]. 
Wilson and colleagues demonstrated that HDAC4 can promote proliferation of cancerous 
colon cells by down regulating the p21 gene promoter. Hence, HDACs have also become 
viable therapeutic drug targets. In humans, there are 18 different types of HDAC 
enzymes, which are divided into 4 classes [75]: I, IIa, IIb, III, and IV. Every type with the 
exception of class III enzymes can be inhibited by “classical” small molecule HDAC 
inhibitors (HDACi). Class I and II HDACi possess a bidentate pharmacophore that can 
coordinate to and chelate an essential zinc ion within the active site of class I and II 
HDACs [76].  The third class of HDACs is structurally related to Sir2 yeast proteins, uses 
NAD+ as a co-substrate, rather than simply hydrolyzing the acetyl group from lysine 
residues in the target protein. The class III HDACs are not inhibited by “classical” 
HDACi that block class I and class II enzymes. Once HDACi are bound to an enzyme’s 
catalytic core, deacetylase activity is blocked, histones become hyperacetylated, and 
target genes activated through chromatin remodeling (see Figure 1.9). Several research 
groups, including Marks and colleagues, have shown that HDACi can block proliferation 
or kill tumor cells by triggering G1/S cell cycle arrest, differentiation, increased levels of 
reactive oxygen species (ROS), and apoptosis [77]. Furthermore, HDACi can trigger 
hyperacetylation of non-histone proteins such as transcription factors (E2F1, p53, 
STAT1). Transcription factor and histone hyperacetylation can act synergistically to shift 
the equilibrium to reactivate tumor suppressor genes. To date, only two HDACi have 
been approved by the US food and drug administration for treatment of cutaneous T-cell 
lymphoma.  The most successful and extensively studied HDACi is the Merck chemical 
Vorinostat (Zolinza), a hydroxamic acid based molecule that inhibits a wide spectrum of 
class I and II HDAC enzymes. However, the ability of pan-HDACi to alter the 
acetylation patterns of other proteins has raised concern about toxicity and potential side 
effects; this has led to research aimed at developing more selective HDACi that target a 
smaller group of enzymes. 
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Figure 1.9: Epigenetic drug therapy. In acute promyelocytic leukemia (APL), 
chromosomal translocations result in fusion proteins that recruit DNMTs and HDAC 
enzymes to silence tumor suppressor genes. Treatment with HDAC inhibitors can disrupt 
these complexes, hyperacetylate histones, and reactivate the required genes which trigger 
cell cycle arrest, differentiation or apoptosis of cancer cells. From reference [78]. 
 
 
1.4  Protein analysis: the early years 
 
 
The word protein is derived from the Greek word “proteios”, meaning “of first 
importance or rank” [1]. The term was coined by Jons Jacob Berzelius [79] in 1838 to 
highlight the biological significance of these molecules. Proteins are present in virtually 
all cells and are involved in almost all cellular processes, from mitosis to catalysis of 
xenobiotics. The structural building blocks of proteins are amino acids, which occur 
naturally in 20 different forms [80]. These structural components are responsible for 
synthesizing the vast amounts of different proteins in all organisms, from single cell 
amoeba to complex mammals. The amino acid sequence determines the protein’s 
structure, chemical properties, folding, and ultimately, its function.  
 
A great interest in the structural biology of proteins started in 1950’s, with the 
pioneering work of Corey and Pauling. Their research focused on bond lengths, atomic 
arrangements, and peptide configurations, which eventually led to the elucidation of an 
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important structural motif: the α-helix [81]. This caused a great interest in protein and 
peptide research in the scientific community, and fuelled the start of the research 
explosion into protein structure and function. During the same period, there was another 
important contribution made in analyzing protein structure: the Edman degradation [82]. 
This reaction enables the N-terminal sequencing of proteins by sequentially removing 
one amino acid at a time from the polypeptide backbone. The reaction is a three-step 
process [80], whereby the polypeptide is reacted with phenyl isothiocyanate (PITC) to 
form a stable phenylthiohydantoin (PTH) derivative. The PTH-amino acid can be easily 
analyzed using chromatographic methods, such as HPLC. Repeated cycles of Edman 
degradation will liberate the amino acids, thus allowing the determination of the protein 
sequence. Edman degradation has serious limitations [83], including a practical limit of 
40 to 60 residues before side reactions make sequencing unreliable, the necessity of a 
substantial amount of purified protein, and long reaction times. Furthermore, if the N-
terminus is modified, the amino acid will not be derivatized, and the method would fail 
completely [84]. Despite these limitations, it was the principle method that researchers 
would use for the next thirty years. 
 
1.5  Mass spectrometry: the driving force of proteomics 
 
A sample containing multiple components from an in vivo source can provide a 
serious challenge from an analytical perspective. “Classical” methods of analysis consist 
of gas or liquid chromatography with various types of spectroscopic detection (i.e. ultra-
violet, fluorescence). Although rugged and reliable, these techniques can sometimes 
result in ambiguity or uncertainty in the identity of the peaks detected.  Mass 
spectrometry (MS) provides another analytical methodology to detect various analytes, 
including peptides and proteins.  Instead of using a spectroscopic property to detect and 
measure the component of interest, MS discriminates analytes based on their mass-to-
charge (m/z) ratio [85]. Analytes are converted to gaseous ions, and their m/z ratio is 
recorded onto a mass spectrum. Since the mass is used to identify chemical species, this 
results in much better specificity in analytical determinations compared to spectroscopic 
methods. Hence, using MS to investigate a proteome (the protein complement to the 
genome) resulted in a new paradigm of protein analysis, i.e., proteomics. During the 
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1990’s, this new approach in protein analysis would take over as the method of choice for 
protein and peptide analysis due to its speed, sensitivity, and specificity. 
 
 
1.5.1 The emergence of electrospray ionization 
 
A key breakthrough that would change the landscape of protein analysis by mass 
spectrometry was the optimization of the electrospray ionization (ESI) process for large 
biomolecules by John Fenn [86] and colleagues at Yale University. Using data and 
observations reported by both Rayleigh and Dole [87, 88], Fenn’s group capitalized on 
this preliminary research and successfully applied it to larger charged species, i.e., 
proteins [89]. This ionization method uses high voltage (kilo volt range) applied to a 
narrow diameter capillary with the aid of a counter current flow of drying gas (e.g. 
nitrogen). Species that are ionizable in solution are placed in a solvent.  This solution is 
passed through the capillary in order to produce charged species in the gaseous phase. 
During this process (depicted in Figure 1.10), liquid emerging from the tip of the 
capillary generates the Taylor cone [90] and experiences opposing electrostatic and 
surface tension forces [91], forming a mist of droplets. Solvent molecules gradually 
evaporate until the Rayleigh instability limit [92] is reached. Beyond this point, repulsive 
coulombic forces between species of the same charge overcome the surface tension of the 
sprayed droplet, releasing ions into the gaseous state. Additives present in the liquid 
effluent (i.e. acid) undergo charge transfer reactions with analytes in the gaseous phase, 
producing protonated adducts and pseudomolecular ions [93]. An important feature of 
ESI is the generation of intact multiply charged ions without fragmentation or 
decomposition. There are currently two models used to rationalize the generation of ions 
from charged droplets in the gaseous phase by ESI. The first is the charged residue model 
(CRM) [94], or single ion in droplet (SIDT) [95] theory, formulated by Dole. In this 
description, it is assumed that total solvent evaporation results in one analyte molecule 
being contained per charged droplet at the end of a series of coulombic explosions; this 
analyte molecule then accepts a charge from the last droplet formed. In the ion 
evaporation model (IEM) developed by Iribarne and Thomson [96], ions are desolvated 
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and ejected by a sufficient amount of electrostatic force from the surface of “highly 
electrified cloud droplets” containing many charges.  
 
 
 
 
Figure 1.10: A close-up view of the formation of gas phase ions during electrospray 
ionization. From reference [97]. 
 
1.5.2 Analytical LC-MS instrumentation for proteomics 
 
There are five main components that make up an MS-based analytical system for 
proteomics: (a) a sample introduction device, (b) an ion source, (c) a mass analyzer, (d) a 
detection module, and (e) data processing station. Each component will be discussed in 
more detail below. 
 
1.5.2.1 Sample introduction for mass spectrometry 
 
The two most common sample introduction devices for MS include liquid and gas 
chromatographs. Capillary electrophoresis (CE) has also been used to introduce samples 
into the mass spectrometer [98]. For protein and peptide analysis, capillary HPLC and CE 
are the two most widely used separation methods [99]. Prior to mass analysis, complex 
protein extracts or tryptic digests require some form of column separation to decrease the 
sample complexity and resolve the components individually. This can be accomplished 
by chromatographic or electrophoretic separation methods. LC column separation by 
partition chromatography on reversed phase (RP) sorbents [100] is the conventional 
method for both protein and peptide applications. Two dimensional chromatography with 
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strong cation exchange (SCX) [101] sorbents installed before the RP column enable 
orthogonal separations and higher amounts of starting material to be loaded.  
Alternatively, CE methods in free solution using an applied voltage to separate 
components based on electrophoretic mobilities have been used to separate complex 
samples with high efficiency [102].  
 
1.5.2.2  The ionization source 
 
The ion source is present at the exit of the separation column, taking in the liquid 
effluent and converting it to gaseous phase ions. The ESI emitter, transfer capillary, and 
electronic control components are contained within the source housing. Since the report 
by Fenn’s group, ESI has been researched and improved extensively; over the past twenty 
years, these improvements include atmospheric pressure ionization (API) sources [103], 
pneumatically-assisted ESI [104], heat-assisted ESI [105], and nano-ESI for higher 
sensitivity [106, 107]. For proteomics applications, ion sources have been designed to 
accommodate lower and stable flow rates in the nL/min range, enabling the detection of 
very low abundance species from biological extracts. Narrow bore emitters also aid in the 
generation of smaller diameter microdroplets in the submicron range [108], thus resulting 
in more efficient desolvation and transfer of ions into the gas phase. Modular 
microfluidic devices (chip-LC) [109] comprising of chromatographic media, transfer 
lines, and nano ESI emitters have also been developed to integrate all components and 
simplify routine nano-ESI operation. Using nano-ESI sources, detection limits in the 
attomole range can be achieved.  
 
1.5.2.3 The mass analyzer 
 
The principle hardware that allows for discriminating ions based on their m/z ratio 
is the mass analyzer. The ability of a mass analyzer to differentiate neighboring ions is 
defined as the mass resolution [94]. This can be described by the following equation: 
 
                                                    R = m/Δm                                                          (1)    
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where R is the mass resolution, m is the m/z ratio under investigation, and Δm is the 
spacing between two neighboring mass spectral peaks (resolving power). Hence, the 
higher the value of R, the better the ability of the mass analyzer to separate two closely 
spaced m/z values. There are several types of mass analyzers (see Figure 1.11) for 
proteomic applications [110], each with their inherent advantages and disadvantages. 
These include the following: ion trap (IT), triple quadrupole (QqQ), time-of-flight (TOF), 
Orbitrap, and Fourier transform ion cyclotron resonance (FT-ICR). These analyzers can 
also be used in tandem in a hybrid type instrument. Storage based mass analyzers like IT 
use a three dimensional RF-field to capture and release ions [111]. The IT analyzer can 
been used to detect peptides and proteins, enabling the determination of m/z ratio, while 
taking advantage of their rapid duty cycle. However, because of low mass resolution 
(about 1000) and space charge effects, stand-alone ion trap instruments are not totally 
suited for the analysis of complex proteomic samples.  
 
 
     g  
     Orbitrap 
 
Figure 1.11: Examples of different mass analyzers used for proteomics (a-g). From 
references [110] and [112]. 
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Both TOF and quadrupole-TOF (Q-TOF) instruments rely on the principle of 
separating ions in time during their travel through a fixed flight tube of a certain length 
[113]. Accurate calculation of this flight time results in the determination of the m/z ratio. 
Development of the reflectron as an “ion mirror” by Mamyrin [114] allowed TOF 
analyzers to better focus ions and elongate the flight path, resulting in higher resolution. 
The TOF analyzers can achieve mass resolution between 10 000 to 20 000, while more 
recent instrumentation can reach up to 40 000.  The Orbitrap mass analyzer recently 
developed by Makarov [115] consists of 2 electrodes that form an electrostatic field. Ions 
are injected into the device and oscillate back and forth along the inner electrode. The 
frequency of these oscillations is used to calculate the m/z ratio with very high precision; 
mass resolutions of up to 100 000 are attainable with this type of mass analyzer. Lastly, 
FT-ICR (or FT-MS) is another type of mass analyzer used for both intact protein and 
peptide analysis. In FT-MS, ions are introduced into a cell (Penning trap) in the presence 
of a magnetic field [116]. Once the ions are trapped and in orbit, they can be excited by 
the application of a rotating RF electric field oscillating at the frequency of the ions of a 
given m/z value. Like the Orbitrap analyzer, cyclotronic frequencies for each ion can be 
converted to m/z ratios. FT-MS analyzers allow the highest attainable mass resolution, 
i.e., over 100 000. 
 
1.5.2.4  Tandem mass spectrometry 
 
The accurate determination of the ion m/z ratio is only one of the powerful 
features of a mass analyzer within the LC-MS analytical system. The second attribute that 
further extends the mass analyzers’ capability is fragmentation of precursor ions and 
detection of fragment ions. This process is called tandem MS or MS/MS, and is the most 
widely used technique for fragmenting ions generated through “soft ionization” methods 
(ESI) [117]. The analysis of fragment ions in a single MS experiment allows for higher 
selectivity, structural elucidation, and sequencing of both proteins and peptides. A good 
example is the triple quadrupole mass spectrometer (see Figure 1.12). Triple quadrupole 
and hybrid triple quadrupole instruments with two mass analyzers and an RF-only 
collision cell in series [118] (QqQ and QqLIT) enable tandem MS capability, and provide 
a versatile mass analyzer with multiple types of scan modes, including precursor ion 
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scan, neutral loss, and multiple reaction monitoring (MRM).  These scanning modes 
allow a researcher to not only obtain further structural information, but also to quantitate 
analytes with a high degree of precision while increasing signal-to-noise (S/N) ratios for 
detected species within complex mixtures. The MRM scan mode has been applied 
extensively by Aebersold’s group to detect and quantify peptides with high precision and 
sensitivity in a targeted approach [119]. Other instrumental platforms use a TOF, 
Orbitrap, and FT-ICR to detect fragment ions with higher resolution. 
 
 
 
Figure 1.12: Principle of operation of the MRM mode in a triple quadrupole mass 
analyzer for peptide quantitation. From reference [120]. 
 
There are two principles modes of fragmentation used in conventional bottom-up 
proteomic analyses to elucidate the structure and sequence of peptides. The first is 
collision-induced dissociation (CID), and the second is electron transfer dissociation 
(ETD). These mechanisms require a collision or activation cell to fragment ions prior to 
mass analysis in a second stage.  
 
1.5.2.5  Peptide fragmentation by collision-induced dissociation 
 
In this mechanism, ions detected in the first mass analyzer (i.e., quadrupole or 
Orbitrap) are transferred to a collision cell along an ion path of increasing electric 
potential. Depending on the type of instrument, this cell can be an RF only quadrupole, or 
even an IT analyzer. Neutral molecules (i.e., helium, nitrogen) within the collision cell 
serve as targets for inelastic collisions with peptide ions.  Upon collision, the precursor 
ions are activated to a higher energy state, whereby a portion of the translation energy 
imparted to peptide ions is converted to internal energy [121]. This energy is then 
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redirected and randomized throughout the peptide molecule, leading to the most 
thermodynamically stable bond cleavage (i.e., the path of least resistance) and fragment 
generation. The end result of this activation process is a charged fragment ion and a 
neutral species. This can be summarized in the following two-step reaction: 
 
Mp+ + N Æ Mp+ (act) Æ mf+ + n0                                          (2) 
 
Where Mp+  is the precursor peptide ion, N is the neutral collision gas molecule, Mp+ (act) 
is the activated precursor peptide ion, mf+ is the charged peptide fragment, and n0 is the 
neutral peptide fragment.  
 
Basic sites at the N-terminus and amino acid side chains provide anchor points for 
protonation. These protons are not totally static, but can move about, creating a 
heterogeneous population of peptide ions with the same sequence but protonated at 
different amide linkages [122]. According to the mobile proton model [123], these 
protons can migrate along the peptide backbone by internal solvation, and upon 
activation by CID, contribute in the fragmentation of the peptide in a “charge-directed” 
manner. In low-energy (up to 50 eV) collision instrumentation (i.e. quadrupole, Q-TOF,) 
this fragmentation scheme generates a predictable series of peptide fragment ion pairs by 
cleavage along the amide backbone [124], along with loss of water and ammonia. The 
fragmentation and generation of peptide ions is depicted in Figure 1.13.  
 
 
Figure 1.13: Peptide fragment ion generation. The types of ions produced depend upon 
where the cleavage site occurs. From references [125] and [126]. 
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Fragments ions generated from peptide amide bond cleavages are classified as 
either b- or y-type ions, depending on which terminal end the fragmentation is initiated 
(N- or C-terminus) [127]. Cleavages of bonds adjacent to the amide bond result in either 
a,x or c,z ion pairs (see figure 1.13). Under CID conditions, the predominant ion pairs 
formed are b and y ions. Each amino acid will produce its own characteristic b and y 
fragment ions (see Figure 1.14); thus, the sequence of a given peptide can be deduced 
based on the type of fragment ions generated by tandem MS.  
 
Figure 1.14: The CID fragmentation mechanism demonstrating the formation of b- and 
y-type ions. From reference [128]. 
 
1.5.2.6  Peptide fragmentation by electron transfer dissociation 
 
Although a very powerful activation technique, CID does have inherent 
limitations. These include lower fragmentation efficiency of higher charge state ions (i.e., 
+4 and greater), as well as inducing loss of labile post translational modifications 
(PTMs), i.e, phosphorylation, sulfonation, and glycosylation (e.g. O-GlcNAcylation). The 
application of CID has been used successfully by many groups in the sequencing and 
localization of phosphorylation sites; for example, Gygi demonstrated the sequencing of 
over 2000 phosphopeptides from the nucleus of HeLa cells in a large scale study using 
CID [129]. Even though very functional and reproducible, tandem MS by CID is only 
providing a limited view of the modified peptides present in a given proteome. To further 
enable and extend the capabilities of tandem MS to sequence larger peptides, proteins, 
and labile PTM, new activation methods were required. A key breakthrough was reported 
in 1998 by McLafferty and Zubarev in the development of a new activation process 
called electron capture dissociation (ECD) [130]. In this technique, low energy, near-
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thermal electrons are reacted with multiply charged protein/peptide cations [131], 
generating an odd-electron, hypervalent species. The dissociation of this radical species 
and subsequent rearrangement leads to fragmentation of the peptide. The bonds that are 
preferentially ruptured during ECD fragmentation are disulphide bridges and N-Cα by a 
non-ergodic mechanism [132]; these bonds are broken faster than the rate at which the 
vibrational energy is redirected throughout the molecule. Unlike CID, the most prominent 
ions formed in ECD are c- and z-type (see Figure 1.15).  Furthermore, the fragmentation 
mechanism is gentle enough to preserve labile bonds and PTMs, as shown by Kelleher in 
the localization of carboxy and sulfated peptide residues [133]. The challenging aspect of 
ECD is the requirement of using FT-ICR instrumentation capable of producing the 
electrons, and the physical space for the capture with cations to occur. Also, FT-ICR 
instruments are the most expensive type of mass spectrometers to both purchase and 
maintain. This led researchers to the development of ECD-like fragmentation mechanism, 
but using more common and available instrumentation, such as quadrupoles and ion 
traps. The pioneer of electron transfer dissociation (ETD) was Donald Hunt at the 
University of Virginia. Instead of using FT-ICR with an electron generating source, his 
group used anionic molecules with a low affinity for electrons (i.e. anthracene) to deliver 
the electron, and a linear quadrupole ion trap as the reaction cell to perform ETD [128]. 
The anionic reagent molecules are produced in a chemical ionization source, and injected 
into a linear ion trap, where they react with peptide cations for a brief period of time 
(~100 milliseconds). The excess reagent is then purged out of the reaction cell, peptides 
fragmented, then scanned out. Since its introduction in 2004, ETD has been well 
characterized and improved. In a large scale study using both CID and ETD for the 
analysis of yeast extracts, Coon and colleagues demonstrated that ETD outperformed 
CID in the detection and sequencing of higher charge state species (+4 and higher), while 
at the same time sequencing peptides unique to ETD [134]. At present, ETD has been 
introduced in hybrid instruments, such as LTQ-Orbitrap, enabling both CID and ETD on 
the same platform on a chromatographic time scale [135]. Phosphopeptides can be easily 
sequenced and localized, while preserving the phosphate group on the peptide backbone. 
This allows for increased peptide sequencing rates, greater protein sequence coverage, 
and discovery of novel PTMs.  
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Figure 1.15: The ETD fragmentation mechanism demonstrating the formation of c- and 
z-type ions. From reference [128]. 
 
1.5.2.7  The detection module 
 
After mass analysis, ions must make contact with a detector, and generate a 
digital signal. Ultimately, the sensitivity of the instrument relies upon how well the 
detector can sense the ions emerging from the mass analyzer. The two most common 
types of detectors used in mass spectrometers are the electron multiplier, and the 
microchannel plate (MCP) [94]. Electron multipliers can be either discreet or continuous 
[85], the latter form is usually referred to as a channel electron multiplier (CEM). The 
discreet form has a series of “cup” shaped dynodes coated with a surface that will release 
secondary electrons upon impact by an incident ion. Each dynode is held at higher 
potential, and will attract the electrons emitted from the previous dynode, causing an 
increasing cascade of electrons. The output gain from such a device can be from 106 up to 
108. The final current generated can be transformed to a measurable signal using an 
analog-to-digital converter. The CEM is the continuous form of this detector. Rather than 
using discreet set of dynodes, the CEM is present in a curved open tube coated with a 
semi-conductive material. A beam of ions will generate the secondary ion cascade effect, 
and produce gains up to 108.  A linear electron multiplier can be downsized to a few μm 
in diameter; the coupling of a high number (106) of these microscaled components linked 
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together forms a microchannel plate (MCP). The gain of such a detector is lower than a 
CEM (i.e., 103 – 104). To improve the sensitivity, MCP’s are usually stacked together.  
 
1.5.2.8  Database searching and processing of proteomics data 
 
A typical LC-MS run of a complex tryptic digest can result in the acquisition of 
thousands of MS/MS spectra. Manual interrogation of every spectrum in order to assign 
the peptide sequence and identify the source protein would be a very time consuming and 
laborious process. To expedite this task, internet database searching was designed and is 
now available. Mathematical algorithms for data processing were developed to assign a 
statistical score between an acquired and an “ideal” MS/MS spectrum. Peptide MS/MS 
spectra can be uploaded to a server (e.g. Mascot, see Figure 1.16) [136] and searched 
against a library of proteins. Raw data files are first converted to a mascot generic file 
(.mgf) which can be read by the search algorithm. A spectral library (e.g. NCBInr) can be 
selected, and the modifications of interest specified. After the search is initiated, the 
results are relayed back and provide a researcher with the most statistically relevant and 
plausible peptide sequences and PTMs present. A list of identifications includes the 
source protein, peptide sequence, modifications, and the Mascot score. In principle, a 
higher Mascot score for a given peptide is indicative of a more confident sequence 
assignment.   
 
 
 
 
 
 
 
 
 
 
Figure 1.16: The Mascot server page for peptide MS/MS database searching 
(www.matrixscience.com). 
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1.6  The analysis of histones by mass spectrometry 
 
 
Histone proteins are a challenging class of biomolecules to prepare, analyze, and 
sequence.  The high content of basic amino acids renders them very polar with a high 
isoelectric point (pI ~ 11). The many, near isobaric forms, and combinatorial nature of 
PTMs on the N-terminus further complicates analysis and identification. Furthermore, 
biological relevant epigenetic markers may be present at very low abundance (< 1% of 
the unmodified precursor protein). The extent of histone PTM can be quite large; multiple 
modifications can occur on the same protein on different residues at different stages of 
the cell cycle. These hurdles require highly sensitive, robust, and versatile analytical 
instrumentation in order to quantitate and sequence histones and their PTMs. Hence, 
mass spectrometry is an obvious choice to characterize histones due to high sensitivity, 
speed of analysis, quantitative capability, and precise sequencing. The first reported 
usage of MS to identify methylated lysine residues in histones was by Murray in 1964 
[137]. However, this was a rather isolated and rare publication; MS would not be used or 
documented routinely in histone research until the turn of the 21st century.  Many 
research groups have attempted to tackle the challenge of analyzing histones by MS over 
the past 10 years, using both top-down and bottom-up sequencing strategies. 
Nevertheless, the stoichiometry, multiplicity, and half-life of these modifications still 
present a considerable challenge to any researcher. The use of top-down MS for 
analyzing intact histones [138],[139] was initiated by Neil Kelleher at the University of 
Illinois. This method is capable of providing complete sequence coverage and separation 
of many different isoforms within a group of core histone molecules. However, top down 
MS usually requires expensive FT-ICR instrumentation, hardware alteration, and 
sophisticated data processing software. Furthermore, the sample preparation for top down 
MS necessitates extensive HPLC fractionation, and a high amount of starting material. 
Only a few specialized laboratories can invest in such instrumentation. The alternative 
strategy, i.e., bottom-up sequencing, has been the most widely used approach for 
analyzing histones. Using enzymatically derived peptides (i.e., tryptic digestion) instead 
of intact histones simplifies the analysis and data interpretation, and more commonly 
available instrumentation (ion trap, Q-TOF) can be used. An early report by Burlingame 
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[140] was the first attempt at comprehensively mapping out histone PTMs; this consisted 
of tryptic digestion and MALDI-TOF analysis to identify histone H3 modifications from 
chicken erythrocytes. A more streamlined and robust workflow was developed by Hunt’s 
group [141], utilizing chemical derivatization and labeling, HPLC fractionation, different 
enzymes, and high resolution LC-MS.  This strategy was successfully used to map out 
histone H3 PTMs from HeLa cells. Mapping out and characterizing histone PTMs is an 
important first task, yet quantifying the relative abundance of histone PTMs under 
different experimental conditions is also vital in understanding their biological role and 
impact. Many reports to date utilized some form of chemical addition to perform 
differential PTM quantitation. These include stable isotopic labeling [142] to determine 
the in-vitro stoichiometry of acetylation at each lysine residue in the N-terminal tail of 
histone H4. Other in-vivo based methods consist of metabolic labeling with SILAC [143], 
and iTRAQ reagents [144] to compare the abundance of proteins or PTMs in two 
different samples (e.g. histones derived from control cells versus histones obtained from 
cells treated with DNA damaging agents). Although the labeling chemistry is well 
understood and functional, these procedures do suffer in reproducibility and dynamic 
range. Label-free methods represent the second approach for quantifying histone PTMs. 
This technique uses no incorporation of a chemical label at any stage of the sample 
preparation; peptides are analyzed in their natural state after proteolysis. However, this 
label-free approach requires rugged sample introduction (i.e., stable chromatography), 
and some form of bioinformatic tools to perform data mining. Without any software 
programs to aid in the data processing and interpretation, label-free methods result in a 
great deal of laborious and time consuming manual inspection of raw LC-MS data. Very 
few software tools are available commercially to aid researchers in applying label-free 
proteomic analyses.  Some groups have addressed this need by designing in-house 
software to perform label-free analysis of their raw data. For example, VEMS software 
[145] and differential mass spectrometry (dMS) [146] have been documented for 
analyzing raw data; recently, Garcia’s group also reported a new algorithm (PILOT 
PTM) [147] to rapidly search raw data in order to identify histone modifications. 
Regardless of which strategy is utilized, total comprehensive analysis of histone PTMs 
remains extremely challenging. 
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1.7  Research Objectives 
 
 
Firstly, this Ph.D. research project focused on developing analytical strategies to 
analyze and characterize intact histone proteins and tryptic peptides. An analytically 
robust workflow had to be developed by combining all the necessities of performing such 
analyses, namely a rugged sample preparation procedure, modern high resolution MS 
instrumentation, and in-house developed bioinformatic data mining tools. These 
components were used together in order to comprehensively analyze and quantitate 
known and novel histone PTMs in a variety of biological matrices. The extent of histone 
PTMs can vary over a large range (some are very low in abundance, while others are very 
abundant). This range can extend up to three orders of magnitude, placing a heavy burden 
on the detection capabilities of current MS instrumentation. Modifications of interest can 
be present at very low stoichiometry, and result in high degrees of analytical error and 
uncertainty in measurement. The determination of analytical error is rarely assessed or 
reported in the literature; this became a second objective in this section of the project. 
Even in a rather simple organism such as yeast (S. cerevisiae), a great deal of histone 
PTMs are present in a large distribution of abundances. One key modified histone H3 
peptide, i.e., acetylated lysine 56 (H3K56ac) is known to play a vital role in the DNA 
damage response in S. cerevisiae [148]. Current methods used to characterize and 
quantitate this PTM rely on either immunoblots, or generic LC-MS experiments to detect 
this peptide. The last objective of this section was to reproducibly quantitate the relative 
abundance of this important PTM in WT and mutant yeast strains using our in-house 
developed workflow. 
 
Secondly, novel uses of existing MS instrumentation were investigated and 
developed.  Not all laboratories have the luxury of possessing an instrumental platform 
from each major MS vendor. In some instances, researchers must use and adapt the 
technology at hand to answer biological questions. Ion trapping instruments are both 
versatile and readily available. However, these instruments are rather limited in their 
proteomic applications due to lower resolution, and space-charge effects. Alterations in 
the instrument software and scanning functions of a hybrid quadrupole-linear ion trap 
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instrument were tested and optimized in order to expand the analytical capabilities of the 
mass spectrometer, and apply these improvements to perform both intact histone profiling 
and bottom-up sequencing on the same MS platform. The objective of this work was to 
determine if trapping instruments could be used to analyze intact proteins from complex 
mixtures, and use this newly developed scan mode to profile changes in histone PTMs in 
WT and DOT1L-deficient DT40 cells. 
 
Thirdly, using the analytical workflow developed and validated, the effects of 
HDAC inhibitors on histones derived from both normal and cancer cells were examined. 
Most published literature rely on immunoblots to assess which modification sites are 
affected by exposure to HDAC inhibitors. These methods are limited by the potential of 
cross-reactivity, poor quantitative capability, and may lead to erroneous results and 
conclusions. In mammalian cells, histone PTMs can vary in a large range of abundance 
and isobaric species, thus making detection and quantitation challenging. The primary 
objective of this study was to determine with a high degree of accuracy which core 
histones were affected, which PTMs were up-regulated, and the extent of the fold-change 
in histone PTMs induced by treating cells with HDAC inhibitors. Furthermore, we 
wanted to shed some light on important biological questions, such as: (1) do HDAC 
inhibitors affect normal cells in the same manner as cancer cells? (2) Does H3K56ac have 
the same function in mammalian cells as in yeast cells? (3) Can this information be used 
to develop more specific HDACi as therapeutic agents with fewer side effects? 
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1.8  Contents of the Thesis 
 
 
The second chapter of the thesis presents an overview of the experimental aspects 
used in the generation and interpretation of proteomics data.  
 
The third chapter of the thesis presents the development and validation of an 
analytical workflow to analyze and quantitate histone PTMs. A dual approach is 
described, whereby both intact mass profiling and peptide sequencing are utilized. The 
reproducibility of the workflow was assessed in order to generate analytical figures of 
merit. A tailored sample preparation for histones was adapted and developed, while 
applying in-house developed bioinformatic tools (Mass Sense peptide miner and 
clusterer) to probe the data. Modern high resolution LC-MS instrumentation (Agilent 
TOF and Waters Q-TOF premier) was used to analyze and sequence histone peptides. 
The methodology was validated using histones extracted from yeast wild-type and mutant 
strains to establish structure-function relationships. 
 
The fourth chapter of the thesis presents the development of a new scanning mode 
on the AB Sciex 4000 Q-trap hybrid quadrupole-linear ion trap instrument. The modified 
scanning mode (named targeted EMC) was designed by altering the scanning parameters 
and voltages of the instrument. This resulted in both higher sensitivity and resolution, 
while minimizing space charge effects. Figures of merit and practical instrumental limits 
were established. Histones from chicken DT40 cells were analyzed to demonstrate the 
applicability of this new scanning mode to profile both intact histones, while using 
conventional MRM mode to localize and quantitate differentially abundant histone PTMs 
on the same instrument.  
 
The fifth chapter of the thesis presents the results and findings of an HDAC 
inhibitor study. Two clinically relevant HDAC inhibitors, namely Vorinostat (SAHA, 
marketed as Zolinza) and Entinostat (MS-275), were selected for investigation. Both 
normal and leukemic K562 cells were used in this study. The methodology developed 
and presented in the third chapter of the thesis was applied to determine the global effects 
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on histone PTMs by these small molecule inhibitors. Several known acetylation sites on 
histones H3 and H4 exhibited a significant increase in acetylation of histones derived 
from K562 cells treated with HDAC inhibitors. Surprisingly, the HDAC inhibitors did 
not increase histone acetylation in non-transformed cells. Every type of MS platform in 
the laboratory was exploited to gain a better understanding of how histone PTMs were 
affected by the various HDACi. Targeted MRM was also used to detect and quantitate 
low abundance PTMs.  
 
Lastly, the sixth chapter presents a conclusion that links all the work and findings 
presented in the thesis, as well as potential future perspectives for the analysis of histones 
by mass spectrometry. 
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When this Ph.D. project was initiated, there was no analytical workflow 
developed in-house in order to prepare and analyze histone PTMs by mass spectrometry. 
The four key elements responsible for the success of this project were the following: (1) a 
sample preparation and digestion procedure designed for histones, (2) nano scale HPLC, 
(3) state of the art MS detection for quantitation and sequencing, and (4) the use of 
specially designed bioinformatic tools and database search engines to rapidly analyze 
proteomics raw data. The following sections provide greater detail on these important 
aspects. 
 
2.1 Sample Preparation for Histones 
 
Histones derived from cellular extracts are present in many different modified 
forms. To simplify the sample complexity and allow comparison between different 
experimental conditions, an HPLC separation method using a reversed-phase C18 column 
was developed. This resulted in core histones being almost baseline resolved from each 
other. A solvent system using acetonitrile and water both containing trifluoroacetic acid 
(0.1% v/v) was used with gradient elution (e.g. 5 to 90% organic component) to separate 
the intact histones. Histones contain a great deal of basic residues, especially on their N-
terminus. Direct tryptic digestion would result in the generation of many small 
proteolytic fragments, many of which would not retain on a conventional C18 column. 
Although sufficient for mapping studies, direct tryptic digestion is not totally suitable for 
quantitative studies, where the generation of many digestion products can result in a 
PTMs being present on multiple peptides. To circumvent this challenge, a different 
approach was taken. Using a chemical derivatization method initially developed and 
reported by Hunt and colleagues [1], we tested and fine-tuned the reaction for histone 
preparation in our laboratory. HPLC purified histones were placed in basic media (0.1 M 
ammonium bicarbonate buffer, pH 8), and reacted with a propionic anhydride reagent. 
This reaction modifies all free lysines and converts them to a propionyl lysine. Digestion 
was performed with trypsin in order to reproducibly and efficiently produce a limited set 
of derived peptides. Since all lysines become occupied, trypsin cannot cleave at these 
residues. After the chemical reaction with proprionic anhydride, only arginine cleavage 
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on the C-terminal end can occur. The chemical reaction between propionic anhydride and 
lysine is shown below in Figure 2.1: 
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Figure 2.1: Chemical derivatization of lysine residues using propionic anhydride, 
resulting in the generation of a propionyl lysine. 
 
2.2 Biological Models 
 
For each individual chapter reported in this thesis, a different cell line was used. 
The primary reasons for the usage of different types of cells were availability and scope 
of the research. In the development of our histone analysis workflow, we validated our 
two-pronged strategy using histones extracted from yeast. The use of this organism had 
several advantages, including a relatively small genome, easy manipulation of its cell 
cycle, generation of mutant strains, and capability of growing large volumes of cell 
culture [2]. Moreover, we used mutant strains deficient in acetyltransferase activity that 
are known to modify a specific residue (i.e., H3K56). Hence, we could easily predict and 
validate our findings on structure-function relationships without too many biological 
changes. A more complicated biological model comprising of many differentially 
expressed PTMs could have impeded the validation process, and led to confounding and 
complicated results. In chapter four of this thesis, the histones that we investigated by 
targeted EMC and MRM were derived from DT40 cells. This cell line was derived from 
an avian leukosis virus (AVL)-induced bursal lymphoma [3]; features of this cell line 
include facile genetic manipulation and production of gene knockouts, and rapid 
generation times. This enabled the preparation of a single methyltransferase mutant 
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(DOT1L) in DT40 cells. Since this enzyme is known to methylate primarily one residue 
(H3K79), only a limited set of predictable peptides are differentially expressed between 
WT and mutant strains; this facilitated the demonstration of the novel targeted EMC scan 
mode, as well as MRM for relative peptide quantitation. In chapter five of this thesis, we 
used histones derived from K562 cells. These cells originated from human erythroid cells 
from a patient afflicted with chronic myelogenous leukemia (CML). These cells not only 
proliferate rapidly (12 hour doubling time) [4], but can be induced for erythroid 
differentiation when treated with nucleotide containing compounds [5]. As a model of 
transformed human cells, we selected the erythroleukemic cell line K562 for the 
following reasons.  Several research groups at the Institute for Research in Immunology 
and Cancer (IRIC) and the “Centre de Recherche de l’Hôpital Maisonneuve-Rosemont” 
(HMR, a research institute with a close affiliation with IRIC) focus their studies on 
hematological cancers, with a particular emphasis on leukemia. We therefore hoped that 
our studies of the effects of HDAC inhibitors on K562 cells might foster collaborations 
with other research teams at IRIC and HMR. K562 cells are well defined genetically. As 
is the case in most patients suffering from CML, the K562 cell line carries a specific 
chromosome translocation. The translocation generates an abnormal chromosome, known 
as the Philadelphia chromosome [6], which encodes the key oncogenic protein BCR-ABL 
that drives the development of CML. The BCR-ABL fusion protein is a dysregulated 
(hyperactive) tyrosine kinase that is essential for the progression of CML; no other 
known genetic alteration appears to be involved in triggering CML. Because of this, 
patients suffering from leukemias driven by the BCR-ABL fusion protein (not only CML 
patients, but also a fraction of patients with acute lymphoblastic leukemia and acute 
myelogenous leukemia) are often treated with imatinib [7], a pharmacological agent that 
inhibits the kinase activity of BCR-ABL. However, about 30 to 40% of CML patients 
express an isoform of the BCR-ABL kinase that is poorly inhibited by imatinib because 
of a mutation in the kinase domain [8]. Hence, other chemotherapeutic agents, possibly in 
combination with imatinib derivatives, are needed to treat these patients. Because SAHA 
and other HDAC inhibitors seem to be most efficacious against hematological cancers, it 
seemed appropriate to study the extent to which HDACi affect histone acetylation in 
K562 cells. These cells are malignant and represent an ideal in vitro system for studying 
 51
the effects of small molecule HDAC inhibitors on the expression of histone modifications 
in cancerous cells. Histones from normal cells isolated from human lung fibroblasts [9] 
(e.g. WI-38, IMR90) were used as a control, and represent a healthy cellular state. Unlike 
K562 cells, IMR90 and WI-38 fibroblasts are not transformed or immortalized. 
Therefore, they have a short finite lifespan, which is empirically defined as the maximal 
number of passages for which the cells can be propagated in culture before they cease to 
proliferate (typically between 20 and 50 passages depending on culture conditions). 
These diploid cells proliferate more slowly than K562 cells, are closely indicative of cell 
biology in vivo [10], and can enter a replicative senescent state after a limited number of 
growth cycles [11]. IMR90 and WI-38 fibroblasts have been extensively studied to define 
the molecular mechanisms that trigger oncogene- and DNA damage-induced senescence. 
Since one of the mechanisms by which HDAC inhibitors have been reported to exert their 
anti-proliferative effect on cancer cells is the induction of DNA damage leading to either 
apoptosis or senescence, we felt that IMR90 and WI-38 fibroblasts might be particularly 
sensitive to increases in histone acetylation triggered by HDACi. 
 
2.3 Nano scale HPLC 
 
To maximize sensitivity using MS detection, nano scale separations were utilized. 
One dimensional reversed phase chromatography was applied to perform either intact 
histone or tryptic peptide separation prior to MS detection. The separation module used 
was either an Agilent 1100 series, a Waters Acquity, or an Eksigent 2D-nano LC system, 
all capable of generating low and stable flow rates in the nL/min range. Such low flow 
rates allow peptide sensitivity to reach low femto- and even attomole levels. Both a 
loading and an analytical column were connected to the liquid chromatograph. Column 
dimensions were 100 mm x 150 µm I.D. for the analytical column, and 4 mm x 360 µm 
I.D. for the trapping column. Both columns were packed in-house using fused silica and 
Teflon tubing; the columns were packed with C18 stationary phase. The use of a loading 
column enabled the loading of more material for MS analysis, and also provided an on-
line cleanup of the sample prior to the analytical separation. Both intact histones and 
tryptic peptides were analyzed using the same HPLC method.  Intact histones were 
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diluted with LC-MS mobile phase, while tryptic peptides were directly injected onto the 
HPLC system. The solvent system consisted of water and acetonitrile, both containing 
dilute formic acid (0.2% v/v). After a three minute loading step at 10 µL/min, the loading 
column was brought in-line with the analytical column, and gradient elution at 600 
nL/min initiated to elute and separate histones.  
 
2.4 MS detection and sequencing 
 
In this Ph.D. project, a variety of MS instrumentation was used to analyze and 
sequence histones and their PTMs. The theory behind these instruments was covered in 
the previous chapter (section 1.5.2). More details about the experimental aspects used in 
each chapter are described below. All instrumental parameters are fully described in the 
following chapters. 
 
2.4.1 Agilent TOF, Waters Q-TOF, and AB Sciex 4000 Q-trap for differential 
expression profiling and peptide sequencing (chapter three) 
 
In our dual, two-pronged approach, both intact histones and tryptic peptides are 
analyzed. Intact histone LC-MS analysis was performed on a Waters Q-TOF Premier 
mass spectrometer. The instrument was operated in positive ion mode, while scanning a 
mass range between m/z 400 to 1600, with a mass resolution of 10 000. Application of a 
Q-TOF mass analyzer allowed the many different core histone isoforms to be resolved. 
Deconvolution of mass spectra by mathematical algorithms (MaxEnt) generated a mass 
profile for direct comparison between wild-type and mutant yeast strains, and selection of 
primary histone protein candidates for peptide analysis. Tryptic peptides for global 
expression profiling were analyzed using an Agilent TOF instrument, using the same 
parameters as above. The TOF analyzer provided a good linear range (three orders of 
magnitude), with accurate peptide mass determination. To sequence peptides and locate 
PTMs, the same extracts were re-injected onto the Waters Q-TOF premier using LC-
MS/MS in data-dependant acquisition mode. Tandem MS was performed on the three 
most intense ions from the MS survey scan. Precursor ion selection was performed in the 
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quadrupole mass analyzer, while scanning product ions in the TOF analyzer. This 
allowed for high resolution fragment ion analysis as well. The stoichiometry of one 
peptide detected (H3K56ac) was further assessed using the AB Sciex 4000 Q-trap. Using 
data acquired in the global LC-MS/MS analysis, an MRM method was built using 
precursor and product ions generated on the Q-TOF instrument. A combination of three 
MRM peptide ion pairs was monitored, using a dwell time of 50 milliseconds. When the 
precursor and product ions are known, this allows for the creation of a highly sensitive 
and precise quantitation method in MRM mode using a triple quadrupole instrument. The 
stoichiometry of H3K56ac in wild type and mutant yeast strains was measured with high 
accuracy using MRM. 
 
2.4.2 AB Sciex 4000 Q-trap for targeted EMC and differential PTM profiling 
(chapter four) 
 
The 4000 Q-trap mass spectrometer was used to detect and profile intact proteins. 
The enhanced multiply charged (or EMC) scan performed in the linear ion trap (LIT) 
allows for selectively evacuating singly charged ions while trapping multiply charged 
ions. This was initially designed by AB Sciex to enhance the sensitivity and detection of 
peptides. The MCS voltage is the trapping voltage applied to the exit lens of the LIT to 
contain multiply charged species while allowing singly charged ions to escape. The MCS 
voltage was optimized using infusion at 0.8 V. Two model analytes were used for this 
optimization: apomyoglobin and leucine enkephalin. However, the EMC scan failed to 
perform adequately in LC-MS mode due to space-charging effects. With the aid of AB 
Sciex, we modified the conventional EMC mode by changing the RF applied to the 
protein ions, gating all the ions through Q0, and selectively transmitting only a limited 
m/z range into the LIT in a sequential fashion. This way, the LIT was not overloaded with 
too many ions. After trapping the ions, the charge separation step was applied to remove 
excess singly charged ions from the LIT. Using BioAnalyst software tools, the mass 
profiles could be generated and compared. This modified scan mode (targeted EMC) 
allowed for not only higher sensitivity and resolution, but also minimized space charge 
effects. Histones derived from DT40 wild type and mutant cells were examined. As 
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expected, differences in the histone H3 intact profiles were detected between wild type 
and DOT1L mutant. The abundance and localization of differentially expressed histone 
PTMs were monitored by MRM on the same instrument. Precursor and product ion pairs 
were generated by importing histone H3 sequences into AB Sciex MRM pilot software, 
and generating theoretical MS/MS spectra. MRM ion pairs were designed based on the 
most intense fragments to maximize the MS response. Three to four ion transitions were 
monitored for each peptide using a rapid dwell time (10 milliseconds) without 
compromising sensitivity. To confirm the sequence of the peptides detected by MRM, 
MS/MS in the LIT was performed in a data-dependant fashion using enhanced product 
ion (EPI) scan when a peptide peak was detected.  
 
2.4.3 Agilent Q-TOF, Thermo LTQ-Orbitrap XL, and AB Sciex 4000 Q-trap for 
differential PTM expression and targeted MRM (chapter five) 
 
In the HDACi exposure study, we used three different instrument platforms to 
profile intact histones and tryptic peptides. The Agilent Q-TOF instrument was used to 
profile intact histones from control and HDACi treated cells using the same parameters as 
in section 2.3.1. For global LC-MS/MS analysis of histone peptides, the Thermo LTQ-
Orbitrap XL was used for both expression profiling and MS/MS sequencing. This way, 
both types of information can be acquired from the same injection. Precursor ions were 
detected in the Orbitrap mass analyzer. The instrument was operated in positive ion 
mode, while scanning a mass range between m/z 300 to 2000, with an Orbitrap mass 
resolution of 60 000. The higher mass resolution allowed for better discrimination of near 
isobaric species. The three most intense ions detected in the Orbitrap survey scan were 
selected for tandem MS and transferred to the LTQ ion trap. A decision tree was designed 
to select ions for either CID or ETD fragmentation, based on m/z and charge state. Lower 
charge state peptide ions were fragmented by CID, while higher charge state by ETD. 
MS/MS sequencing was performed in the LTQ ion trap by either fragmentation 
mechanism. Low abundance peptides (i.e. H3K56ac) were detected and sequenced by 
both the AB Sciex 4000 Q-trap and the Thermo LTQ-Orbitrap XL. An MRM method 
based on precursor-product ion pairs was built to screen for H3K56ac in different cell 
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types.  A high resolution absolute quantitation method was designed on the Thermo LTQ-
Orbitrap XL to detect and sequence H3K56ac using only CID. A calibration curve for 
H3K56ac was prepared and each individual standard was analyzed on the Thermo LTQ-
Orbitrap XL to determine the absolute concentration of this peptide in histones derived 
from various biological sources. 
 
2.5 Bioinformatic tools and database searching 
 
2.5.1 Peptide map generation 
 
Raw data acquired from complex proteomic analyses contain many peptides, 
contaminants, singly charged species, etc. Manual inspection of the raw data for 
differential expression profiling would be too laborious and time consuming. Software 
tools were developed in-house to expedite the analysis of raw data. The software tools 
utilized were Mass Sense peptide miner and clusterer. The peptide miner detection 
software converts LC-MS/MS raw data from high resolution acquisition into a two-
dimensional peptide maps (see Figure 2.2). Peptides are detected and highlighted 
graphically based on m/z value, LC retention time, and charge state.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Raw LC-MS total ion chromatogram (left) is converted into a two-
dimensional peptide map by Mass Sense peptide miner detection software (right).  
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2.5.2 Clustering analysis 
 
Peptide maps generated from replicate injections of different experimental 
conditions (e.g. control vs. mutant) were imported into the clusterer software. Peptide 
maps across multiple LC-MS runs were aligned with each other, and detected ions 
clustered together based on pre-defined m/z and LC retention time tolerances (see Figure 
2.3). For example, using high resolution LTQ-Orbitrap data, the m/z tolerance is usually 
set to 0.02 Th, and 1 minute LC retention time variation. This segmentation analysis of 
all ions detected allows for the rapid comparison of abundance values across different 
experimental conditions, and greatly reduces the time required to examine the raw data. 
The results of this clustering analysis can be exported into a Microsoft Excel spreadsheet 
for further analysis and generation of graphs (e.g. scatter and volcano plots).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Two-dimensional peptide maps generated by Mass Sense peptide miner 
overlaid together from triplicate LC-MS runs. Alignment of peptide clusters across 
triplicate runs using Mass Sense peptide clusterer. Peptide ions of different m/z values are 
represented by different colors (i.e., red, green, black circles). Peptide ions are grouped 
together based on m/z, LC retention time, and charge state, with pre-defined tolerances. 
 
2.5.3 Database searching 
 
Raw data files from global LC-MS/MS were uploaded to the Mascot server 
(www.matrixscience.com). This is a web based search engine that allows rapid 
assignment of ion spectra and peptide sequences from vast amounts of acquired MS/MS 
data. Search parameters such as type of enzyme, number of missed cleavages, peptide 
m/z
Time
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Run 2
ΔT
Run 3
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charge state, modifications and database were pre-defined prior to launching a Mascot 
search. For histone peptide MS/MS spectra analysis, the enzyme used was trypsin, and 
due to the chemical reaction with propionic anhydride, the maximum allowed missed 
cleavages was selected, i.e., nine. This high number was used in order to not discard any 
peptides bearing a long amino acid sequence. Modifications included acetylation, 
propionylation and methylation of lysine, methylation of arginine, phosphorylation of 
serine, threonine and tyrosine, and oxidation of methionine. Histone sequences from 
different species were obtained from the Swiss-Prot database (http://ca.expasy.org/sprot). 
Once the search is completed, the search engine reports all peptides found in a compiled 
list, along with their probability scores. Furthermore, the peptides identified by the 
Mascot search were linked together with the clustered data generated by Mass Sense. At 
the end of this process, all vital information including peptide m/z, LC retention time, 
abundance, and Mascot MS/MS identification are all grouped together in one Excel file. 
The processing of LC-MS/MS raw data is summarized in Figure 2.4. 
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Figure 2.4: A visual flowchart of the treatment of raw LC-MS/MS data using 
bioinformatic tools and Mascot database searching. From reference [12]. 
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3.1 Abstract 
 
A two-pronged approach using specialized peptide detection and clustering tools 
was developed to profile changes in histone post-translational modifications (PTMs). The 
extent and nature of modification was inferred by comparing the mass profiles of intact 
core histones from nano LC-MS experiments. Histones displaying changes in their intact 
mass profiles were fractionated, derivatized with propionic anhydride, and digested with 
trypsin prior to nano LC-MS analyses. Our methodology was validated by comparing the 
abundance of histone PTMs in wild type (WT) and mutant strains of Saccharomyces 
cerevisiae lacking the histone acetyltransferase Rtt109 and a nucleosome assembly factor 
known as Asf1. Both Rtt109 and Asf1 were previously found to be essential for 
acetylation of histone H3 lysine 56 (H3K56ac), a modification that plays an important 
role in the response to genotoxic agents that interfere with DNA replication. The 
generation of ion abundance distribution plots enabled a rapid and comprehensive 
profiling of histone peptides. Our analytical methodology and data mining approach 
showed that most common histone PTMs were unaffected in mutant yeast cells lacking 
Rtt109 and Asf1. However, a subpopulation representing 17% of all H3 histones in wild 
type cells showed an acetylated K56 residue that was significantly reduced in both 
mutant strains. Our generic strategy for histone PTM profiling can be applied to assess 
global changes in histone PTMs across sample sets and to establish structure-function 
relationships.   
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3.2 Introduction 
 
In eukaryotic cells, long DNA chains are compacted within the cell nucleus 
through their association with octamers of highly basic histone proteins. This generates a 
complex and dynamic nucleoprotein structure known as chromatin. The basic repeating 
subunit of chromatin is the nucleosome core particle (NCP) [1], which consists of 147 
base pairs (bp) of DNA wrapped nearly twice around a histone octamer. This octamer is 
composed of two molecules each of four types of core histones (H2A, H2B, H3, and H4). 
Adjacent NCPs are connected by variable lengths of linker DNA (between 18 and 65 bp), 
and histone H1 family members bind to the linker DNA to promote folding of chromatin 
into a higher-order structure known as the 30-nm fibre [2]. The globular domains of the 
four core histones, known as histone-fold domains, are structurally related to each other 
and responsible for the majority of histone-histone and histone-DNA contacts in NCPs 
[1]. In contrast, the N-terminal “tails” are solvent accessible and protrude beyond the 
DNA gyres of NCPs. Several residues within the histone N-terminal tails are sites of 
post-translational modifications (PTMs), and recent advances in mass spectrometry (MS) 
have also uncovered a bewildering diversity of PTMs within the globular domains of core 
histones [3, 4]. Histone PTMs can affect chromatin structure directly by modifying the 
affinity of histones for specific segments of nucleosomal DNA. In addition, histone 
PTMs can act indirectly, by serving as docking platforms for either nonhistone 
chromosomal proteins, histone modifying enzymes or ATP-dependent chromatin 
remodeling machines [5]. Histone PTMs participate in many DNA metabolic processes, 
such as nucleosome assembly, transcription, DNA repair and chromosome segregation. 
In addition, some histone PTMs function in a heritable epigenetic “histone code” that 
mediates stable transcriptional silencing in proliferating cells [6]. Histone PTMs often 
silence the expression of tumour suppressor genes [7]. Thus, many inhibitors of histone 
modifying  enzymes are under close scrutiny as potentially novel cancer 
chemotherapeutic agents [8]. Hence, the identification and accurate quantitation of 
histone PTMs is crucial in understanding their biological functions and assessing the 
effects of novel pharmacological agents that target histone-modifying enzymes. 
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MS has been successfully applied to study histone PTMs using both bottom-up [9, 
10] and top-down sequencing strategies [11, 12]. MS is ideal for PTM characterization 
because of its high sensitivity, specificity, and ability to pinpoint exact modification sites. 
Even complex patterns of PTMs can be determined in either proteolytic digests or intact 
proteins. However, the diversity, low stoichiometry, and short in vivo half-life of some 
histone PTMs still represent a formidable challenge from an analytical MS perspective. 
At least eight different types of PTMs have been reported in histones, including 
acetylation, methylation of lysine (mono-, di- and trimethylation) and arginine residues, 
phosphorylation, as well as larger PTMs such as sumoylation, ubiquitylation and ADP-
ribosylation [5]. Over 60 modification sites have been detected using either antibodies or 
MS [5]. Further complexity is imparted by the existence core histone sequence variants. 
These variants perform unique biological functions and often do not exhibit the same 
PTMs as canonical core histones [13].  
 
The ability to detect and quantify the differential distribution of histone PTMs 
makes MS an important tool not only in chromatin research, but also in the discovery of 
novel pharmacological agents that inhibit histone modifying enzymes such as histone 
deacetylases (HDACs) [14, 15]. A few research groups have addressed the challenge of 
quantifying histone PTMs using MS. One approach for rapid profiling of global changes 
in PTMs of intact histones has been reported in acute myeloid leukemia cell lines treated 
with HDAC inhibitors (HDACi) [16]. However, the identification of modification sites 
cannot be achieved using histone mass profiles alone due to the natural sample 
heterogeneity, the presence of confounding peaks, and overlapping PTMs. Recent 
advances in high resolution Fourier Transform mass spectrometry using emergent “top-
down” approaches enabled the direct sequencing of intact histones and their variants by 
tandem MS, albeit larger amounts of fractionated nuclear extracts are typically required 
than with other MS approaches [11, 12]. Enzymatic digestion of histones using 
endoprotease Glu-C to generate relatively large N-terminus peptides was also reported to 
identify sites of modifications using electron capture dissociation [17] or electron-transfer 
dissociation [18]. Alternative strategies for “bottom-up” sequencing, using either label-
free approaches or stable isotope labeling [19-23] have been investigated for comparing 
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differential distribution of histone PTMs. A recent publication, exploiting LC-MS/MS 
and data mining software, demonstrated the use of label-free ion profiling for monitoring 
changes in histone PTMs in response to HDACi treatment [24]. Hunt and colleagues 
reported the development of a “bottom-up” MS sequencing platform [25] utilizing 
chemical derivatization and stable isotope labeling to profile the PTMs of histone H3 in 
mammalian cells [26]. The widespread use and applicability of the aforementioned 
approaches is limited by the requirement of either growing cells in stable isotope media 
to promote metabolic labeling of histones, or using multiple chemical derivatization and 
labelling steps with stable isotopes, extensive sample preparation, and manual inspection 
of raw data from LC-MS/MS runs. Furthermore, very few data mining approaches exist 
for in-depth raw data analysis, and most published methods do not demonstrate any 
analytical figures of merit for reproducibility or their ability to assess the extent of 
modifications. 
 
In this report, we present an approach that addresses the inherent difficulties in 
profiling the relative abundance of PTMs across different histone sample sets. We 
describe a two-pronged strategy using both intact histones and tryptic peptides. First, 
intact histones are screened for changes in their mass profiles that could be attributed to 
PTMs. Second, peptide maps generated from LC-MS analysis of the corresponding 
tryptic digests are compared to identify peptides showing statistically meaningful changes 
in abundance across conditions and replicate runs. This is facilitated using scatter and 
volcano plots that readily reveal outlier histone peptides differentially abundant across 
sample sets. Both data-dependant and targeted nano LC-MS/MS analysis are used to 
sequence these outlier peptides and locate their PTMs. Using this approach, less time is 
spent on manually inspecting all the raw data, and the differential abundance of peptides 
is quantified in a reproducible and unbiased manner. The validity of this approach will be 
illustrated by expression profiling of PTMs in histones derived from wild type (WT) cells 
and mutants lacking Rtt109 (rtt109Δ cells), and Asf1 (asf1Δ cells). Rtt109 is required for 
the acetylation of newly synthesized H3 histones during the S-phase of the cell cycle, 
while Asf1 is a histone chaperone that presents new histones as substrates for Rtt109-
catalyzed acetylation in Saccharomyces cerevisiae [27]. 
 65
3.3 Experimental section 
 
3.3.1 Reagents 
 
Nonidet P40 (NP-40) and zymolyase were obtained from Fluka, and hydrochloric 
acid for histone extraction from Sigma. Total protein was measured using the micro-BCA 
assay (Pierce). Microbore HPLC C18 columns for intact histone fractionation were 
purchased from Phenomenex; capillary HPLC columns for LC-MS were packed in-house 
using Jupiter C18  (3 µm) particles from Phenomenex, and fused-silica tubing (Polymicro 
Technologies). Trapping columns were packed in-house using the same bulk material in 
Teflon tubing (Supelco). Solvents for chromatographic analysis were all HPLC grade 
(Fisher Scientific and in-house Milli-Q water).   Trifluoroacetic acid (TFA), anhydrous 
methanol, ammonium bicarbonate, ammonium hydroxide, D6-acetic anhydride and 
propionic anhydride were all purchased from Sigma. Formic acid was obtained from 
EMD Science. Porcine modified trypsin (sequencing grade) was obtained from Promega.  
 
3.3.2 Yeast Biological Model 
 
Yeast strains were constructed and grown in-house. The haploid wild-type S. 
cerevisiae strain (MATa his3Δ1 lys2Δ0 leu2Δ0 ura3Δ0), and the asf1Δ::KanMX and 
rtt109Δ:KanMX mutants were derived from the BY4743 heterozygous diploid collection 
[28]. The hst3Δ hst4Δ double mutant strain was previously described [29].  
 
Recombinant yeast histone H3 was expressed and purified from Escherichia coli 
as previously described [30], except that the buffers contained three HDAC inhibitors of 
different specificity: 100 mM sodium butyrate, 1 μM trichostatin A and 10 mM 
nicotinamide. The wild-type and mutant strains were treated with zymolyase to digest the 
cell wall and generate spheroplasts, which were lysed in a buffer containing 0.5 % NP-
40, and histones were extracted with 0.25 M hydrochloric acid.  
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3.3.3 Sample Preparation and Protein Digestion 
 
After acid extraction, the total protein content in the yeast histone-enriched 
samples was measured with the micro-BCA assay, using BSA as the reference standard. 
Intact core histones (~15 μg) were separated using an Agilent 1100 HPLC system 
equipped with a microfraction collector. Separations were performed on a microbore 
Jupiter C18 column (3 μm, 300 Å), 150 x 1 mm i.d., with a solvent system consisting of 
0.1 % TFA in water (v/v) (solvent A), and 0.1% TFA in acetonitrile (v/v) (solvent B). 
Gradient elution was performed from 5 to 90% B in 60 min at 35 µL/min. Fractions were 
collected in a 96-well plate at 1-min intervals. Individual histone peaks that eluted over 
multiple fractions were pooled together. Histone fractions were dried in a Speed-Vac 
evaporator and resuspended in 0.1 M ammonium bicarbonate buffer (without pH 
adjustment). This solution of intact histones was derivatized in 1:1 volume ratio with a 
propionic anhydride (PA) reagent solution (deionized water/propionic anhydride, 3:1 
(v/v) ). The reaction mixture was maintained at a basic pH by the addition of 
concentrated ammonium hydroxide to each tube. After a 30 minute derivatization period 
at room temperature, samples were evaporated a second time, resuspended in 0.1 M 
ammonium bicarbonate, and digested overnight at 37 °C using 1 µg of trypsin. Samples 
were acidified with 5% TFA in water (v/v) prior to LC-MS analysis. For targeted analysis 
of H3 tryptic peptides, propionic anhydride was substituted with D6-acetic anhydride; 
derivatization and digestion were performed using the same protocol as outlined above. 
 
3.3.4 Nano LC-MS of Analysis of Intact Histones 
 
Intact histone analysis was performed on a Waters Q-TOF Premier mass 
spectrometer equipped with a nanoelectrospray interface. The instrument was operated in 
positive ion mode and scanned from m/z 400 to 1600.  Whole protein samples were 
diluted to 200 ng/µL using the initial LC-MS mobile phase (see below). An aliquot was 
loaded onto a capillary C18 trapping column (4 mm x 360 µm I.D.) for 3 minutes at 10 
µL/min using a 90:10 water/acetonitrile solution containing 0.2 % formic acid (v/v). 
Trapped histones were eluted onto the analytical column (100 mm x 150 µm i.d.) using a 
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solvent system consisting of 0.2% formic acid in water (v/v) (solvent A), and 0.2% 
formic acid in acetonitrile (v/v) (solvent B). Gradient elution was performed from 10 to 
90% B in 60 min at 600 nL/min. Intact histone mass profiles were generated from 
acquired mass spectra using the MaxEnt1 deconvolution algorithm in the MassLynx 
software. 
 
3.3.5 Nano  LC-MS Analysis of Tryptic Peptides 
 
Tryptic digests from histone peptide fractions were injected in triplicate for ion 
profiling on either an Agilent MSD TOF or a Waters Q-TOF Premier mass spectrometer 
equipped with a nanoelectrospray interface. The instrument was operated in positive ion 
mode and scanned from m/z 400 to 1600, using the same HPLC columns and solvents as 
for the intact histone analysis. Gradient elution was performed from 0 to 50% B in 60 
min at 600 nL/min. Targeted nano LC-MS/MS analyses of H3 tryptic peptides using 
multiple reaction monitoring (MRM) were performed on an AB/Sciex API 4000 Q-Trap 
mass spectrometer equipped with a Nanospray II interface.  A 50 ms dwell time was 
applied to each unique histone peptide ion MRM transition; tryptic peptides were eluted 
from the HPLC column using the same conditions specified above. 
 
3.3.6 Ion Abundance Profiling and Peptide Sequencing 
 
All raw data files (.wiff) from triplicate injections on the MSD TOF were 
converted to 2-D peptide maps using the Mass Sense [31] peptide detection software 
(version 2.5) to identify peptides based on m/z values, retention time, abundance, and 
charge state. An intensity threshold of 100 counts (or 5 counts for Q-TOF analyses) was 
set as a cutoff for peak detection. Segmentation analysis was performed by clustering 
peptide ions across each condition based on their respective m/z ratio, charge, and LC 
retention time with Peptide Clusterer software (version 2.5) using m/z tolerance of ± 0.05 
Th and a time difference of 1 min.  Normalization of retention time is then performed on 
the initial peptide cluster list using a dynamic and nonlinear correction. A moving-
average, time window interpolation scheme is used to compute the time shifts for each 
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peptide across the different data sets. This alignment confines the retention time 
distribution to less than ±0.1 min (< 0.3% RSD) on average. Clustered data sets were 
exported to Microsoft Excel to generate either scatter or volcano ion distribution plots. 
Sequencing of histone peptides was performed using the Waters Q-TOF Premier mass 
spectrometer equipped with a nanoelectrospray interface. The instrument was operated in 
positive ion mode and scanned from m/z 400 to 1600 using MS/MS in data dependant 
mode. The same HPLC conditions were used as for the ion abundance profiling. 
Database searches were performed against the SWISSPROT database using Mascot. 
Histone peptides with Mascot scores greater than 30 were selected and manually verified 
to confirm their sequence assignment.  Expression data and Mascot searches were aligned 
together using the Peptide Clusterer software. 
 
 
 
Figure 3.1: Overview of the two-pronged analytical strategy combining protein 
identification and data mining approaches  
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3.4 Results and Discussion 
 
3.4.1 Nano LC-MS of Intact Histones 
 
Our two-pronged strategy is summarized in figure 3.1. As a first step, intact 
histones were screened to monitor any changes in their mass reconstruction profile. The 
total ion chromatograms from the LC-MS analysis of core histones is shown in figures 
3.2a and b for acid extracts from WT and mutant strain rtt109∆. Histones eluted between 
25 and 45 min in the following order: H4, H2B, H2A, and H3 (figure 3.2a and b). The 
peak labelled 1 contains both H4 and H2B, while H2A and H3 eluted in peaks 2 and 3, 
respectively. For histones H2A and H4, the mass profiles of intact histones derived from 
WT, asf1Δ, and rtt109Δ cells showed no significant changes and were virtually 
superimposable (figure 3.2c). However, histones H2B and H3 showed significant 
changes. In S. cerevisiae, there are two forms of histone H2B that exhibit few differences 
at the amino acid sequence level, and are encoded by distinct genes: H2B.1 (encoded by 
HTB1) and H2B.2 (encoded by HTB2). In the H2B profiles, the unmodified H2B.1 
protein is observed (14121 Da), along with two extra acetylations (14163 and 14205 Da, 
respectively). The 14121 Da component corresponds exactly to the mass predicted for 
removal of the N-terminal methionine without N-terminal amino group acetylation. 
Consistent with this, previous studies had suggested that a fraction of H2B molecules are 
not acetylated on their N-terminal amino group, unlike H2A and H4 [32]. When 
comparing intact H2B.1 mass profiles derived from WT and asf1Δ cells, there is a 
distinct change in the peak abundance for all three peaks (figure 3.2c). However, this was 
not the case when WT histones were compared to those derived from rtt109Δ cells; the 
intact H2B.1 mass profiles were superimposable (figure 3.2c). Based only on the intact 
mass profile, this observation suggests that a higher proportion of H2B.1 is observed in 
WT cells compared to that of asf1Δ mutant cells. A second set of peaks with +42 Da 
differences were also observed, with a +16 Da offset from the first set of H2B.1 peaks. 
This second set of mirror peaks was rationalized as being chemical artifacts from the 
oxidation of Met 62 during the sample preparation process. 
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Figure 3.2: Nano LC-MS total ion chromatograms of intact core histones from (a) WT 
and (b) mutant yeast strain rtt109Δ. Histones eluted within the peaks labelled 1-3. (c) 
Intact histone mass profiles were generated for the four core histones (H2A, H2B, H3, 
and H4) derived from each yeast strain. 
 
Another significant change was observed when comparing the chromatographic 
profiles of H3 derived from WT cells with those obtained from the two yeast mutant 
strains. A tailing shoulder was apparent in the LC-MS chromatogram of H3 from WT 
cells (figure 3.2a), while in the rtt109Δ mutant this late-eluting peak was partly resolved 
(figure 3.2b). Mass reconstructions were performed for both the main peak and shoulder 
(figure 3.2a); histone H3 was only found in the main peak, while the later component was 
a nonhistone protein contaminant. Comparison of intact profiles of histone H3 derived 
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from WT cells and each mutant revealed a more complex distribution of variants spaced 
by 14 and 42 Da (figure 3.2c). Closer examination of the H3 profiles indicated a 
subpopulation with a peak at 15 266 Da in WT cells that was shifted to 15 224 Da in both 
asf1Δ and rtt109Δ mutant strains (figure 3.2c). The addition of 42 Da over the intact mass 
predicted for unmodified S. cerevisiae H3 (15 224 Da for H3 with the initiator 
methionine removed and the N-terminal amino group nonacetylated) suggested the 
presence of abundant acetylation in WT cells. 
 
3.4.2 Sample Preparation and Reproducibility of Abundance Measurements 
 
To determine the heterogeneity and site occupancy of modified histones, yeast 
cell extracts were fractionated into individual core histones by HPLC prior to chemical 
derivatization of free lysine residues using PA based essentially on previously reported 
protocols with a few noted changes [33, 34]. The propionylation reaction is required due 
to the high number of lysine and arginine residues present in histones, resulting in a large 
number of small tryptic peptides that are hydrophilic and therefore poorly retained by 
reversed-phase HPLC. Derivatization appends a propionyl group to both free and mono-
methylated lysines, which cannot be cleaved by trypsin. Di- and trimethylated lysine 
residues are not propionylated, but are not cleaved by trypsin either [34]. Thus, in vitro 
propionylation restricts trypsin digestion to the C-terminal side of arginine residues. This 
results in larger tryptic fragments that are better retained on a reversed-phase HPLC 
column. Consequently, these hydrophobic peptides elute at higher acetonitrile 
concentrations, thereby increasing sensitivity under nanoelectrospray conditions. 
 
The addition of a propionyl group provides a traceable mass shift (addition of  
+56 Da) that can be easily distinguished from lysine residues modified in vivo. In 
preliminary experiments, we compared a single round of propionylation to the method of 
Garcia et al. using multiple rounds of propionic anhydride in methanol [33]. These 
experiments revealed that a significant decrease in ion abundance was observed for 
tryptic peptides that had undergone multiple derivatization steps compared to the same 
peptides using only one round of propionylation. For example, using two rounds of 
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propionylation, the intensity of the H3K56ac peptide decreased by 48% with a CV of 
26%; this value was slightly higher than that observed for the single propionylation (see 
below). Also, the propionylation reagent was prepared and delivered in water rather than 
methanol to minimize the methyl esterification of Glu and Asp residues [34] to less than 
1%, in addition to a significant decrease in amidation products. The single propionylation 
procedure provided a more rapid and streamlined sample preparation by reducing the 
number of evaporation steps, while minimizing variability in the peptide abundance 
measurements. Furthermore, during our data analysis and manual validation of peptides, 
there was no evidence of underivatized peptide present in the samples prepared using a 
single round of propionylation. These comparative analyses prompted us to use a single 
round of propionylation to maintain good reproducibility while avoiding the generation 
of side reaction products and chemical artifacts. In order to verify that the propionylation 
and tryptic digestion produced reproducible and representative histone peptides, the 
variability of the entire sample preparation process, including the nano LC-MS analyses, 
was ascertained by collecting three replicate injections of yeast histones. Chemical 
derivatization and tryptic digestion were performed on the fractionated core histones. 
After digestion, each histone fraction was analyzed by nano LC-MS in triplicate, and 
peptide maps were generated for cross sample comparison. The results of the 
reproducibility tests for all detected ions contained within the histone H3 fraction are 
shown in figure 3.3. A total of 273 ion clusters with intensity values ranging over 2 
orders of magnitude were identified in all replicates. The variability across three 
fractionated samples and triplicate analyses by nano LC-MS produced a CV ≤ 15% for all 
peptides detected. A direct linear relationship was observed when comparing individual 
and average intensities of all ions detected on the scatter plot, highlighting the 
reproducibility of the approach. Accordingly, changes in abundance measurements 
representing more than 25 % can be identified reliably with a degree of confidence 
necessary for expression profiling and MS/MS sequencing. 
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Figure 3.3: Scatter plot of reproducibility tests from sample preparation and nano LC-
MS analysis using histone H3 fractions from three separate LC fractionation replicates. 
Circles, squares, and triangles correspond to the intensity of all ions detected in the first, 
second, and third fractionation replicates (same sample, fractionated three times), 
respectively. 
 
3.4.3 Linearity and Dynamic Range of Quantitative Proteomics Approach for 
Histone Modifications 
 
Recombinant histone H3 purified from E. coli is devoid of PTMs [35]. Hst3 and 
Hst4 are the deacetylases for H3K56ac in S. cerevisiae [29, 36, 37]. In hst3Δ hst4Δ yeast 
mutants, virtually all of histone H3 (98%) is K56-acetylated [29]. In order to evaluate 
system performance and dynamic range of peptide detection, histone H3 samples purified 
from either E. coli or hst3Δ hst4Δ mutant yeast cells were fractionated by HPLC to 
isolate comparable amounts of each form of histone H3 (~ 2 μg). After propionylation 
and tryptic digestion, the two digest samples were mixed in varying proportions ranging 
from 1 to 100 % (1:99, 5:95, 20:80, 50:50, 0:100) of H3 from hst3Δ hst4Δ mutant strains 
spiked with increasing amounts of unmodified histone H3 purified from E. coli. Each 
sample was prepared separately rather than by aliquoting a stock mixture to mimic 
variability in sample preparation. Triplicate injections were performed for each sample. A 
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total of 31 identified peptide clusters detected in at least two replicate injections were 
related to histone H3.  
 
For the acetylated K56 peptide from histone H3, we next compared the calculated 
and observed abundance changes for all 10 combinations of spike amount ratio (fold-
change). Results from these analyses are shown in figure 3.4, along with error bars 
defining maximum variations observed for individual ratios. Also reported on this plot is 
the error bar observed for peptide clusters unrelated to H3K56ac, which are present in 
constant levels among the different spike samples (e.g., VTIQKKDIKLAR, 
KSTGGKAPR, YKPGTVALR, KQLASKAAR).  In figure 3.4, a linear relationship (r2 = 
0.995) was obtained between the observed and calculated abundance ratio measurements, 
with an average CV value of 9.8%. It is noteworthy that the observed abundance ratios 
were within 2.7% of their corresponding calculated values with larger variations noted 
for low spike levels showing higher variability of lower abundance ion signals. These 
experiments indicated that reliable change in abundance measurements can be monitored 
over two orders of magnitude in intensity ratio.  
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Figure 3.4: Ratio of observed and calculated intensity changes for histone H3 tryptic 
peptides from hst3Δ hst4Δ double mutant yeast cells spiked into a tryptic digest of 
recombinant histone H3 purified from E. coli. Spiking ratios were as follows: 1:99, 5:95, 
20:80, and 50:50 of H3 from hst3Δ hst4Δ double mutant strain versus recombinant 
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histone H3. Error bars calculated for all pairwise ratios of H3K56ac tryptic peptide ions. 
The graph shows a nearly linear relationship between the experimentally observed fold-
change increase in K56ac (solid diamonds) as a function of the calculated fold-change. In 
contrast, the abundance of H3 peptides (VTIQKKDIKLAR, KSTGGKAPR, 
YKPGTVALR, KQLASKAAR, denoted by the superimposed solid squares) that are not 
modified in either recombinant histones or H3 purified from hst3Δ hst4Δ double mutant 
cells was constant over the same range of molar ratio of the two sources of histones. 
 
3.4.4 Differential Expression Profiling and Peptide Sequencing 
 
Off-line LC-UV fractionation of histones from WT cells and a representative 
yeast mutant strain (rtt109Δ) gave almost superimposable chromatograms with the 
sequential elution of H2B, H4, H2A, followed by H3 (figure 3.5). It is noteworthy that 
off-line fractionation was achieved using TFA as an ion pairing reagent to improve 
separation efficiency and resolution of histone variants in contrast to nano LC-MS 
analyses where formic acid was selected to minimize ion suppression effects (figure 3.2) 
The only difference noted in the LC-UV chromatogram of histones from the yeast mutant 
strain (rtt109Δ) was the presence of a peak closely eluting with that of histone H3, which 
was not observed in the WT histone extract (figure 3.5b). This peak was at first suspected 
to be isoforms of H3, and, hence, was collected and pooled in the same tube as H3. 
Histones H2B and H3 were well resolved by the LC column and eluted in discrete 
fractions, while H4 and H2A eluted together in the same fraction. 
 
 
 
 
 
 
Figure 3.5: LC-UV fractionation of core histones from (a) WT and (b) rtt109Δ mutant. 
The fractionation was performed by reversed-phase HPLC on a Phenomenex Jupiter C18 
column, 150 x 1 mm i.d. Flow rate 35 μL/min. Fractions were collected every minute in a 
96-well plate. Gradient elution was performed from 5 to 90% acetonitrile in 60 min. 
 
H2B
H4
H2A
H3
Time (min)
a)  b)
H2B
H4
H2A
H3
Time (min)
 76
Since only histones H2B and H3 showed significant changes in their intact mass 
profiles, these two histones were the most promising candidates for the second step of our 
two-pronged strategy. However, as previously pointed out, minor modifications can be 
missed when generating intact mass profiles, due to overlaps in the mass reconstructions 
when many isoforms and isobaric shifts are present [16]. To avoid missing small changes 
in PTMs and demonstrate proof of principle, histones H2A and H4 were also subjected to 
the next step of our analytical strategy. After propionylation and tryptic digestion, each 
histone fraction was injected in triplicate for abundance profiling. The nano LC-MS raw 
data files were then converted into peptide maps for clustering analysis. All peptide 
clusters from each condition were exported to an Excel spreadsheet for direct 
comparison. Scatter plots of peptide intensity enable the rapid identification of histone 
peptide ions showing differential abundance between two sample sets. For histones H2A, 
H2B, and H4, no PTMs were found differentially expressed among WT and mutant cells. 
Only histone H3 showed differentially expressed histone peptides. Scatter plots of H3 
peptides derived from WT and either rtt109Δ or asf1Δ mutants are shown in figure 3.6. 
The scatter plot for the yeast mutant strain rtt109Δ indicated that almost all identified 
peptide ions had no statistically significant change in ion intensities compared to those of 
the WT strain (figure 3.6a).  The only notable exception (solid diamond) was observed 
for a doubly-protonated peptide ion at m/z 638.9+2 showing a 79-fold decrease in ion 
abundance in the yeast mutant strain rtt109Δ.  This ion was subsequently identified as 
tryptic peptide FQKSTELLIR bearing an acetylated K56 residue (see below). The 
reconstructed ion chromatograms (RIC) demonstrated that this peptide ion was highly 
abundant in the H3 sample from WT cells, but was almost completely absent in histones 
derived from the two mutant yeast strains (inset figure 3.6a). The scatter plot obtained for 
the comparison of histone H3 from asf1Δ mutant and WT strains (figure 3.6b) showed an 
ion abundance profile similar to that observed for the yeast mutant strain rtt109Δ.  Again, 
the only statistically significant change in ion abundance observed was for m/z 638.9+2, 
where we observed a 153-fold decrease in acetylation, while all other ions showed no 
change in abundance. The RIC of the corresponding ions showed similar profiles to those 
of the mutant strain rtt109Δ (figure 3.6b inset).  
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Figure 3.6: Scatter plots of ion distribution from nano LC-MS analyses of histone 
peptides from WT, rtt109Δ, and asf1Δ mutant cells. All data points plotted from triplicate 
nano LC-MS analyses with p-values of < 0.05. Peptides with an assigned MS/MS 
spectrum are denoted by diamonds for the H3 fraction, triangles for the H4 and H2A 
fractions, and squares for the H2B fraction. (a) Comparison of histone peptides from WT 
and rtt109Δ mutant cells. (b) Comparison of histone peptides from WT and asf1Δ mutant 
cells. The data point denoted by a solid diamond is a differentially abundant histone 
peptide containing a K56ac residue derived from histone H3. Conversely, the data point 
denoted by a solid circle corresponds to a propionylated K56 residue that exhibited no 
difference in abundance. Insets correspond to the RIC for m/z 638.9+2 corresponding to 
the H3K56ac tryptic peptide. 
 
Nano LC-MS/MS analysis of significant outliers was performed to obtain peptide 
sequences and determine their PTMs. Tandem MS sequencing of the ion at m/z 638.9+2 
revealed this to be H3K56ac peptide, a histone H3 peptide containing an acetylated lysine 
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56 (K56) residue; the MS/MS fragmentation produced an almost complete y ion series 
(figure 3.7a). In contrast, the ion at m/z 703.4+2 was determined to be equally abundant in 
histones from WT and mutant cells (figure 3.6a and b), and corresponds to a histone H3 
peptide containing a monomethylated and propionylated K79 residue (figure 3.7b). 
Mascot searches revealed that the rest of the outliers in the scatter plots were in fact non-
histone proteins (for example, yeast peptides derived from transposon Ty1-DR1) that 
were coextracted with histones during sample preparation. 
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Figure 3.7: Histone peptide sequencing by tandem mass spectrometry. (a) MS/MS 
spectrum of m/z 638.9+2 identified as an H3K56ac peptide. (b) MS/MS spectrum of m/z 
703.4+2 revealed a monomethylated (and propionylated) K79 residue in histone H3.  
 
Interestingly, the peptide FQKSTELLIR comprising a propionylated K56 residue, 
hence a free ε-amino side chain in the native H3 histone, was also observed in high 
abundance in the tryptic digests of all yeast strains.  No other modified form of the K56 
side chain (e.g. methylation, ubiquitylation, etc.) was detected in our histone extracts. The 
scatter plots of ion abundance (figures 3.6a and b) indicated that the peptide with a free 
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K56 ε-amino group showed a variation of less than 27% between the mutant and WT 
strains. The variability in the type of modification observed for K56 suggests that only a 
minor subpopulation of histone H3 bear an N-acetylated side chain residue. To determine 
with higher precision the stoichiometry of H3 K56 acetylation in both WT and rtt109Δ 
strains, free NH2 groups on a separate extract of histone H3 were derivatized using D6-
acetic anhydride, and the corresponding tryptic digests were analyzed by nano LC-
MS/MS using positive ion MRM mode on an API 4000 Q-Trap mass spectrometer. The 
abundance ratio obtained from these targeted LC-MS/MS experiments revealed that in 
vivo acetylation of K56 accounts for 17% of all histone H3 molecules in the WT strain 
whereas this proportion decreased to only 0.4% in the rtt109Δ strain (data not shown). 
Accordingly, the present ion profiling approach enabled the identification of 
stoichiometric changes in modifications representing only 17% of all H3 histones. The 
abundance changes and modification sites determined for all core histones are 
summarized in figure 3.8 for yeast histones derived from WT, rtt109Δ and asf1Δ mutant 
strains. 
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Figure 3.8: Modification maps and corresponding fold-changes in all the core histone 
PTMs detected in our analysis. The only modification that was differentially expressed 
was H3K56ac. The other modifications detected showed equal expression. Gray bars 
correspond to the relative abundance of histone PTMs in WT versus asf1Δ mutant cells. 
Black bars correspond to the relative abundance of histone PTMs in WT versus rtt109Δ 
mutant cells. ac: acetyl-lysine. me, me2, me3: mono-, di- and trimethyl-lysine. 
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3.5 Conclusion 
 
The use of ion profiling and data mining approaches enabled the identification of 
K56ac as the only histone H3 modification site targeted by the histone acetyltransferase 
Rtt109 and the histone chaperone Asf1. Mutant strains lacking the acetyltransferase 
Rtt109 or the histone-binding protein Asf1 showed minimal K56ac, representing 
typically 0.4% of all H3 histones. None of the other histone PTMs examined substantially 
changed in abundance between WT and mutant cells (figure 3.8). H3K56ac showed a 79- 
and 153-fold increase in WT cells compared with histone H3 from rtt109Δ and 
asf1Δ cells, respectively. This difference may not be significant because the residual 
levels of H3K56ac in both mutant strains were very low and near the limit of detection of 
MS instrumentation, making it difficult to assess their abundance with high accuracy.  
 
Identifying and profiling changes in histone modifications can be a daunting and 
challenging task. The methodology presented here is a rapid, comprehensive, and reliable 
procedure to profile and quantitate changes in the abundance of many histone 
modifications using scatter plots of ion distribution. The use of the MassSense peptide 
miner software developed in-house allows the generation of peptide maps for convenient 
clustering of ion abundance across sample replicates and conditions, thereby reducing the 
manual interpretation of large LC-MS data sets. This data mining approach can be used 
to identify differentially abundant modifications that can be subsequently validated using 
targeted analysis with isotope labeling and MRM. Among the plethora of ions generated 
by tryptic digestion, histone peptides could be identified and their relative abundance 
quantified in a reproducible fashion. Without the need for extensive sample preparation 
or peptide labeling, our generic profiling approach can be exploited in any scenario 
requiring a comparison of the relative abundance of histone PTMs in different samples. 
First, as illustrated here, our method is suitable to pinpoint which of the many known 
histone PTM sites are significantly affected by mutation of histone-modifying enzymes 
or other proteins. This approach will be very helpful to define the in vivo substrates of 
histone modifying enzymes. These findings should obviously be verified with in vitro 
enzyme assays to confirm that the changes in PTM abundance identified by MS are not 
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indirect effects of the mutation of a given histone-modifying enzyme. Second, our 
method makes it relatively straightforward to compare and contrast histone PTMs under 
two physiological conditions (e.g. control cells and cells treated with cancer 
chemotherapeutic agents). Third, our method may prove useful to profile global changes 
in histone PTMs during cell cycle progression or other changes in cell physiology. 
Finally, using tandem affinity purification strategies, it is now relatively simple to purify 
complexes of chromatin-modifying enzymes bound to their histone substrates. Our 
profiling method could be helpful to identify histone PTMs that are specific to certain 
chromatin-modifying enzymes. 
 
3.6 Acknowledgment 
 
IRIC receives infrastructure support funds from the Fonds de la Recherche en Santé 
du Québec (FRSQ) and from a Canadian Institutes for Health Research (CIHR) multi-
resource grant. This work was carried out with the financial support of operating grants 
from the National Science and Engineering Research Council (NSERC) Strategic Grant 
Initiative (PT), the Canada Research Chair (AV, PT), and the CIHR (AV). 
 
 
 
 
 
 
 
 
 
 
 
 
 82
3.7 References 
 
1. Davey, C.A., et al., Solvent mediated interactions in the structure of the 
nucleosome core particle at 1.9 a resolution. J Mol Biol, 2002. 319(5): p. 1097-
113. 
 
2. Robinson, P.J. and D. Rhodes, Structure of the '30 nm' chromatin fibre: a key role 
for the linker histone. Curr Opin Struct Biol, 2006. 16(3): p. 336-43. 
 
3. Mersfelder, E.L. and M.R. Parthun, The tale beyond the tail: histone core domain 
modifications and the regulation of chromatin structure. Nucleic Acids Res, 
2006. 34(9): p. 2653-62. 
 
4. Zhang, L., et al., Identification of novel histone post-translational modifications 
by peptide mass fingerprinting. Chromosoma, 2003. 112(2): p. 77-86. 
 
5. Kouzarides, T., Chromatin modifications and their function. Cell, 2007. 128(4): p. 
693-705. 
 
6. Jenuwein, T. and C.D. Allis, Translating the histone code. Science, 2001. 
293(5532): p. 1074-80. 
 
7. Jones, P.A. and S.B. Baylin, The epigenomics of cancer. Cell, 2007. 128(4): p. 
683-92. 
 
8. Altucci, L., et al., Acute myeloid leukemia: therapeutic impact of epigenetic 
drugs. Int J Biochem Cell Biol, 2005. 37(9): p. 1752-62. 
 
9. Johnson, L., et al., Mass spectrometry analysis of Arabidopsis histone H3 reveals 
distinct combinations of post-translational modifications. Nucleic Acids Res, 
2004. 32(22): p. 6511-8. 
 
10. Zhang, K., et al., Histone acetylation and deacetylation: identification of 
acetylation and methylation sites of HeLa histone H4 by mass spectrometry. Mol 
Cell Proteomics, 2002. 1(7): p. 500-8. 
 
11. Pesavento, J.J., et al., Shotgun annotation of histone modifications: a new 
approach for streamlined characterization of proteins by top down mass 
spectrometry. J Am Chem Soc, 2004. 126(11): p. 3386-7. 
 
12. Thomas, C.E., N.L. Kelleher, and C.A. Mizzen, Mass spectrometric 
characterization of human histone H3: a bird's eye view. J Proteome Res, 2006. 
5(2): p. 240-7. 
 
 83
13. Kamakaka, R.T. and S. Biggins, Histone variants: deviants? Genes Dev, 2005. 
19(3): p. 295-310. 
 
14. Dokmanovic, M. and P.A. Marks, Prospects: histone deacetylase inhibitors. J 
Cell Biochem, 2005. 96(2): p. 293-304. 
 
15. Kelly, W.K., et al., Phase I study of an oral histone deacetylase inhibitor, 
suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol, 
2005. 23(17): p. 3923-31. 
 
16. Zhang, L., et al., Differential expression of histone post-translational 
modifications in acute myeloid and chronic lymphocytic leukemia determined by 
high-pressure liquid chromatography and mass spectrometry. J Am Soc Mass 
Spectrom, 2004. 15(1): p. 77-86. 
 
17. Garcia, B.A., et al., Pervasive combinatorial modification of histone H3 in human 
cells. Nat Methods, 2007. 4(6): p. 487-9. 
 
18. Mikesh, L.M., et al., The utility of ETD mass spectrometry in proteomic analysis. 
Biochim Biophys Acta, 2006. 1764(12): p. 1811-22. 
 
19. Knapp, A.R., et al., Quantitative profiling of histone post-translational 
modifications by stable isotope labeling. Methods, 2007. 41(3): p. 312-9. 
 
20. Ong, S.E., G. Mittler, and M. Mann, Identifying and quantifying in vivo 
methylation sites by heavy methyl SILAC. Nat Methods, 2004. 1(2): p. 119-26. 
 
21. Smith, C.M., et al., Mass spectrometric quantification of acetylation at specific 
lysines within the amino-terminal tail of histone H4. Anal Biochem, 2003. 316(1): 
p. 23-33. 
 
22. Su, X., et al., Histone H4 acetylation dynamics determined by stable isotope 
labeling with amino acids in cell culture and mass spectrometry. Anal Biochem, 
2007. 363(1): p. 22-34. 
 
23. Zhu, H., et al., Residue-specific mass signatures for the efficient detection of 
protein modifications by mass spectrometry. Anal Chem, 2002. 74(7): p. 1687-94. 
 
24. Beck, H.C., et al., Quantitative proteomic analysis of post-translational 
modifications of human histones. Mol Cell Proteomics, 2006. 5(7): p. 1314-25. 
 
25. Syka, J.E., et al., Novel linear quadrupole ion trap/FT mass spectrometer: 
performance characterization and use in the comparative analysis of histone H3 
post-translational modifications. J Proteome Res, 2004. 3(3): p. 621-6. 
 
 84
26. Hake, S.B., et al., Expression patterns and post-translational modifications 
associated with mammalian histone H3 variants. J Biol Chem, 2006. 281(1): p. 
559-68. 
 
27. Tsubota, T., et al., Histone H3-K56 acetylation is catalyzed by histone chaperone-
dependent complexes. Mol Cell, 2007. 25(5): p. 703-12. 
 
28. Pan, X., et al., A robust toolkit for functional profiling of the yeast genome. Mol 
Cell, 2004. 16(3): p. 487-96. 
 
29. Celic, I., et al., The sirtuins Hst3 and Hst4p preserve genome integrity by 
controlling histone H3 lysine 56 deacetylation. Curr Biol, 2006. 16(13): p. 1280-
9. 
 
30. Poveda, A., et al., Hif1 is a component of yeast histone acetyltransferase B, a 
complex mainly localized in the nucleus. J Biol Chem, 2004. 279(16): p. 16033-
43. 
 
31. Bonneil, E., et al., Proceedings of the 55th ASMS conference, Indianapolis, IN, 
June 3-7, 2007. 2007. 
 
32. Song, O.K., et al., An Nalpha-acetyltransferase responsible for acetylation of the 
N-terminal residues of histones H4 and H2A. J Biol Chem, 2003. 278(40): p. 
38109-12. 
 
33. Garcia, B.A., et al., Characterization of phosphorylation sites on histone H1 
isoforms by tandem mass spectrometry. J Proteome Res, 2004. 3(6): p. 1219-27. 
 
34. Garcia, B.A., et al., Chemical derivatization of histones for facilitated analysis by 
mass spectrometry. Nat Protoc, 2007. 2(4): p. 933-8. 
 
35. Luger, K., et al., Characterization of nucleosome core particles containing 
histone proteins made in bacteria. J Mol Biol, 1997. 272(3): p. 301-11. 
 
36. Maas, N.L., et al., Cell cycle and checkpoint regulation of histone H3 K56 
acetylation by Hst3 and Hst4. Mol Cell, 2006. 23(1): p. 109-19. 
 
37. Thaminy, S., et al., Hst3 is regulated by Mec1-dependent proteolysis and controls 
the S phase checkpoint and sister chromatid cohesion by deacetylating histone H3 
at lysine 56. J Biol Chem, 2007. 282(52): p. 37805-14. 
 
 
 
 
 
 
 
 
 
 
4.  Enhanced Protein Detection Using a Trapping Mode 
on a Hybrid Quadrupole Linear Ion Trap (Q-Trap) 
 
 
 
 
Paul Drogaris, J.C. Yves Le Blanc, Jennifer E. Fitzgerald, Noel F. Lowndes, 
Alain Verreault, and Pierre Thibault     
Analytical Chemistry, 2009, Aug 1; 81 (15): 6300-6309 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86
4.1 Abstract 
 
A novel method to improve the detection of protein ions using a linear ion trap 
mass spectrometer is presented.  A scan function combining charge separation with 
segmented transmission of multiply charged ions was developed to enhance the 
sensitivity and resolution of the linear ion trap for the nanoLC-MS analysis of intact 
proteins.   The analytical benefits of the present method are particularly apparent in 
protein analyses, where the increased proportion of multiply charged ions can exacerbate 
space-charge effects and compromise the dynamic range of the linear ion trap instrument. 
The enhanced ion storage and charge separation capabilities of our targeted and enhanced 
multiply charged scan mode provided a 4-fold increase in signal-to-noise and 5-fold 
increase in resolution, thus enabling the detection of closely related protein isoforms. The 
application of this method is demonstrated for low femtomole detection of protein 
standards and nuclear extracts enriched in histone proteins. The enhanced resolution of 
this scan mode also enabled us to monitor subtle changes in the methylation of a 
subpopulation of histone H3 that occurs in chicken DT40 cells lacking specific 
methyltransferase activity. The extent of the fold change and PTM site localization was 
performed using predictive software tools and targeted multiple reaction monitoring 
analysis of histone peptides. Monomethylation of Lys 79 in histone H3 (H3K79me1) was 
down-regulated by 240-fold in methyltransferase deficient cells. 
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4.2 Introduction 
 
The proteome of eukaryotic cells is relatively complex and further diversified by 
over 200 possible post translational modifications (PTM) [1]. Proteomics consists in 
applying global experimental approaches to determine the biological function of proteins 
[2]. Mass spectrometry (MS) is now the method of choice to characterize the proteins 
present in cells and tissues due to its speed, sensitivity, and selectivity.  Two MS 
strategies can be utilized to characterize proteins and their PTM, namely the “bottom-up” 
[3, 4] and the “top-down” approaches [5, 6]. The bottom-up strategy consists of 
performing enzymatic and chemical digestion of protein slices from SDS-polyacrylamide 
gels or HPLC fractions using enzymes or chemicals that cleave the polypeptide chain at 
specific amino acid residues. This is followed by MS analysis to establish a peptide mass 
fingerprint, and tandem MS to determine sequence information. In the “top-down” 
strategy, the intact protein is introduced directly into the gaseous phase prior to mass 
analysis; fragmentation of the whole protein ions gives rise to sequence information. 
 
When studying the vast array of PTM, initial MS profiling of intact proteins from 
cellular extracts can provide a rapid overview of the types and extent of post-translational 
modifications. Covalent protein modifications such as methylation, acetylation, and 
phosphorylation can be inferred by the observations of common mass shifts (+14, +42, 
and +80 Da, respectively) in the deconvoluted mass spectrum. There are numerous types 
of instrumentation available for MS-based proteomic profiling. These include: time-of-
flight (TOF), Q-TOF, ion trap, Orbitrap, and Fourier transform ion cyclotron resonance 
(FT-ICR) [7, 8]. The use of FT-ICR is the gold standard for performing intact protein 
analysis due to its high mass resolution and accuracy. More recently, the profiling of 
intact proteins and the identification of partial sequences using collision activated 
dissociation (CAD) and multistage activation have been reported using hybrid LTQ-
Orbitrap MS [9]. Q-TOF instruments with medium range resolution have also been used 
successfully [10-12] to study intact proteins and generate sequence tags from MS/MS 
data. Ion traps modified to perform ion-ion reactions in the gas phase for charge state 
reduction of intact proteins [13-15] have shown to be a robust and low-cost alternative to 
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FT-ICR and Orbitrap mass analyzers for whole protein analysis. However, high-end 
resolution instruments are not always available in most analytical laboratories, leaving 
researchers to multitask the usage of instrumentation at hand. 
 
Ion trap instruments that have a small footprint, rapid acquisition rate, and provide 
good sensitivity are ideal instruments for performing quick, preliminary PTM screening 
on intact proteins. An earlier report by Claverol and colleagues [16] demonstrated that 
intact proteins eluted from 1- and 2-D gels could be stored and detected using an LCQ 
deca ion trap instrument. However, the detection levels were significantly high, and the 
samples analyzed were model standard proteins of low complexity. Although the mass 
spectrometer could generate enough resolution to identify single isoforms of unmodified 
proteins, a sample of higher complexity containing many PTM would have been too 
challenging to characterize and distinguish all the components present.  Historically, the 
use of ion traps for intact protein analysis has been limited by two factors: low mass 
resolution and space-charge effects. Protein charge state determination is not possible due 
to the low resolution of the instrument. Trapping capacity is hampered by introducing a 
high number of multiply charged protein ions in a limited physical area, leading to space- 
charge. This last phenomenon has been extensively studied [17-19] to understand its 
detrimental effects on mass analysis, which include apparent shifts in m/z ratio, peak 
broadening, and loss of ion signal.  
 
The introduction of two dimensional (2-D) linear ion traps (LITs) [20, 21] has 
offered a new technology for investigating intact proteins due to their increased ion 
storage capacity and faster scan rates for resonance ejection of ions. For example, Reid 
and colleagues [22] performed top-down analysis and sequencing of Staphylococcus 
aureas aldolase site-directed mutagenesis products using an LTQ ion trap instrument. 
While this study was impressive in showing the capabilities of the instrument, a relatively 
simple mixture was interrogated, and no analysis was performed on an LC time scale. 
Another study by Hunt and colleagues [23] was performed on intact ubiquitin, bovine 
serum albumin (BSA), and large histone peptides from Glu-C digestion using an LIT 
with electron transfer dissociation (ETD) capability. This demonstrated the ability of 
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these instruments to contain and detect simple protein or peptide mixtures with on-line 
LC-MS. A recent report by Kelleher and colleagues [24] was one of the few studies that 
established the ability of LITs to analyze intact yeast proteins fractionated from whole 
cell lysates by on-column chromatography.  
 
The 4000 Q-Trap, a hybrid quadrupole linear ion trap, is another mass 
spectrometer that can be used to profile intact proteins for rapid PTM screening. The 
third quadrupole on this instrument serves as both a conventional RF/DC resolving mass 
filter and a 2-D LIT using axial ion ejection [25]. The scanning and trapping capabilities 
present on the same instrument result in versatile scan modes that are very useful in 
proteomics applications [26], such as precursor ion, constant neutral loss, and enhanced 
multiply charged (EMC) scan. The EMC scan mode enables elimination of singly 
charged ions from the LIT prior to mass analysis. Originally developed on conventional 
triple quadrupole and Q-TOF instruments [27, 28], the charge state separation can be 
performed in the LIT once analyte ions are trapped and thermalized. Adjustment of the 
DC voltage on the LIT exit lens or IQ3 results in the preferential release of singly 
charged ions, while multiply charged species are retained in the linear trap prior to mass 
analysis. The removal of singly charged species can result in higher signal-to-noise ratios 
and mass spectra with less chemical noise, while simultaneously reducing space-charge 
effects.  In essence, the LIT is filled to its maximum analytical capacity with ions of 
interest, in this particular case, multiply charged ions. 
 
In this report, we describe a novel trapping method on the 4000 Q-Trap based on 
a targeted EMC (tEMC) to capture and detect intact protein ions in the LIT with 
increased mass resolution and dynamic range compared to conventional scanning and 
trapping functions. This was accomplished by modifying a conventional scan function, 
and selecting narrow m/z regions sequentially into the LIT followed by charge separation 
to minimize the presence of singly charged ions prior to mass analysis and detection. 
Model compounds and cellular extracts were used to optimize MS parameters, 
benchmark performance, and establish figures of merit. The analysis of histone proteins 
from complex cellular extracts by LC-MS is used to illustrate the utility of the tEMC scan 
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mode to generate molecular mass profiles for rapid screening of changes in PTM 
abundance in intact proteins from different sample sets.  Finally, targeted peptide 
detection and sequencing using predictive software tools on the same instrumental 
platform was performed to localize and quantitate differentially expressed histone PTM. 
 
4.3 Experimental Section 
 
4.3.1 Reagents and Separation Media 
 
Protein concentrations in cell extracts and fractionated samples were measured 
using the micro-BCA assay kit (Pierce, Rockford, IL). Microbore HPLC C18 columns 
(150 mm x 1 mm i.d.) for histone fractionation were purchased from Phenomenex 
(Torrance, CA). Capillary LC-MS columns were packed in-house using Jupiter C18 
particles, (300 Å, 3 µm, Phenomenex) and fused-silica tubing (Polymicro Technologies, 
Phoenix, AZ). Trapping columns were packed in-house using Jupiter C18 material in 
Teflon tubing (Supelco, Bellefonte, PA). Solvents for instrumental analysis were all 
HPLC grade (Thermo Fisher Scientific, Whitby, ON, Canada and Milli-Q water, in-
house). Trifluoroacetic acid (TFA), ammonium bicarbonate, apomyoglobin, cytochrome 
C, leucine enkephalin, and propionic anhydride were purchased from Sigma (Oakville, 
ON, Canada). Formic acid (FA) was obtained from EM Science (Mississauga, ON, 
Canada).  Porcine modified trypsin (sequencing grade) was obtained from Promega 
(Madison, WI). 
 
4.3.2 Histone Purification 
 
Recombinant yeast histone H3 (rH3) was expressed and purified under denaturing 
conditions as previously described [29] . Histones were isolated by acid extraction from 
wild-type and DOT1L-deficient chicken DT40 cells using the protocol described by Hake 
and colleagues [30]. Using reversed phase HPLC, rH3 in 8M urea was fractionated 
several times to concentrate and purify the histone. The protein content was determined 
using the micro-BCA assay, with BSA as the calibration standard. Using this assay, the 
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concentration of rH3 was 142 ng/µL. The rH3, as well as histones partially purified from 
wild-type (WT) and DOT1L-deficient cells, were diluted with the initial mobile phase 
and injected directly onto the LC-MS for analysis. The chicken histone samples were 
fractionated and prepared as outlined in a previous report [31]. Briefly, core chicken 
histones from DT40 cells were purified in the same manner by reversed phase HPLC 
(~10 µg total protein).  Individual histone fractions of DT40 cells were dried in a 
SpeedVac evaporator, derivatized with propionic anhydride, and digested overnight at 
37° C using 1 µg of trypsin. Enzymatic digests were acidified with 5% TFA in water 
(v/v) prior to LC-MS analysis.  
 
4.3.3 Mass Spectrometry 
 
All infusion and LC-MS experiments were carried out on an AB/MDS Analytical 
Technologies 4000 Q-Trap hybrid quadrupole-LIT instrument, equipped with the 
Nanospray II ion source, and controlled through Analyst 1.4 software.  For the 
conventional quadrupole experiment, the Q3 mode was used and scanned from m/z 400 – 
1600. The conventional Enhanced MS (EMS) and Enhanced Multiply Charged (EMC) 
modes were performed in a looped experiment while monitoring m/z 400 – 1600 at 1000 
amu/sec, with an LIT fill time of 20 msec. The targeted EMC (tEMC) scan is essentially 
EMC controlled through the MS3 method editor. This scan mode is a modified EMC scan 
function that provides control of the Q1 resolution as well as the center of mass of the 
transmission window. All tEMC scans were performed with Q1 set to open resolution 
using an 8 volt offset, thus providing uniform transmission windows of ~ 150-200 m/z 
units through Q1. The original MS3 method table (.mtb) was modified to allow for ion 
cooling as RF levels are lowered prior to charge separation in the LIT and finer 
adjustment of the multiple charge separation (MCS) voltage using the collision energy 
spread (CES parameter) within the MS3 mode. All tEMC parameters, scan ranges, and 
LC-MS data acquisition was controlled using the MS3 method editor.  Mass ranges from 
m/z 400 to 1600 in 200 m/z  increments were entered once in the tEMC method editor, 
and used for infusion and LC-MS experiments. No other manual set-up was required.  A 
total of five narrow m/z windows were introduced and mass analyzed sequentially to 
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monitor from m/z 400 to 1600 in a looped fashion to cover the multiply charged state 
distribution of proteins ions. The MCS voltage and Q3 empty time (both controlled by 
CES parameter and excitation time in MS3) were set to 0.8 volts and 200 msec, 
respectively. 
 
Peptide detection and sequencing were performed on the same instrumental 
platform. Chicken histone H3 amino acid sequences from the Swiss-Prot database were 
imported into AB/MDS Analytical Technologies MRM pilot software. The four most 
intense b and y fragment ions were chosen to generate theoretical MRM transitions in 
Analyst software. The masses of the precursor ions containing chemically modified 
(propionylated) H3 peptides were calculated using molecular weight calculator 6.4 
(http://ncrr.pnl.gov/software/). A 10 ms dwell time was used to monitor the multiple 
reaction monitoring (MRM) transitions. The MRM experiment was followed by an 
enhanced product ion (EPI) scan in information dependant acquisition (IDA) mode to 
confirm the sequence of the detected peptides using the MIDAS strategy. EPI scan was 
monitored at 1000 amu/sec, with a fixed LIT fill time of 25 ms and Q0 trapping switched 
on. 
 
4.3.4 NanoLC-MS of Intact Histones 
 
Yeast rH3 and crude histone extracts from WT and DOT1L-deficient chicken 
DT40 cells were serially diluted from 50 ng/µL down to 1 ng/µL using the initial LC-MS 
mobile phase [95:5 water:acetonitrile, 0.2% FA (v/v)]. The Agilent 1100 series HPLC 
system with dynamic flow splitting was used as the separation module. An aliquot was 
injected onto a C18 trapping column (4 mm x 360 µm i.d.) for 3 min at 10 µL/min. 
Isolated proteins were eluted onto a  C18 analytical column (100 mm x 150 µm i.d.) at 600 
nL/min using a solvent system of 0.2% FA in water (A), and 0.2% FA in acetonitrile (B). 
Gradient elution was performed from 5 to 80% B in 80 min. Intact histone mass profiles 
were generated from acquired mass spectra using Bayesian protein reconstruction in 
BioAnalyst tools 1.4.  
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4.3.5 NanoLC-MS of Histone Tryptic Peptides 
 
Histone tryptic peptides from WT and DOT1L mutant were analyzed using the 
same chromatographic system, columns, and mobile phases as outline above. Gradient 
elution was performed from 0 to 50% B in 60 min. Samples were injected a single time 
for the MIDAS strategy, and in triplicate using MRM only for quantitation, after the 
peptide ion transitions and sequences were confirmed. 
 
4.4 Results and Discussion 
 
4.4.1 Trapping Mode Conceptualization 
 
Quadrupole ion traps have the ability to trap and scan analytes sharing the same 
physical space. However, there is a practical limit on the number of ions that can be 
stored in ion traps before distortion of the electric fields and decreased performance is 
observed due to space-charge effects. To circumvent this, features such as automatic gain 
control (AGC) and dynamic fill time (DFT) were implemented to provide optimum ion 
storage capacity for trapping instruments. AGC and DFT can be applied efficiently for 
small molecules and peptides, whose charge density is relatively small, but are far more 
problematic to implement for multiply charged protein ions, where space-charge effects 
readily override the benefits of AGC and DFT. Thus, introducing too many ions of 
different charge states into the trapping device is a major hurdle in the analysis of intact 
protein ions. This prompted us to develop the current capture and detection strategy on 
the 4000 Q-Trap, the concept of which is outlined in figure 4.1. The voltage ramping and 
duty cycle time allocation for each part of the tEMC scanning sequence are shown in 
figure 4.1a. After introducing and cooling the ions, the exit lens voltage is lowered to 
evacuate singly charged species (charge separation).  This voltage is controlled via the 
MCS parameter, which is expressed as the potential difference between the exit lens and 
the Q3 rod offset.  After the charge separation step, the auxiliary AC and RF drive are 
ramped simultaneously for mass selective axial ejection of ions (mass analysis).  Finally, 
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any residual ions trapped in the system are emptied from the LIT prior to the next fill 
step.  The functional aspects of the tEMC scanning mode are depicted in figure 4.1b. 
First, a fraction of the ions generated at the source are introduced into the LIT by gating 
them with the first quadrupole, where the resolution is set to open, and maximum voltage 
offset (8 V). This allows for a narrow yet uniform m/z window to be transmitted (~ 150-
200 m/z units) into the LIT. This m/z region is the result of using an 8 volt offset on Q1, 
and is the maximum m/z window that can be transmitted. This process is repeated five 
times within the MS3 method editor in a looped experiment to obtain enough narrow 
regions to cover the m/z range of interest (m/z 400 – 1600) and generate a complete mass 
spectrum. Once thermalized, singly charged species are evacuated from the LIT by 
applying an MCS of 0.8 V at the exit lens of the LIT. The MCS acts an energy “barrier” 
that is proportional to the charge state of the ion (i.e., energy ‘barrier’ = z x MCS). Hence, 
singly charged species experience a lower energy barrier and are evacuated first, while 
higher charge states will remain in the LIT at the same applied MCS potential difference. 
Once charge separation is completed, the remaining multiply charged species are scanned 
out of the LIT. The acquired mass spectral segments are then summed together in Analyst 
software to generate a full mass spectrum, and Bioanalyst tools are used to generate the 
molecular mass profile. The overall ion population during the scanning sequence is 
shown in figure 4.1c, illustrating that the number of singly charged ions is significantly 
decreased at each stage of the scanning sequence, thereby minimizing the overfilling of 
the ion trap and space-charge effects. The total capture and release of all ion species, both 
singly and multiply charged, is not possible; there is a loss of both types of species. 
However, singly charged ions are preferentially released, and their abundance is 
significantly reduced compared to multiply charged ions. 
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Figure 4.1: Overview of the ion trapping strategy for the targeted enhanced multiply 
charged (tEMC) scanning mode.  (a) Schematic diagram of the Q-trap instrument and 
potential energy diagram for different lenses across the path of ions undergoing charge 
separation. (b)  Schematic representation of segmented tEMC scan illustrating the 
transmission of narrow m/z regions, MCS separation, molecular mass reconstruction. (c) 
Distribution of singly (circles) and multiply charged ions (triangles) over the scanning 
time.  
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4.4.2 MCS Voltage Optimization and Space-Charge Effects 
 
During the initial phase of development, we used conventional scan modes to 
determine if charge separation could be applied to intact proteins showing a distribution 
of multiply charged ions. These scan modes performed efficiently during infusion 
experiments and small scale optimization, but were significantly compromised during 
nanoLC-MS experiments. Figure 4.2a depicts the MCS voltage optimization using 
apomyoglobin (0.5 pmol/μL) as a model protein, spiked with 1 ng/μL of the singly 
charged leucine enkephalin (LE).  The MCS was varied in 0.1 V increments, and 10 
MCA scans were acquired for each value. The intensity of the [M+25H]25+ ion from 
apomyoglobin ions (m/z 679) is plotted along with the [M+H] + (m/z 556) for LE. At low 
MCS values, the abundance of the m/z 556 for LE was significantly reduced during the 
infusion. As observed in Figure 4.2a, there is a critical voltage range between 0.7 and 0.8 
V, where the apomyoglobin ions dominated the mass spectrum. The abundance of the LE 
ions increased rapidly beyond 0.9 V, resulting in progressively reduced charge 
separation. We used an optimized MCS voltage of 0.8 V in subsequent nanoLC-MS 
experiments.  
 
The performance of the EMC detection mode for the nanoLC-MS analysis of 
intact proteins was evaluated for an acid extract of chicken histones and compared to that 
of a conventional quadrupole scan. Figure 4.2b shows the nanoLC-MS analysis of a 100 
ng injection of intact chicken histones using a conventional Q3 scan. This scan mode was 
used for comparison purposes to provide an unaltered representation of the ion population 
without space-charge effects, while keeping transmission conditions through the ion 
optics (including collision cell) constant. Core histone peaks eluted between 42 to 50 
minutes, with H4 and H2A eluting at 46 min, H2B at 47.5 min, and H3 at 50 min. The 
mass spectrum for the H3-containing peak, denoted by *, is shown as an inset to figure 
4.2b. When the same sample was analyzed using the conventional EMC scan mode, there 
was a significant loss in sensitivity, and no histone protein ions were detected (figure 
4.2c). The inset of Figure 4.2c shows the mass spectrum taken at the same elution time as 
in Figure 4.2b and illustrates that no envelope of histone H3 protein ions could be clearly 
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discerned under conventional LIT trapping. Similar effects were observed using 
enhanced MS (EMS). Because no ion gain control is implemented for the EMC scan, 
nanoLC-MS introduces a large number of ions of all charge states simultaneously into the 
LIT, leading to a loss of the multiply charged ion current during the elution of histones. 
This was evident from an overall decrease in ion current at 40 min with the elution of 
more abundant proteins (figure 4.2c). Using complex protein extracts, the amount of 
other components present, as well as the flux of singly charged species entering the LIT, 
is unknown. An extensively purified protein sample of known concentration was required 
to evaluate the onset of space-charge and understand the ion capacity and instrumental 
limits of the EMC mode. For these reasons, we compared the ion chromatograms and 
mass spectra of purified recombinant yeast histone H3 (rH3) and equine cytochrome C 
(Cyt C), whose protein concentrations were accurately determined. 
 
 
 
Figure 4.2: MCS voltage optimization and nanoLC-MS analysis using the conventional 
EMC scanning mode. (a) Changes in ion intensity for the [M+25H]25+ ion from 
apomyoglobin (m/z 679) and the [M+H] + (m/z 556) of leucine enkephalin in response to 
incremental changes in MCS voltage. Total ion chromatograms of 100 ng of intact 
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chicken core histones from nanoLC-MS analysis using (b) Q3 and (c) conventional EMC 
scanning modes. Insets show mass spectra obtained from the peak denoted by *. 
 
 
4.4.3 Characterization of Protein Ion Profiles Using Q3 and tEMC Modes 
 
As indicated in the previous section, the relatively limited analytical performance 
of conventional EMC mode when charge state and ion flux cannot be determined 
accurately results in deleterious charge space-effects and reduced ion transmission. To 
overcome these limitations, we designed a modified EMC mode by changing the MS3 
method table to perform ion cooling and RF ramping before charge separation, and 
enable finer control of the MCS voltage. Instead of scanning the entire mass range all at 
once, we partitioned the effective scanning range into five regions of ~ 150-200 m/z units 
that were scanned in a sequential looped fashion. We prepared serial dilutions of Cyt C 
ranging from 0.01-60.0 ng/uL and analyzed them by nanoLC-MS using Q3 and tEMC 
modes. Panels a and b of figure 4.3 show a comparison of extracted mass spectra 
obtained from the nanoLC-MS analysis of 0.2 ng/μL (100 fmol injection) Cyt C using Q3 
and tEMC modes, respectively. Two salient features are immediately noticeable when 
comparing the two corresponding mass spectra. First, a higher noise level was observed 
from m/z 600 to 1100 in the Cyt C spectrum obtained with the Q3 scan (figure 4.3a).  
This contrasts with the tEMC mass spectrum where multiply charged ions were detected 
with higher signal-to-noise, while the absolute intensity of the analyte ions remained the 
same (figure 4.3b). Second, the full width at half-maximum (fwhm) is significantly larger 
for the Q3 scan compared to that of the tEMC acquisition (insets of Figure 4.3).  
Typically, we observed an overall reduction of 50% in fwhm in the tEMC scan compared 
with that of a conventional Q3 scan. The increased resolution observed for the tEMC 
scan is attributed in part to the segmented m/z range selected, although the scanning cycle 
period remained comparable in both modes (i.e., 3 s/cycle for the Q3 and tEMC modes). 
In Q3 scan, the instrument is scanning a larger m/z range and thus spending less effective 
time on detected ions, whereas the tEMC mode benefits significantly from the longer 
collection time of individual ions for each segment, resulting in more resolved mass 
spectral peaks. 
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Figure 4.3: Enhancement of resolution in nanoLC-MS analysis of cytochrome C using 
tEMC. Comparison of extracted mass spectra obtained from the nanoLC-MS analysis of 
0.2 ng/mL (100 fmol) of cytochrome C using (a) Q3 and (b) tEMC modes. Insets show 
the expanded view of the [M+15H]15+ region (m/z 816). 
 
The analytical performances of the Q3 and tEMC modes were further evaluated 
using rH3 to define practical limits of operation. The purified stock solution of rH3 was 
diluted serially to obtain protein concentrations of 0.2-20 ng/μL that were subsequently 
injected on the nanoLC-MS system. Extracted mass spectra obtained from the injection 
of 0.2 and 2 ng/μL are presented in figure 4.4. Mass spectra comparing the data collected 
in the Q3 and tEMC modes are shown in panels a and b of figure 4.4, respectively. An 
on-column sample loading of 1 ng of rH3 approached the detection limit of conventional 
Q3 scan, and the charge state envelope was interspaced with considerable background 
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and chemical noise (figure 4.4a). The molecular mass profile derived from the Q3 scan 
showed two prominent components at 15225 and 15268 Da.  The rH3 protein was 
purified from Escherichia coli and does not comprise any PTM [32]; hence, explaining 
the simple molecular mass profiles observed here compared to the extensive acetylation 
and methylation usually taking place on the wild-type histone H3 from other organisms. 
The expected average mass of yeast histone H3 without the initiator Met residue is 15225 
Da, in close agreement with that observed in figure 4.4a. The additional peak at 15268 Da 
is most likely a carbamylation artifact, because rH3 was isolated under denaturing 
conditions with 8 M urea prior to HPLC fractionation.  
 
 
 
 
Figure 4.4: Increased sensitivity in nanoLC-MS analysis of intact proteins using tEMC. 
Extracted mass spectra obtained from the on-column injection of 1 ng of recombinant 
yeast histone H3 (rH3) using (a) Q3 and (b) tEMC modes. Extracted mass spectrum for 
the on-column injection of 10 ng of rH3 using the (c) tEMC scanning mode. Insets show 
the reconstructed molecular mass profile for the corresponding mass spectrum. 
 
The analysis of the same sample using tEMC is shown in figure 4.4b and 
provided enhanced resolution and sensitivity compared to that of the Q3 scan (figure 
4.4a). This was clearly evidenced by a 4-fold increase in signal-to-noise and 5-fold 
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increase in resolution (inset figure 4.4b). Interestingly, when 10 times more rH3 was 
injected, not only was the tEMC scan mode able to contain and detect the intact protein 
ions, but a bias in ion distribution favoring lower charge state protein ions was also 
observed (figure 4.4c).  
 
To evaluate ion storage capacity of the LIT with respect to analyte concentration 
and space-charge limitations, we injected 10 ng of rH3 under nanoLC-MS conditions 
using fill times ranging from 2 to 500 ms. Figure 4.5a shows the changes in intensity for 
different multiply charged rH3 protein ions for the LIT fill times examined. Higher 
charge state ions ([M+22H]22+ at m/z 693 and [M+21H]21+ at m/z 726) showed a steady 
increase in ion abundance up to a fill time of 20 ms, after which a decline in intensity was 
observed. Conversely, lower charge state ions ([M+12H]12+ at m/z 1269 and [M+11H]11+ 
at m/z 1385) showed an extended linear progression in ion intensity up to 100 ms, 
followed with an abrupt decrease beyond this fill time period. It is noteworthy that the 
change in ion intensity was also accompanied by peak broadening and a shift in m/z 
values, which was more exacerbated for lower charge state ions (figure 4.5b). The 
proportional changes in m/z values resulted in a progressive increase of up to 4 Da in the 
apparent molecular mass of rH3 over fill times of 2 to 500 ms.  
 
The bias in the distribution of multiply charged ions according to fill time was 
unexpected given the uniform storage of ions in the LIT.  Indeed, the progressive increase 
in fill time is expected to provide a higher number of ions with a consistent distribution in 
multiply charged ions. However, when long fill periods increase the ion population 
beyond the capacity of the LIT (estimated to 105 ions for the 4000 Q-Trap), space-charge 
phenomena will have a more profound effect not only on ions of higher charge state, but 
also on those affected by the timing of the ejection and analysis sequence. For example, 
when Q1 is operated in RF-only mode, the LIT will typically store all ions from m/z 300-
3000, irrespective of the scan region selected. Ions below the lower boundary of the 
scanning region will be ejected prior to the acquisition of the selected m/z range. Because 
the analysis sequence acquires segments from low to high m/z values, ions of a higher 
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charge state will experience greater ion population and space-charge effects than those of 
lower charge state.  
 
 
Figure 4.5: Effect of space-charge on ion intensity and shift in m/z values using the 
tEMC scanning mode. Variation in (a) ion intensity and (b) m/z values with LIT fill time 
for different multiply charged protein ions of rH3 (n =1). (c) LIT fill times of 2 ms (top) 
and 500 ms (bottom) differentially affect peak broadening and m/z shifts for rH3 ions 
with a high number (+22, m/z 693, left) and lower number (+12, m/z 1270, right) of 
positive charges. 
 
This is illustrated in figure 4.5c for two scanning segments representing multiply 
protonated ions of rH3 with either 12 (m/z 1270) or 22 charges (m/z 693). As indicated, 
peak broadening and m/z shift are more significant for higher charge state ions as the fill 
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time is increased. Unlike EMS scan, where DFT can dynamically monitor the ion flux to 
avoid LIT overfilling, EMC does not possess this feature at the present time. The 
alternative taken in this work was to provide further control on the population of ions 
entering the LIT section by using Q1 as a high pass/low pass filter therefore transmitting 
a subset of the ion population and limiting deleterious space-charge effects. On the basis 
of these preliminary experiments and in order to maximize sensitivity while minimizing 
space-charge effects in tEMC mode, we used a LIT fill time of 20 ms during LC-MS 
acquisition. 
 
4.4.4 LC-MS of Complex Histone Extracts 
 
We evaluated the analytical potential of the tEMC scanning mode using acid-
extracted proteins from wild-type chicken DT40 cells. These extracts contain not only 
histones, but also many other non-histone proteins [30]. Serial dilutions ranging from 1 to 
20 ng/μL were prepared from the original protein extracts prior to nanoLC-MS analyses. 
A Q3 scan was used as a benchmark for instrument performance and was compared with 
conventional and modified EMC acquisition. We monitored the molecular mass profiles 
of histone H3 because of its extent in microheterogeneity and occurrence of different 
modifications. Panels a and b of figure 4.6 show the total ion chromatograms (TIC) and 
molecular profiles (inset) corresponding to the on-column injection of 5 and 50 ng of 
histone acid extracts derived from WT DT40 cells using a Q3 scan mode. The last eluting 
peak at 50.5 min (denoted by *) corresponds to histone H3, and the molecular mass 
profiles showed a relatively broad peak centered at 15329 Da (figure 4.6b). The 
complexity and heterogeneity of histone H3 isoforms could not be resolved by this scan 
mode, nor could any preliminary PTM screening be achieved. In contrast, panels c and d 
of figure 4.6 present the nanoLC-MS analyses of the same samples using a conventional 
EMC scan. The on-column injection of 5 ng revealed clearly detectable histone peaks 
with significantly higher resolution enabling the separation of histone isoforms.  The 14 
Da mass shifts observed in figure 4.6c suggest extensive methylation of the protein at 
different sites. When sample loading was increased up to 50 ng, space-charge effects led 
to an almost complete loss of ion current. This is exemplified in figure 4.6d for the on-
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column injection of 50 ng where no clear peak was observed. The TIC and molecular 
mass profiles obtained using our tEMC acquisition mode are shown in panels e and f of 
figure 4.6.  
 
 
 
 
Figure 4.6: NanoLC-MS analysis of histones derived from acid extracts of WT chicken 
DT40 cells using different scanning modes. Total ion chromatograms (TIC) 
corresponding to the on-column injection of (a) 5 ng and (b) 50 ng of acid-soluble 
proteins using the Q3 scan. TIC for the on-column injection of (c) 5 ng and (d) 50 ng of 
acid-soluble proteins using the conventional EMC scan.  TIC for the on-column injection 
of (e) 5 ng and (f) 50 ng of acid-soluble proteins using the modified (targeted) EMC scan. 
Insets show the reconstructed molecular mass profile for the histone H3 peak denoted by 
*.    
 
Initial inspection of the TIC revealed better peak shapes and higher sensitivity for 
the different sample sizes that were examined. The difference in analytical performance 
between the conventional and modified EMC acquisition modes for 50 ng injection can 
be explained by deleterious space-charge effects that arise from unbalanced ion 
distribution and result in an overfilled LIT.  The segmentation of m/z scanning regions 
enabled a partitioning of the ion population to minimize space-charge effects when 
numerous protein ions are present simultaneously. The histones were detectable and 
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eluted at the expected retention time; other acid-soluble components were also present 
and eluted before the proteins of interest. Furthermore, the molecular mass profiles of 
histone H3 were comparable at low and high sample loading (figure 4.6e and f). These 
results demonstrate that the tEMC scan mode can be an effective approach to reduce 
space charge-effects, extend the dynamic range of conventional EMC, and enhance 
resolution and mass measurements with performances approaching those of TOF 
instrumentation.  
 
4.4.5 Profiling Changes in Histone Modifications Using tEMC 
 
We next evaluated the potential of tEMC to profile changes in modifications of 
intact histone proteins caused by specific histone-modifying enzyme activities. DOT1L is 
a non-SET domain enzyme known to methylate histone H3 predominantly at Lys79 [33, 
34]. Mutant cells lacking this enzyme should therefore exhibit a different histone H3 
methylation pattern compared with that of wild-type cells. Protein mixtures that were 
acid-extracted from wild-type and DOT1L-deficient cells were analyzed and compared to 
correlate the extent of modification for the different core histones. The molecular mass 
profiles for all four core histones obtained from the corresponding nanoLC-MS analyses 
(50 ng on-column injection) are shown in figure 4.7. H2A profiles from wild type and 
DOT1L-deficient cells showed a series of peaks consistent with the removal of the 
initiating Met residue, followed by N-terminal acetylation (13851 Da).  Mass shifts of 
+42 and +80 Da were also observed, suggesting possible acetylation and phosphorylation 
(13893 and 13931 Da) on the major H2A peak. This histone is known to be acetylated on 
the N-terminal amino group and lysine residues within the N-terminal tail. It is also 
known to be phosphorylated at Ser-1 and Thr-120 [35]. A relatively limited number of 
abundant modifications were also observed for H2B, as evidenced from the 
corresponding molecular mass profiles (figure 4.7). The most prominent component of 
H2B was consistent with the unmodified H2B-I variant lacking the initiating Met (13791 
Da). The two other prominent forms that were observed (13819 and 13833 Da) could be 
attributed to other sequence variants of the protein (i.e., H2B V and H2B VII, 
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respectively). The profile for intact histone H4 was more heterogeneous than those of 
H2A and H2B.  The unmodified form of the protein, with initiating Met removed and N-
terminal acetylation, is observed at 11278 Da. The molecular mass profiles of H4 derived 
from both wild-type and DOT1L-deficient cells present a distribution of isoforms spaced 
by 14 and 42 Da, corresponding to Lys methylation and acetylation, respectively.  The 
molecular mass profiles for H2A, H2B, and H4 from WT and DOT1L-deficient cells are 
essentially superimposable, indicating that the absence of the DOT1L methyltransferase 
did not lead to any significant change in the extent and heterogeneity of modifications for 
these core histones. However, this was not the case for histone H3, where subtle but 
detectable changes in modification patterns were observed (figure 4.7). The unmodified 
form of histone H3 lacking the initiator Met is present at 15257 Da, along with several 
distinct 14 Da mass shifts, suggesting a high degree of methylation. For the most part, the 
histone H3 profiles from WT and mutant cells share the same masses. However, the 
proportion of a number of isoform peaks is different. For example, histone H3 from cells 
lacking DOT1L showed lower abundance of the peaks at 15285 and 15 313 Da compared 
to H3 prepared from WT cells. An extra peak at 15383 Da was also present in the sample 
from DOT1L mutant cells, but was significantly less abundant in H3 from WT cells. As 
exemplified in figure 4.7, the possibility of probing subtle changes in histone 
modification patterns using the tEMC approach demonstrates the utility of this novel 
trapping mode for rapid profiling of PTM on intact proteins. Obviously, this would be 
impossible to achieve using regular quadrupole or ion trap scan modes because of their 
limited resolution.  
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Figure 4.7: Changes in intact histone modifications between wild-type (WT) and 
DOT1L-deficient chicken DT40 cells detected by the tEMC scan mode.  Molecular mass 
profiles of individual core histones were obtained from the mass spectra of peaks 
identified in the corresponding nanoLC-MS analysis (50 ng on-column injection).  
 
4.4.6 Peptide Quantitation and Sequencing Using Targeted MRM 
 
We subjected the DT40 cellular extracts to peptide analysis and sequencing in 
order to localize the histone H3 modification sites and quantify their relative abundance. 
After HPLC fractionation, propionylation, and sample preparation, the histone H3 tryptic 
digests from WT and mutant cells were injected onto the 4000 Q-trap using MRM for 
quantitation and the MIDAS [36, 37] strategy for peptide sequence confirmation. 
Theoretical MRM transitions were designed by in silico digestion of imported chicken 
histone H3 sequences from the Swiss-Prot database using MRM pilot software. Peptide 
transitions with known histone H3 methylation sites (i.e., K9, K27, K36, and K79) were 
incorporated into the MRM list. Two types of normalization were applied to the data. 
First, the protein amount was normalized on the basis of LC-UV peak areas collected for 
each histone fraction. Second, during the LC-MS analysis, the unmodified histone H3 
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tryptic peptide YRPGTVALR was monitored to normalize the amount of protein loaded, 
and to compensate for fluctuations in MS response. Peak area ratios for each modified 
histone H3 peptide were calculated using the YRPGTVALR peptide. The TIC from the 
MRM analysis of the H3 tryptic fraction is shown in figure 4.8a. The TICs from WT and 
mutant digests looked similar upon initial inspection, except for the peak at 
approximately 40 min (denoted by *). This peak was significantly more intense in the 
WT than in the mutant. An expanded view of this peak is shown as an inset in 4.8a, 
which revealed a doubly charged ion at m/z 703.4, containing four overlaid MRM 
transitions. This ion corresponded to the in silico generated H3K79me1 peptide with the 
following sequence: EIAQDFKTDLR.  Figure 4.8b compares the abundance in WT and 
DOT1L-deficient cells of y5 fragment ion originating from the m/z 703.4+2 precursor. 
This MRM transition belonged to a chemically modified (propionylated) K79 bearing a 
single methylation for both WT and mutant cells. The MRM peak for this transition was 
very intense in the WT (about 6.0 x 104 cps), while it was reduced to about 500 cps 
(shown 20 times expanded) in the mutant. The MS/MS spectrum of the m/z 703.4+2 
precursor ion is shown in figure 4.8c. Tandem MS sequencing confirmed the identity of 
this peptide as a monomethylated (and propionylated) K79 residue, and provided an 
almost complete y ion series. The dimethylated form of the same peptide was detected in 
the WT at very low abundance, but not in the mutant sample. No H3K79me3 was 
detected in either WT or mutant. The peak area ratio generated from MRM analysis 
enabled the calculation of the fold change difference of H3K79me1 at 240-fold. The peak 
area ratio of H3K79me1 for the WT analysis had a CV of 3.6%, while for the mutant, the 
CV was 15% (n=3). The higher variation in the mutant sample analysis could be 
attributed to the low abundance of the peptide being close to the limit of detection. 
However, this result was still within acceptable confidence limits [38]. Other histone H3 
tryptic methylated peptides were also detected at K9, K27, and K36, but these did not 
exhibit any significant changes in abundance between WT and mutant analyses (data not 
shown). 
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Figure 4.8: Peptide quantitation and sequencing using MRM. (a) TIC of the WT tryptic 
digest, with the peak showing significant change denoted *. Inset of panel (a) shows an 
expanded view of this denoted peak with a precursor m/z ratio of 703.4+2. (b) MRM 
transitions comparing the y5 fragment ion between WT and DOT1L mutant analyses. (c) 
MS/MS sequencing of m/z 703.4+2 confirming the identity of H3K79me1.  
 
 
4.5 Conclusion 
 
This study demonstrated the successful development and implementation of a 
novel tEMC trapping mode for profiling intact proteins and their modifications on the 
4000 Q-Trap mass spectrometer. A combination of a segmented ion gating strategy and 
mass selective charge separation were successfully applied to decrease space-charge 
effects in the LIT. This approach also resulted in higher mass resolution enabling the 
separation of different protein isoforms. This was demonstrated for protein standards and 
complex mixtures of acid-extracted proteins that contained, among other proteins, core 
histones with a wide diversity of sequence variants and PTMs.  Our method provided 
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enhanced resolution and sensitivity compared to conventional quadrupole or EMC scans. 
The improved resolution of the tEMC mode facilitated the profiling of intact histones in 
wild- type and DOT1L mutant cells to determine global changes in modifications across 
sample sets and to establish structure-function relationships. This was evidenced in the 
present report for the profiling of histone modifications in wild-type and DOT1L mutant 
chicken DT40 cells, where changes in the methylation pattern could be identified in only 
10% of the histone H3 population.  This methodology can be of practical use to enhance 
the performance of existing trapping instruments in laboratories where an increase in 
sensitivity and resolution are required. The scan mode modifications enabled automated 
acquisition of LC-MS data for enhanced protein detection and did not require any 
hardware additions or adjustments. Finally, using conventional bottom-up sequencing 
and predictive software tools (MRM pilot), we were able to localize differentially 
expressed histone H3 PTM and quantitate their relative abundance 
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5.1 Abstract 
 
Histone deacetylase inhibitors (HDACi) represent a promising avenue for cancer therapy. 
However, in order to improve their clinical efficacy, it is important to obtain a more 
detailed representation of how HDACi affect histone acetylation in normal and cancer 
cells. Towards this goal, we applied a two-pronged mass spectrometric strategy to 
determine the impact of clinically relevant HDACi on histone acetylation in human cells. 
Intact histone profiling revealed that H3 and H4 acetylation strongly increased after 
treatment of several transformed cell lines with a number of HDACi, whereas H2A and 
H2B only showed small changes in acetylation. Our LC-MS/MS analyses indicated that 
HDACi dramatically increased the acetylation of several residues in the terminal tails of 
H3 and H4. Absolute quantification with a calibration curve spiked with the synthetic 
peptide standard and targeted mass spectrometry approaches demonstrated that H3K56 
acetylation (H3K56ac) is rare in transformed human cells and, unlike other sites of 
acetylation, the abundance of H3K56ac did not increase upon prolonged incubation with 
inhibitors of each class of HDAC. In addition, we found that SAHA, a potent HDACi 
currently used for treatment of cutaneous T-cell lymphoma, globally increased H3 and 
H4 N-terminal tail acetylation in transformed cells. Remarkably, SAHA had little effect 
on histone acetylation in normal human fibroblasts. These results demonstrate that, at 
least under certain conditions, SAHA (and possibly other HDACi) globally affects 
histone acetylation in transformed cells while having minimal effects in normal cells. 
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Deacetylase, HDAC inhibitor, HDACi, SAHA, MS-275, post-translational modifications, 
histone, nano-LC/MS/MS 
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5.2 Introduction 
 
Eukaryotic DNA is packaged into a nucleoprotein structure known as chromatin. 
The primary function of this structure is to compact DNA within the cell nucleus. The 
fundamental repeating unit of chromatin is the nucleosome core particle (NCP), which is 
composed of 147 bp of DNA wrapped nearly twice around the surface of an octamer of 
small basic proteins known as histones [1]. This octamer is formed from two molecules 
each of four types of core histones: H2A, H2B, H3, and H4. Although the structure of 
chromatin is inherently dynamic, it also considerably restricts access to genetic 
information [2]. Cells have evolved mechanisms to either control access to DNA 
packaged into chromatin. These include ATP-driven nucleosome remodelling machines, 
histone variants and histone post-translational modifications (PTMs) [3]. Each core 
histone consists of a conformationally flexible N-terminal extension, commonly referred 
to as “histone tail”, and a globular domain that mediates protein-protein interactions and 
DNA binding within NCPs [1]. The N-terminal tails of core histones protrude beyond the 
DNA gyres of NCPs, and are therefore readily accessible to histone-modifying enzymes 
[1]. These tail domains contain multiple residues that are covalently modified by a wide 
diversity of PTMs [3]. Advances in mass spectrometry (MS) have also uncovered a 
number of PTMs in the globular domains of core histones [4-6]. Histone PTMs occur 
either alone or in combination, leading to the notion of a “histone code”, a generic term 
used to describe how specific patterns of histone PTMs control the binding of effector 
proteins to NCPs and, as a result, control a variety of processes that require access to 
DNA [7]. 
 
The most intensively studied histone PTMs include acetylation, methylation, and 
phosphorylation [3]. Modifications such as ADP ribosylation, ubiquitylation and 
sumoylation also occur on histones, but the modified residues are poorly defined. The 
addition and removal of an acetyl group on lysine residues, respectively mediated by 
histone acetyltransferases (HATs) and deacetylases (HDACs), is a highly dynamic and 
regulated process that contributes to transcriptional activation and silencing [8]. In 
humans, there are 18 known HDAC enzymes that are subdivided into four classes [9]. 
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The seminal discovery that the histone deacetylase inhibitor (HDACi) trichostatin A 
(TSA) triggered cell cycle arrest and differentiation of Friend erythroleukemic cells 
promoted numerous subsequent studies on various types of cancer cells [10]. In diseases 
such as cancer, HDACs contribute to oncogenesis via at least two distinct mechanisms: 
overexpression of individual HDACs [11] and aberrant recruitment of HDACs to specific 
chromosomal loci by oncogenic fusion proteins (e.g. PML-RARα) [12] These 
perturbations of HDAC function often lead to silencing of tumor suppressor genes. 
Changes in the abundance of specific histone PTMs also occur in cancer cells. For 
example, a study of numerous cancer cell lines, normal tissues and primary tumors 
revealed that a global decrease in H4K16 acetylation and H4K20 methylation is a 
recurring feature of many types of cancers [13]. 
 
The involvement of HDACs in cancer has raised hope that these enzymes may 
represent valuable targets in drug discovery programs. Recent clinical trials demonstrated 
that, at least for hematological cancers [14-16], small molecules that inhibit HDACs can 
be effective pharmacological agents, either when administered alone or in combination 
with other drugs [17]. Through their ability to influence gene expression, HDACi exhibit 
a number of anti-proliferative effects, such as cell cycle arrest, differentiation, 
angiogenesis inhibition and apoptosis [9, 18]. In hematological malignancies such as 
leukemia, the oncogenic effects of fusion proteins encoded by chromosomal 
translocations implicating retinoid receptors are inhibited by HDACi [19]. A significant 
number of HDACi including suberoylanilide hydroxamic acid (SAHA, also known as 
vorinostat or Zolinza), entinostat (MS-275), romidepsin (Istodax), and belinostat (PXD-
101) are at various stages of drug development. At present, only vorinostat [20] and 
romidepsin [21] have been approved by the US food and drug administration for 
treatment of cutaneous T-cell lymphoma. HDACi such as SAHA are non-selective [22]. 
SAHA and many other clinically promising HDACi that contain hydroxamic acid 
moieties inhibit multiple HDACs because they chelate a zinc divalent cation that is 
essential for activity of class I and class II HDACs [18]. There is a growing debate over 
the use of pan-HDACi that cause non-specific inhibition of several distinct HDACs 
versus development of HDACi that would target specific classes of enzymes or even 
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perhaps single enzymes. In addition to histones, HDACs deacetylate many important 
protein substrates, such as transcription regulators (e.g. p53, Rb, E2F1, nuclear hormone 
receptors) [18]; hence, inhibiting multiple HDACs could be cytotoxic to normal cells and 
lead to undesirable side effects. On the other hand, it can be argued that pan-HDACi are 
effective at killing cancer cells precisely because they interfere with the deacetylation of 
multiple substrates. Currently, it is not known whether inhibition of histone deacetylation, 
as opposed to other protein substrates, plays a major role in the anti-neoplastic effects of 
pan-HDACi. As a first step to address these difficult questions, it is important to 
determine to what extent HDACi impair histone deacetylation in normal and cancer cells.  
 
The ability to identify and profile stoichiometric changes in histone modifications 
is of paramount importance to ascertain the pharmacodynamic effects of HDACi and to 
establish structure-function relationships between potential drug candidates and their 
enzyme targets. Moreover, a better understanding of HDACi-induced changes in the 
abundance of specific histone acetylation sites could lead to biomarker discovery for 
therapeutic drug monitoring [23]. Immunoblotting has been used extensively to probe 
changes in histone modifications under a wide variety of physiological conditions [3]. 
However, in our experience, many antibodies are not absolutely modification site-specific 
and often are prone to cross-react with sites that lie within similar primary sequence 
contexts in the same type of core histone molecules. In addition, even with the use of 
fluorescent dye-labelled antibodies, immunoblotting has a very limited linear range 
compared with mass spectrometry-based (MS) approaches. Thus, MS has become the 
method of choice to detect and profile changes in histone PTMs due to its speed, 
sensitivity, and selectivity. There are three main requirements needed for successful 
characterization of histone PTMs in a reproducible and comprehensive fashion: a tailored 
sample preparation strategy, modern LC-MS instrumental platform(s), and bioinformatic 
tools for rapid data mining. Several manuscripts that analyzed and quantified histone 
PTMs were deficient in one of these three aspects. An early report by Smith and 
colleagues described the application of a low resolution LCQ ion trap to profile global H4 
acetylation levels in yeast cells [24]. Hunt and colleagues pioneered the identification and 
quantitation of histone PTMs in various species using a combination of chemical 
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modification, and high-resolution tandem MS [25-27]. Although this workflow is rugged 
and lead to many pioneering insights into histone biology, it suffers from many sample 
preparation steps: multiple rounds of propionylation and chemical labelling that can lead 
to significant sample loss and side reactions. Another drawback of this workflow was that 
it relied solely on manual investigation of raw data and lacked bioinformatic tools. This 
renders any high throughput data analysis impossible. The groups of Jensen and 
Hendrickson utilized a high-resolution tandem MS instrument combined with database 
search engines and ion profiling software to address the combinatorial complexity of 
histone modifications by LC-MS/MS [28-30]. However, their sample preparation strategy 
utilized direct trypsin digestion, which, unlike derivatization of free lysines, precludes 
accurate determination of acetylation stoichiometry. 
 
In this report, we conducted a comprehensive label-free quantitative proteomics 
study to profile histone modifications in normal and cancer cells treated with different 
HDACi treatment. Our experimental strategy included a two pronged-approach that we 
previously developed and validated to identify histone PTMs whose abundance changes 
between wild-type and yeast HAT mutant strains [31]. Global changes in histone 
modifications are first determined from the mass profiles of intact histones. In a second 
step, the modification sites and their respective stoichiometric changes are established by 
a combination of propionylation, trypsin digestion and LC-MS/MS analyses. 
Bioinformatic tools are exploited to rapidly sift through vast amounts of raw MS data. In 
this study, we also designed a targeted approach using multiple reaction monitoring 
(MRM), and high-resolution MS combined with absolute quantitation with a synthetic 
peptide and a [13C615N1]-labelled internal standard peptide, to detect and accurately 
quantify the acetylation of specific amino acid residues whose stoichiometry of 
acetylation is very low.   
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5.3 Experimental Section 
 
5.3.1 Chemicals and Other Reagents  
 
Trichostatin A (TSA, Sigma), valproic acid (Sigma), nicotinamide (Sigma), 
nicotinic acid (Sigma), phenyl butyrate (Calbiochem) were solubilized in water. MS-275 
(Calbiochem) and Vorinostat (SAHA, Cayman chemical) were solubilized in DMSO. 
Human H3K56ac peptide (YQKacSTELLIR) and its isotopically-labeled analogue 
(YQKacSTELL[13C615N1]-IR) were synthesized by Midwest Biotech (Fishers, IN). HPLC 
columns for histone fractionation were purchased from Phenomenex (Torrance, CA) and 
Canadian Life Sciences.  Pre-columns (4 mm x 360 µm I.D.) and nanoLC-MS/MS 
columns (100 mm x 150 µm i.d.) were packed in-house using Jupiter C18, 3 µm particles 
(Phenomenex) and fused silica tubing (Polymicro Technologies). Milli-Q water and 
Optima grade acetonitrile (Fisher Scientific) were used as HPLC solvents. Trifluoroacetic 
acid (TFA), ammonium bicarbonate, and propionic anhydride were obtained from Sigma. 
Formic acid was obtained from EMD Science. Porcine modified trypsin (sequencing 
grade) was obtained from Promega. The protein content in histone extracts was measured 
using the Micro-BCA assay (Thermo Fisher Scientific). Cell viability was assessed using 
the alamar blue assay kit (Invitrogen). 
 
5.3.2 Cell Culture and Histone Preparation 
 
K562 cells were cultured in RPMI-1640, IMR90 and WI-38 cells in DMEM with 
10% FBS and 1% Pen-Strep in a 5% CO2 incubator at 37°C. For experiments with 
HDACi, cells were seeded in 150 cm2 dishes at 0.5 million cells/mL in 25 mL of culture 
medium. Cells treated with HDACi were collected and lysed in hypotonic lysis buffer (10 
mM Tris-HCl pH 7.5, 3mM CaCl2, 2mM MgCl2, 1 mM DTT, 1X EDTA-free protease 
and phosphatase inhibitor cocktail, 1 mM PMSF, 10 mM sodium butyrate, 10 µM 
trichostatin A and 10 mM nicotinamide). Cells were lysed in a metallic dounce 
homogenizer and nuclei were collected by centrifugation (13,500 rpm, 15 min, 4 ºC). The 
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nuclei were then resuspended in 0.4M H2SO4 to extract histones as previously described 
[32]. Histones were dissolved in 0.2% formic acid and stored frozen at -80° C.  
 
5.3.3 Immunoblotting 
 
Histone proteins were resolved on SDS-polyacrylamide gels and transferred onto 
PVDF membranes. After transfer, the presence of equal amounts of core histones was 
assessed using either Ponceau S staining or by immunoblotting using an antibody against 
non-modified histone H4. The membranes were then probed with the primary antibodies 
against H3K56ac (Upstate/Millipore 07-677 or Epitomics 2134-1), H4K12ac (Cell 
Signaling 2591S) and H4K16ac (Upstate/Millipore 07-329) overnight at 4°C. The blots 
were then washed extensively in 1X Tris-buffered saline (25mM Tris-HCl pH 8.0, 
137mM NaCl, 3mM KCl). After incubation with secondary antibodies (anti-rabbit IgG 
coupled to horseradish peroxidase) for one hour at room temperature, the blots were 
washed extensively in 1X Tris-buffered saline (25mM Tris-HCl pH 8.0, 137mM NaCl, 
3mM KCl) containing 0.1% (w/v) Tween-20, and antibody binding was detected by 
enhanced chemiluminescence (GE Healthcare).  
 
5.3.4 Flow Cytometry and Cell Viability 
 
After HDACi treatments, 1 million cells were washed with cold PBS and fixed in 
a 70% cold ethanol-PBS solution overnight at -20ºC. Cells were washed three times with 
PBS and DNA stained with a propidium iodide (PI) solution (50 µg⁄ml PI, 0.1% sodium 
citrate, and 0.2 mg⁄ml ribonuclease A) for 30 min at 4°C. DNA content was measured by 
flow cytometry (BD Biosciences). Viability of cells after HDACi treatment was assessed 
using the Alamar Blue cell viability assay (Invitrogen). Cells were seeded in a 96-well 
plate at 5000 cells ⁄ well and incubated for three hours at 37ºC with 10% Alamar Blue. 
Absorbance was read at 570 and 600 nm to determine cell viability by calculating the 
percentage of Alamar Blue reduction [33].  
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5.3.5 Sample Preparation and Protein Digestion 
 
The total protein content of enriched histone samples was measured with the 
Micro-BCA assay. Approximately 15 μg of starting material was separated using an 
Agilent 1100 HPLC system equipped with a micro-fraction collector. Separations were 
performed on a Jupiter microbore C18 column (3 μm, 300 Å; 150 x 1 mm i.d.) with a 
solvent system consisting of 0.1% TFA in water (v/v) (solvent A), and 0.1% TFA in 
acetonitrile (v/v) (solvent B). Gradient elution was performed from 5 to 70% B in 60 min 
at 15 µL/min. Fractions were collected in a 96-well plate at 20 second intervals and 
pooled together to combine individual histone peaks. For the targeted analysis of 
H3K56ac, approximately 50 μg of starting material was separated using an Agilent 1200 
HPLC system equipped with a fraction collector. Separations were performed on an ACE 
standard bore C8 column (5 μm, 300 Å; 150 x 4.6 mm i.d.) at 0.7 mL/min. Histone H3 
fractions were collected in 2 mL Eppendorf tubes at 1 minute intervals. Multiple fractions 
were pooled together as described above. Histones were prepared and digested as 
previously described [31]. LC fractions were dried in a Speed-Vac evaporator and 
resuspended in 0.1 M ammonium bicarbonate buffer (without pH adjustment). Intact 
histones were derivatized in 1:1 volume ratio with a propionic anhydride reagent. After a 
30 minute derivatization period at room temperature, samples were evaporated a second 
time, resuspended in 0.1 M ammonium bicarbonate, and digested overnight at 37° C 
using 1 µg of trypsin. Samples were acidified with 5% TFA in water (v/v) prior to LC-
MS analysis. Under our conditions, propionylation proceeded nearly to completion, as 
judged by negligible trypsin cleavage at non-propionylated lysine residues, which we 
verified by MS. Near complete propionylation of non-modified lysine residues is 
important to determine the accurate stoichiometry of histone acetylation because trypsin 
would otherwise cleave after non-modified lysine. This would obviously lead to an 
under-estimation of the fraction of histone molecules that are not acetylated at a given 
site.  
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5.3.6 Intact Histone Profiling 
 
Intact histone analysis was performed on an Agilent 6520 Q-TOF mass 
spectrometer equipped with a nanoelectrospray interface. The instrument was operated in 
positive ion mode (2800 V at interface) and scanned from m/z 400 to 1600. Equivalent 
amounts of histone acid extracts were diluted down to a concentration of 100 ng/μL with 
initial LC-MS mobile phase (see below). An aliquot was injected onto an in-house 
packed capillary C18 trapping column (4 mm x 360 µm I.D.) for 3 min at 10 µL/min 
using a loading solvent (95:5 water:acetonitrile containing 0.2% formic acid (v/v)). 
Histones were eluted onto the C18 analytical column (100 mm x 150 µm i.d.) using 0.2% 
formic acid in water (v/v) (solvent A), and 0.2% formic acid in acetonitrile (v/v) (solvent 
B). Gradient elution was performed from 5 to 90% B in 60 min at 600 nL/min. Intact 
histone mass profiles were generated from acquired mass spectra using the MaxEnt1 
deconvolution algorithm in Mass Hunter software. 
 
5.3.7 Ion Profiling from LC-MS/MS Analysis and Peptide Sequencing 
 
LC-MS/MS analyses were performed using a Thermo Electron LTQ-Orbitrap XL 
mass spectrometer equipped with a nanoelectrospray interface. Tryptic digests were 
injected in triplicate using an Eksigent nano 2DLC system. The same columns and 
solvent systems were used as described above in the intact profiling section. The 
instrument was operated in positive ion mode and scanned from m/z 300 to 1600, 
resolution set to 60 000, with a target value of 1.0 x 106. For tandem MS/MS sequencing, 
the LTQ ion trap was scanned from m/z 50 to 2000, with a target value of 1.0 x 104. One 
full survey scan in the Orbitrap was followed by data dependant MS/MS acquisition on 
the three most intense ions. A decision tree based on peptide m/z ratio and charge state 
was used to trigger either CID or ETD fragmentation. A normalized collision energy of 
35 was used to generate fragment ions in the LTQ by CID, while a 100 ms activation 
time was used for ETD ion-ion reactions. 
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All raw data files (.raw) from triplicate injections on the LTQ-Orbitrap XL mass 
spectrometer were converted into peptide maps using Mass Sense (version 2.5), an in-
house peptide detection  software used to identify peptides based on m/z values, retention 
time, abundance, and charge state. An intensity threshold of 10 000 counts was set as a 
cut-off for precursor ion peak detection. Segmentation analysis was performed by 
clustering identified peptide ions across each treatment condition based on their 
respective m/z ratio, charge, and LC retention time using an m/z tolerance of ± 0.02 Th 
and a time difference of 1 min. Normalization of LC retention time is then performed on 
the initial peptide cluster list using a dynamic and nonlinear correction. Once clustered, 
all peptide intensities were averaged and a mean ratio was calculated to generate a 
correction factor used to normalize for changes in abundance and differences in amount 
of peptide loaded. Normalized intensities are then used to generate a volcano plot for 
differential histone PTM expression profiling. Raw data files were converted to Mascot 
generic files (.mgf) using Mascot Distiller (version 2.2.1) and Mascot Daemon (version 
2.2.2). A mass tolerance of 0.02 Th was used for the precursor ions, and 0.5 Th for the 
fragment ions. A maximum of 9 missed cleavages was permitted during the Mascot 
searches. The following variable modifications were included in the search parameters: 
acetylation, methylation+propionylation, dimethylation, and trimethylation, and 
propionylation on lysine residues, methylation on arginine residues, phosphorylation on 
serine, threonine and tyrosine residues, and oxidation on methionine residues. Manual 
MS/MS spectra verification was performed on each modified peptide with Mascot scores 
greater than 20 to confirm the sequence assignment. Mascot searches were downloaded 
from the Mascot server into an Excel spreadsheet, from which redundant and low scoring 
peptides were removed. All MS/MS spectra corresponding to modified histone tryptic 
peptides are provided as supplementary information (http://pubs.acs.org/journal/jprobs). 
 
5.3.8 Targeted Analysis of H3K56ac by Absolute Quantitation and Multiple 
Reaction Monitoring 
 
Stock solutions at 1 mg/mL in deionized water were prepared for both K56-
acetylated synthetic peptides: a peptide containing only 12C and a peptide where a leucine 
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was fully [13C]-labelled (see below). Unmodified yeast histone H3 was expressed in E. 
coli and purified as described [34], and then resuspended in 0.1 M ammonium 
bicarbonate buffer. Approximately 3 µg of recombinant yeast histone H3 was derivatized, 
digested, and spiked with increasing amounts of synthetic human H3K56ac peptide 
(YQK(ac)STELLIR) ranging from 5 to 1000 pg/mL. To each solution, a constant amount 
of the [13C-leucine] labelled internal standard (IS) peptide (YQK(ac)STELLI*R, wherein 
I* is a [13C615N1]-labelled isoleucine), was added to obtain a final concentration of 100 
pg/mL IS in each vial. A 20-µL aliquot of each mixture was injected onto the LTQ-
Orbitrap XL mass spectrometer, and analyzed using the same parameters as described in 
the LC-MS/MS analysis section.  
 
A multiple reaction monitoring (MRM) method was designed to detect and 
quantify human H3K56ac tryptic peptide using an AB Sciex 4000 Q-trap hybrid triple 
quadrupole-linear ion trap mass spectrometer equipped with a Nanospray II interface. 
Working solutions of human K56ac peptide and its labelled analogue were prepared at a 
concentration of 10 µg/mL in 50:50 water:methanol with 0.2% formic acid (v/v/v) for 
nanoelectrospray infusion. Source parameters and ion optic voltages were optimized by 
constant infusion of the working solutions at 600 nL/min. The electrospray voltage was 
set to 3800V, with a declustering potential of 120V, and an optimized collision energy of 
32V. The four most intense ions were chosen to build MRM transitions within Analyst 
software. Both H3K56ac and its non-modified counterpart (H3K56pr) were monitored in 
parallel; another H3 tryptic peptide (YRPGTVALR) was also monitored to normalize for 
the amount of peptide loaded and fluctuations in the electrospray response. 
 
5.4 Results and Discussion 
 
5.4.1 Cell Viability and Cell Cycle Progression in Response to HDACi 
 
HDACi can trigger apoptosis or cell cycle arrest in transformed cell lines [9, 18]. 
However, we wanted to analyze changes in histone acetylation under conditions where 
HDACi-treated cells did not lose viability or cease to proliferate. This was important 
 126
because newly synthesized histones H3 and H4 are acetylated at several lysine residues 
and incorporated into chromatin throughout the genome during S-phase [35-38]. Because 
new H3/H4 molecules are very abundant (new histones represent 50% of total histones in 
G2 cells), they likely make a significant contribution to global levels of acetylation in 
proliferating cells. We first examined whether HDACi treatment caused cell cycle arrest 
using propidium iodide staining of DNA and flow cytometry. Asynchronously growing 
control K562 (human erythroleukemic) cells show populations of cells distributed in 
three distinct regions of fluorescence intensity, corresponding to G1, S, and G2/M phases 
(figure 5.1a). From the relative proportion of the peaks, we estimated that no more than 
20% of the cells were in S-phase. No significant change in the FACS profile was noted 
for K562 cells exposed to 1 μM MS-275 or SAHA (data not shown) for a period of up to 
24 h (figure 5.1a), showing that these two HDACi did not induce any obvious cell cycle 
arrest. Consistent with this, cell numbers doubled during the 24h period when they were 
exposed to either 1μM MS-275 or 1μM SAHA. Cell viability was monitored using 
Alamar Blue, a non-fluorescent chemical that is converted into fluorescent Resorufin 
upon metabolic reduction [39]. Control cells and cells treated with either 1μM MS-275 or 
1μM SAHA for periods up to 24 h showed no obvious difference in viability (figure 
5.1b). Thus, exposure to 1μM MS-275 or 1μM SAHA for 24h did not cause appreciable 
cell cycle arrest or lethality in K562. Our results are consistent with the fact that the same 
concentrations of MS-275 or SAHA were not cytotoxic to several other human cancer 
cell types [22]. 
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Figure 5.1: Cell cycle distribution and viability of K562 cells are not affected by 
treatment of MS-275. (a) Propidium iodide (PI) staining of DNA detected by flow 
cytometry analyses of K562 cells treated for 6 hour- and 24 hour-treatment with 1 μM of 
the class I HDAC inhibitor MS-275. (b) Cell viability of K562 cells after 6- or 24-hour 
continuous exposure to either 1µM SAHA or 1µM MS-275. Cell viability was measured 
by staining with Alamar Blue as described in the experimental section. 
 
 
 
5.4.2 Global Histone Acetylation Probed by Intact Mass Profiling 
 
We first examined the changes in molecular mass distribution of intact histones 
upon HDACi treatment using LC-MS on the Agilent 6520 Q-TOF mass spectrometer. In 
each case, a total of 500 ng of acid extracts enriched in histones were injected onto the 
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LC-MS system. The total ion chromatogram (TIC) of histones from K562 cells that were 
not treated with HDACi shows that core histones H4, H2B, H2A and H3 eluted 
successively between 50 and 65 min under our chromatographic conditions (see figure 
A.1 in appendix 1). The mass spectra of core histones eluted at different time points were 
deconvoluted and overlaid for comparison. Figures 5.2a and 5.2b show the intact mass 
profiles of the four core histones from control K562 cells and those exposed to either 
SAHA or MS-275 for incubation periods of 6 and 24 h. In most eukaryotes, the initiator 
methionine is removed from the four major types of core histones: H2A, H2B, H3 and 
H4 [40]. The most prominent peak for H2A is at 14002 Da (figures 5.2a and 5.2b). This 
is consistent with the calculated molecular mass for the type 1 form of histone H2A 
(Uniprot P0C0S8) without the initiator methionine, but including acetylation of the N-
terminal amino group (Mcalc.: 14002.3 Da). Consistent with our data, N-terminal 
acetylation occurs in the vast majority of H2A molecules [40]. The most significant 
change observed for H2A upon treatment with SAHA or MS-275 is a small increase in 
the abundance of the peak at 14044 Da corresponding to a diacetylated form H2A. 
However, no significant increase in the abundance of more highly acetylated forms of 
H2A was observed upon HDACi treatment, and the intact H2A profiles were comparable 
during a time course from 0h to 24h with both SAHA and MS-275 (figures 5.2a and 
5.2b). Many minor sequence variants of histone H2B are encoded in the human genome 
[41]. In both normal and transformed cells (figures 5.2 and 5.3), the first prominent peak 
for histone H2B (13761 Da) very closely matched the predicted mass for the type 1H 
(Mcalc.: 13760.9 Da ; Uniprot Q93079) H2B variant devoid of N-terminal methionine 
and amino group acetylation. We examined the abundance distribution of H2B isoforms 
upon treatment with HDACi (figures 5.2a and 5.2b). Another prominent H2B peak at 
13791 Da (figures 5.2 and 5.3), which likely corresponds to lysine or arginine mono-
methylation of the type 3B H2B variant (Mcalc.: 13790.95 Da). Importantly, the H2B 
profiles were similar for all HDACi conditions examined, except for an increase in 
acetylation inferred by in the abundance of peaks at 13803 Da (+1 ac, 5% increase) and 
13845 Da (+2 ac, 15% increase). These peaks may correspond to acetylated forms of the 
type 1H variant, but we cannot rule out the possibility of lysine tri-methylation. 
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The most significant changes in the intact histone mass profiles were observed for 
histones H3 and H4 (figures 5.2a and 5.2b). Unlike H2A, H2B and H3, which exist as 
multiple sequence variants, there is a single H4 protein encoded by several genes [41]. 
Essentially all H4 molecules are acetylated on their N-terminal amino group [40]. This N-
terminally acetylated form of H4 is present at 11278 Da (Mcalc.: 11278.2 Da), along with 
peaks at 11306 Da (+28 Da, dimethylation) and up to three additional acetylated forms at 
11348, 11390, and 11432 Da.  All these H4 peaks were detected in both normal and 
transformed cells (figures 5.2 and 5.3). A rapid increase in mono-, di- and tri-acetylation 
was observed as early as 6h after addition of SAHA. Similar changes in acetylation 
patterns were observed in cells treated with MS-275, although the more highly acetylated 
forms of H4 were apparent only after 24h exposure. Unlike histone H2A and H4, 
virtually all the H3 molecules lack acetylation of the N-terminal amino group [37]. In 
rapidly proliferating cells, the replication-coupled histone H3 variants (H3.1 and H3.2) 
are far more abundant than the replication-independent H3.3 protein [42]. In K562 and 
normal cells, the unmodified form of H3.2 (Mcalc.: 15256.8 Da) was not detected, but 
that of H3.1 (Mcalc.: 15272.9 Da) was observed in low abundance at 15273 Da (figures 
5.2 and 5.3). The intact mass profile of H3.1 revealed a heterogeneous distribution of 
molecular species with incremental shifts of +14 and +42 Da, corresponding to multiple 
forms of methylation and acetylation. Treatment of K562 cells with SAHA or MS-275 
caused an overall shift to more highly acetylated forms. However, as observed for H4, the 
most highly acetylated forms of H3 were accumulated more rapidly with SAHA (6h) than 
with MS-275 (24h). Based on intact mass profiling, both SAHA and MS-275 
predominantly increased the acetylation of H3 and H4, whereas acetylation of H2A and 
H2B was affected to a much lesser extent. 
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Figure 5.2: LC-MS analyses of intact histones derived from transformed cells. Intact 
histone profiles from K562 cells treated with SAHA (a) and MS-275 (b). Color lines 
indicate histones purified from control (black), 6 h (blue) and 24 h (red) treatment with 
1μM SAHA or 1μM MS-275. 
 
 
To determine if the HDACi had the same effect on normal cells, we treated 
normal human diploid fibroblasts (IMR-90 and WI-38 cells) with the same concentration 
of SAHA or MS-275 that was used for K562 cells. A longer treatment time was 
performed for IMR-90 (48h) and WI-38 (72h) because these cells proliferate more slowly 
than K562 cells. As observed with the K562 cell line, the proliferation and viability of 
WI-38 cells were not affected by these HDACi at a concentration of 1 μM (data not 
shown). Interestingly, the intact mass profiles of histones derived from either control or 
 131
HDACi-treated IMR-90 and WI-38 cells showed essentially no difference (figure 5.3). 
The profiles were almost superimposable for each core histone with no significant shift to 
higher acetylated forms. These results indicate that, at least at the concentration that we 
used, SAHA and MS-275 can trigger a global increase in H3 and H4 acetylation in cancer 
cells without significantly affecting global acetylation in normal fibroblasts. 
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Figure 5.3: LC-MS analyses of intact histones derived from normal diploid fibroblasts. 
Intact histone profiles for SAHA-treated IMR-90 cells (a) or WI-38 cells (b). Color lines 
indicate histones purified from control cells (black), and cells with 1μM SAHA for the 
indicated times (red). 
 
 
 132
5.4.3 Mapping modification sites by propionylation, tryptic digestion and LC-
MS/MS analyses 
 
To determine the location and the extent by which each site is modified upon 
HDACi treatment, we purified individual histones by reversed-phase HPLC and 
propionylated free lysine residues prior to tryptic digestion and LC-MS/MS analyses 
[31]. The amount of protein in acid extracts containing histones was quantitated using the 
Micro-BCA assay, and a total of 15 μg was separated by HPLC to isolate individual 
histones. A typical chromatographic separation of histone extracts from K562 control 
cells resulted in near baseline separation of the four major core histones (see figure A.2 in 
appendix 1). We focused primarily on the identification of modification sites on H3 and 
H4, since these core histones showed the most significant global changes upon treatment 
with either SAHA or MS-275. H3 and H4 histones from all cells and HDACi conditions 
(n=3) were subsequently derivatized with propionic anhydride, digested with trypsin, and 
analyzed by LC-MS/MS on the LTQ-Orbitrap XL. Internal calibration using the 
polysiloxane ion at m/z 445.0012 provided m/z measurements within 10 ppm of the 
theoretical mass and facilitated the unambiguous identification of modifications with 
closely related masses (e.g. acetylation versus trimethylation).  
 
The injection of individual histones rather than a complex acid extract digest was 
preferred to maximize the number of peptides detected and sequenced. This approach 
resulted in the detection of a multitude of tryptic peptides including those originally 
containing free and acetylated lysine residues from histones H3 and H4. Peptide maps 
representing the coordinates of all peptide ions (e.g. m/z, charge, LC retention time, peak 
intensity) were obtained from each raw LC-MS data file and aligned across replicates and 
conditions to correlate changes in abundance of identified peptide ions. A list of all 
identified peptides and their abundance is presented in appendix 1 (tables A.1 to A.10).  
The relative standard deviation observed for peptide ions detected across all three 
replicate LC-MS/MS analyses varied between 17-24%, demonstrating the reproducibility 
of the present approach. For all identified H3 and H4 tryptic peptides, the significance 
and fold change in abundance caused by SAHA and MS-275 treatment is depicted in 
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volcano plots (figures 5.4a and b). Histone H3 peptides detected after 6 and 24 hours of 
exposure to HDACi are denoted by triangles and squares, respectively. Histone H4 
peptides detected after 6 and 24 hours of exposure to HDACi are denoted by circles and 
diamonds, respectively. The fold change was determined by calculating the abundance 
ratio of the same peptide in histones from control and HDACi-treated cells. A large 
proportion, representing ~90% of all identified peptides, were unaffected by treatment 
with either SAHA or MS-275. These are clustered near the origin (p-values > 0.05, fold 
change < 2). Two quadrants are highlighted by dashed boxes in the volcano plots for 
peptides showing a statistically significant fold change in either control or HDACi treated 
cells for triplicate measurements (p-values < 0.05, fold change > 2). MS/MS sequencing 
with either CID or ETD fragmentation revealed that all H3 sites acetylated upon HDACi 
treatment were located within the first 36 residues of histone H3.  Most notably, K9, K14, 
K18 and K23 were primary sites of hyperacetylation upon treatment with either SAHA or 
MS-275.  For example, figure 5.4c shows the CID MS/MS spectrum of precursor peptide 
m/z 493.272+, corresponding to the tryptic peptide K9(ac)STGGK14(ac)APR, highlighted 
by arrows in figure 5.4a. This peptide showed a 5- to 17-fold increase in abundance upon 
SAHA or MS-275 treatment. Unexpectedly, the dimethylated tryptic peptide 
K27(me2)SAPATGGVK36(me2)K37(pr)PHR identified by ETD fragmentation increased 
approximately 2- to 4-fold in abundance under the same conditions (figure 5.4a). The 
combined used of CID and ETD fragmentation facilitated the localization of modification 
sites and enabled the identification of 41 differentially modified histone H3 peptides 
following addition of SAHA or MS-275 to asynchronously growing K562 cells.  The use 
of decision tree driven MS/MS sequencing was used to maximize the protein sequence 
coverage and identify any peptides that might have been missed if only one 
fragmentation mode had been used. The majority of ions (70%) were identified using 
CID as doubly charged species, while ETD identified 30% of ions as triply or more 
highly charged species. Our LC-MS/MS analysis of histone H3 tryptic peptides resulted 
in a sequence coverage of 63%, representing 43% of known PTM sites detected. 
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Figure 5.4: Histone H3 and H4 peptide ion intensity profiling using volcano plots. K562 
cells were either left untreated (CTL) or treated with either 1μM SAHA (a) or 1μM MS-
275 (b). Histone H3 peptides after a 6-hour HDACi treatment are denoted by triangles 
and those after a 24-hour treatment by squares. Histone H4 peptides after a 6-hour 
HDACi treatment are denoted by circles and those after a 24-hour treatment by 
diamonds. Arrows show examples of modified histone peptides whose abundance is 
significantly affected by HDACi. Tandem MS sequencing of an N-terminal histone H3 
peptide (c), and an N-terminal histone H4 peptide (d), revealed acetylation sites that 
increased in abundance in response to HDACi treatment. See Appendix 1 for intensity 
measurements used for the generation of volcano plots. 
 
Volcano plots were also generated for histone H4 tryptic peptides to identify 
residues showing the most significant changes in acetylation after SAHA (figure 5.4a) or 
MS-275 treatment (figure 5.4b). Following propionylation, tryptic digestion of histone 
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H4 yielded an N-terminal 14-amino acid peptide (from residues 4 to 17) with four lysine 
residues (K5, K8, K12, and K16). This 14-residue peptide was detected in multiple forms 
corresponding to different modification patterns. As observed for H3, amino acids 
located within the N-terminal tail of H4 were the most prominent targets of acetylation.  
Upon HDACi treatment, we observed a gradual increase in the di-, tri- and tetra-
acetylated forms and the fully acetylated peptide clearly dominated after exposure to MS-
275 (7- and 24-fold increase at 6h and 24h, respectively). The mono-acetylated form did 
not show a significant change in abundance after exposure to any HDACi (see Appendix 
1). Figure 5.4d shows the MS/MS spectrum for the tetra-acetylated tryptic peptide. 
Careful examination of the fold changes in acetylation triggered by SAHA and MS-275 
revealed important differences between these two inhibitors. Indeed, treatment with 1 μM 
SAHA yielded a 17-fold increase in acetylation at 6h with a subsequent reduction to 7-
fold at 24h, suggesting a limited long-term inhibitory activity of SAHA compared with 
MS-275.  The fact that MS-275 caused a more robust long-term hyper-acetylation than 
SAHA was also obvious from the intact mass profiles of H4 (figures 5.2a and b). Some of 
the sites of acetylation whose abundance clearly increased in response to HDACi were 
also analyzed by immunoblotting (figure 5.5). For example, we found that histone 
H4K12 and H4K16 acetylation strongly increased in acetylation in transformed cells 
treated with 1μM SAHA. Consistent with our intact mass analysis, this increase was not 
observed when normal fibroblasts were treated with SAHA for up to 72h. Finally, Our 
LC-MS/MS analysis of histone H4 tryptic peptides resulted in a sequence coverage of 
75%, representing 46% of known PTM sites detected. 
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-H4K12ac
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- H4
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Figure 5.5: 1μM SAHA increases H4K12ac and H4K16ac in transformed cells (K562), 
but not in normal diploid fibroblasts (IMR-90 and WI-38). For normal fibroblasts, the 
passage number is indicated. Immunoblots were probed with antibodies against H4K12ac 
(a) and H4K16ac (b). Similar loadings of histone samples from control (minus signs) and 
SAHA-treated cells (plus signs) were verified by stripping the upper blot and reprobing it 
with an antibody that detects unmodified histone H4 (a) or by Ponceau S staining prior to 
immunoblotting (b). 
 
5.4.4 Abundance of H3K56ac Measured by Targeted MRM and Absolute 
Quantification 
 
Our profiling of tryptic peptides by LC-MS/MS confirmed that lysine residues 
located within the N-terminal tails of H3 and H4 were the most prominent acetylation 
sites following HDACi treatment. Indeed, we observed very few acetylated tryptic 
peptides within the globular domains of the corresponding histones.  This prompted us to 
examine the stoichiometry of acetylation on these sites using more sensitive and 
quantitative proteomics approaches. We were particularly interested to look for H3K56ac 
because several recent publications have implicated this modification in replication-
coupled nucleosome assembly and the DNA damage response [43-48]. In addition, based 
on immunohistochemistry, it has been argued that H3K56ac is a diagnostic and 
prognostic marker of many different types of tumours [43]. To detect H3K56ac and 
determine its stoichiometry, we used two approaches: MRM on an AB Sciex 4000 Q-
Trap hybrid triple quadrupole-linear ion trap mass spectrometer, and a high-resolution 
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quantitative approach on a Thermo Orbitrap-LTQ XL instrument. An absolute 
quantitation method was developed using both an H3K56ac synthetic peptide and an 
isotopically labelled standard of the target tryptic peptide (YQK56(ac)STELLI*R), where 
I* is a [13C615N1]-labelled isoleucine residue. The unmodified (K56 propionylated) ion 
was detected in high abundance in the non-targeted LC-MS/MS analyses described 
earlier. An MRM method was built based on the MS/MS spectrum of both synthetic 
peptides (figures 5.6a and b). Four precursor/fragment ion pairs were selected to build a 
specific MRM method for the detection of the corresponding tryptic peptides (see table 
A.11 in the appendix). We also monitored the unmodified form (YQK56(pr)STELLIR), 
together with another H3 peptide (YRPGTVALR) to normalize for the amount of H3 
present in different samples and for changes in the response of the electrospray signal. 
Following HPLC fractionation of histone extracts (50 μg of starting material), our MRM 
assay was used to screen for the presence of H3K56ac in K562 and HeLa cells treated 
with various HDACi, including sodium butyrate, SAHA, MS-275, and nicotinamide. The 
modified K56ac residue was detected at low abundance in all cell types and conditions 
tested consistent with the LC-MS/MS analyses described in the previous section. Figure 
5.6c shows LC-MS/MS results of H3K56ac in K562 cells treated with SAHA for 6h. 
Four MRM transition channels corresponding to the formation of diagnostic y- and b-type 
fragment ions were monitored. This strategy unambiguously identified a K562 cell-
derived peptide that contained H3K56ac and eluted at 26 min (figure 5.6c). First, the 
K56-acetylated peptide co-eluted with the [13C615N1-isoleucine]-labelled internal standard 
(figures 5.6c and d). Second, as expected, fragment ions from the K562 cell-derived 
H3K56ac peptide were 7 Th lighter than the corresponding fragment ions from the 
internal standard containing [13C615N1]-isoleucine (figures 5.6a and b). The stoichiometry 
of acetylation was calculated using the peak areas of the ion signal corresponding to the 
K56ac peptide divided by the sum of the areas of K56ac and K56pr peptides. The 
stoichiometry of H3K56ac in transformed human cells (K562 or HeLa) is shown in table 
V-1. The stoichiometry of K56ac determined by MRM was 0.03% in all conditions 
tested, and did not change upon prolonged incubation with any of the HDACi that we 
tested.  
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Figure 5.6: Identification and quantitation of H3K56ac from K562 cells using targeted 
MRM on an AB Sciex 4000 Q-Trap instrument. Tandem MS spectra of the light (a) and 
heavy (b) YQK56(ac)STELLIR peptide standards at 10 μg/mL using enhanced product 
ion (EPI) scan. LC-MS/MS analysis (MRM) of the native H3K56ac peptide (c) and the 
[13C615N1-isoleucine]-labelled YQK56(ac)STELLI*R internal standard peptide (d) from a 
digest of histones isolated from K562 cells treated with SAHA for 6h.  
 
We also performed high-resolution LC-MS analyses on the LTQ-Orbitrap XL 
mass spectrometer to determine the stoichiometry of H3K56ac in the same samples. The 
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absolute amount of H3K56ac in transformed cells was determined using a calibration 
curve spiked at levels ranging from 5 to 1000 pg/mL, containing a constant amount of the 
[13C615N1]-labelled internal standard. In order to mimic, as closely as possible, the 
reaction conditions used to process human histones prior to MS, recombinant yeast 
histone H3 was propionylated and digested first, then spiked with increasing amounts of 
the synthetic peptide standard. The rationale was to generate reaction mixtures containing 
similar sets of peptides and chemical species as those produced during analysis of human 
cell-derived histones. Although recombinant yeast histone H3 is less complex and devoid 
of PTM [49], the conditions of propionylation and trypsin digestion are similar, which 
helps tackle challenges to quantitation, such as chemicals that co-elute with the H3K56ac 
peptide of interest and might suppress its ionization. This is particularly important in this 
case because of the very low abundance of the H3K56ac peptide (see below). The first 
residue of the yeast H3 tryptic peptide containing K56 is a Phe, instead of a Tyr residue 
in human H3. Hence, H3K56 tryptic peptides derived from yeast histones do not interfere 
with our quantitative analysis. Our calibration curve showed excellent linearity (r2 = 
0.9993) over the range of concentrations examined (figure 5.7a). We detected the 
authentic H3K56ac peptide at a level approaching the instrumental detection limit in all 
the human histone samples. An example of the precursor ion mass spectrum for the 
H3K56ac peptide derived from K562 cells treated with SAHA for 24h is shown in figure 
5.7b. The mass measurement obtained for the light and heavy labelled doubly protonated 
peptides were within 5 ppm of those calculated from their corresponding theoretical 
masses. An MS/MS spectrum that confirms the identity of the precursor ion 
corresponding to the human K56ac peptide is shown in figure 5.7c. Similar to what was 
described above for the MRM analyses, the H3K56ac stoichiometry was determined from 
the ratio of the peak height of the doubly-protonated K56ac tryptic peptide divided by the 
sum of the peak heights for the K56ac and K56pr peptides. The results from high-
resolution LC-MS analyses are shown in table V-1, together with the absolute amount of 
tryptic peptide detected. The amount of H3K56ac present in all conditions ranged from 
150 to 300 attomols, while the acetylation stoichiometry varied from 0.05-0.08%. No 
significant change in the stoichiometry of H3K56ac was observed under any of the 
conditions examined (table V-1). Thus, based on two different quantitative MS 
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experiments, we find that the stoichiometry of H3K56ac (approximately 0.05%) is 
considerably lower than previously reported (1%) [43, 47]. In addition, unlike other sites 
of acetylation, H3K56ac did not increase in response to several HDACi (table V-1). This 
was very intriguing because two of the HDACi that we used in our MS experiments, 
namely sodium butyrate and nicotinamide, were previously shown to increase H3K56ac 
based on immunoblotting [43, 46]. 
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Figure 5.7: LC-MS/MS analysis of H3K56ac from K562 cells using an LTQ-Orbitrap 
XL mass spectrometer. (a) Standards (n=1, see experimental section) were prepared by 
mixing solutions of increasing concentrations (from 5 to 1000 pg/mL) of [12C-
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isoleucine]-containing K56-acetylated peptide with a fixed amount (100 pg/mL) of 
internal standard (IS) peptide (YQK56(ac)STELLI*R), where I* is the [13C615N1]-labelled 
isoleucine residue). The y-axis is the peak height abundance ratio (as determined by LC-
MS) of the YQK56(ac)STELLIR peptide (containing only the [12C] isotope) to that of the 
[13C615N1]-labelled internal standard (IS) peptide. (b) Precursor ion mass spectrum (from 
LC-MS/MS analysis of histones derived from K562 cells treated with 1μM SAHA for 
24h) showing the detection of the native YQK56(ac)STELLIR peptide along with the 
[13C615N1-isoleucine]-labelled internal standard. (c) MS/MS spectrum of precursor m/z 
646.862+ from the analysis shown in (b). This spectrum confirms the identity of the 
natural peptide containing H3K56ac. 
 
This prompted us to investigate the specificity of two commercially available 
antibodies that were previously used to detect H3K56ac in immunoblots [43, 45]. For 
these experiments, the same histone samples were analyzed either by MS or 
immunoblotting. The amounts of acid-extracted histones typically used in immunoblots 
are sufficiently large to be readily detected by Ponceau S staining after histone transfer 
[43, 45]. Under these conditions, we found that, as previously reported [43, 45, 46], 
histones derived from HeLa cells treated with sodium butyrate showed a strong increase 
in signal with antibodies supposedly specific for H3K56ac (figure 5.8a). However, with 
equal amounts of histones loaded, the same antibodies detected a considerable signal in 
histones derived from yeast rtt109Δ mutant cells (figure 5.8b). In yeast, Rtt109 is the 
main enzyme that acetylates H3K56 and, consistent with this, H3K56ac is severely 
compromised, as judged by MS analysis of histones derived from rtt109Δ mutant cells 
[31]. These observations, combined with the fact that MS did not reveal an increase in 
H3K56ac after extended periods of incubation with several HDACi (table V-1), suggest 
that the two commercial antibodies raised against H3K56 acetylated peptides might react 
against acetylated lysine residues other than H3K56 in human cells. However, further 
experiments would need to be performed to reach a definitive conclusion. For example, a 
peptide competition assay utilizing H3K9ac and H3K56ac peptides present in different 
stoichiometries blotted against the H3K56ac antibody would an important experiment to 
conduct. Cross reactivity with another site with similar sequence homology could be one 
such explanation; one possible candidate would be H3K9ac, given that the stoichiometry 
of H3K9ac increases from 3% in control to 33% in SAHA-treated K562 cells. These 
results may help resolve some of the conflicting data concerning the physiological roles 
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of H3K56ac in human cells [43-48]. In addition, our results demonstrate the importance 
of combining MS and immunoblotting data to address whether antibodies raised against 
certain histone modifications are likely to be modification-specific or not. This is 
particularly important for studies of vertebrate cells where it is not currently possible to 
mutate specific histone residues in order to rigorously prove antibody specificity.  
 
 
 
Figure 5.8: Antibodies supposedly specific for H3K56ac can cross-react against other 
acetylated lysine residues in histone H3. (a) Immunoblot of core histones purified from 
control and butyrate-treated HeLa cells (NaBut), as well as WT and rtt109Δ yeast cells 
probed with an antibody from Upstate/Millipore (07-677). As judged by Ponceau S 
staining, similar amounts of core histones were present on the blot prior to probing. (b) 
Immunoblot of core histones purified from control and butyrate-treated HeLa cells 
probed with the Epitomics antibody 2134-1. As judged from a Coomassie Blue-stained 
gel loaded with the same amounts of histones as the immunoblot, similar amounts of 
histones from control and butyrate-treated cells were immunoblotted cells. (c) 
Immunoblot of core histones purified from yeast cells lacking the H3K56 
acetyltransferase Rtt109 (rtt109Δ) or WT cells. In panels (a) to (c), the “H3K???ac” label 
indicates that the immunoblotting signal generated by these antibodies cannot be ascribed 
to a specific acetylated lysine(s). 
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Table V-1: Stoichiometry and amounts of H3K56ac detected in transformed cells 
exposed to different HDACi (n = 1). 
 
 
Condition cal. conc. (pg/mL) amount inj. (fg) attomols detected K56ac stoichio. (%) K56ac stoichio. (%)
MRM Orbitrap
K562 CTL 0h 10.3 207 160 0.03 0.05
K562 CTL 12h 12.8 255 198 0.03 0.05
K562 CTL 24h 14.4 289 224 0.03 0.05
K562 SAHA 6h Rx. 13.3 266 206 0.03 0.05
K562 SAHA 24h Rx. 10.6 211 164 0.03 0.05
K562 MS-275 6h Rx. 10.9 218 169 0.03 0.05
K562 MS-275 24h Rx. 19.2 384 297 0.03 0.05
K562 Nicotinic acid 12h Rx 13.0 260 201 0.03 0.05
K562 Nicotinamide 12h Rx 10.2 205 158 0.03 0.05
K562 Nicotinamide 24h Rx 14.5 291 225 0.03 0.07
HeLa Butyrate 24h Rx 18.4 367 284 0.03 0.08  
 
 
In separate experiments, we also monitored histone H4K91 acetylation, a 
modification previously reported to be involved in chromatin assembly [6]. We searched 
for the peptide containing this lysine residue, K79TVTAMDVVYALK91R in histones 
from both control and HDACi treated K562 cells. Precursor and fragment ion pairs were 
selected from the five most abundant transitions observed for both K91ac and its 
propionylated counterpart K91pr to determine the corresponding acetylation 
stoichiometry (see table A.12 in appendix 1). The extracted ion chromatogram of the 
unmodified H4K91 peptide (both doubly and triply charged states) yielded an intense 
peak for the K91pr tryptic peptide in all MRM transitions monitored (see figure A.3 in 
the appendix). In contrast, the extracted ion chromatogram of the K91ac tryptic peptide 
showed no detectable signal for any of the MRM transitions monitored under any of the 
conditions tested (see figure A.4 in appendix 1). We estimate that the acetylation 
stoichiometry of H4K91 is below 0.05%, which corresponds to the detection limit in this 
LC-MS/MS experiment. 
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5.5 Conclusion 
 
Our two-pronged approach to identify global changes in histone acetylation that 
arise from HDAC inhibition has enabled us to uncover two unexpected findings about the 
dynamics of histone acetylation in human cells. First, HDACi with either hydroxamic 
acid (SAHA) or benzamide (MS-275) as inhibitory moieties trigger hyperacetylation of 
H3 and H4 preferentially in transformed cell lines compared with normal diploid 
fibroblasts. This observation may well explain why SAHA and other HDACi exert more 
pronounced effects (such as cell cycle arrest, differentiation or apoptosis) on cancer cells. 
This finding raises fascinating questions for future investigation, such as the underlying 
molecular basis of the differential susceptibility of normal and cancer cells to HDACi. 
Second, the development of a robust MS-based quantitative assay to determine the 
stoichiometry of histone H3K56ac in control and HDACi-treated cells has revealed some 
highly unexpected properties of this modification in human cells that are distinct from 
H3K56ac in yeast. In S. cerevisiae and other yeasts, H3K56ac is very abundant during S-
phase and G2 (essentially all new H3 molecules are K56-acetylated) and deacetylated 
genome-wide prior to the subsequent round of S-phase [4, 50]. This is clearly not the case 
for H3K56ac in human cells. In contrast to the acetylation of many other residues in 
H3/H4 N-terminal tails [51], it is puzzling that there is no turnover of H3K56ac that can 
be blocked by either class I/II or class III HDACi in human cells. The very low 
stoichiometry of H3K56ac in human cells and the lack of turnover make it unlikely that 
this modification can enhance genome-wide deposition of newly synthesized histone 
molecules. Our findings certainly do not rule out the possibility that H3K56ac may have 
an important function in human cells. A stoichiometry of 0.03% corresponds to roughly 
one K56-acetylated H3 molecule every 150 nucleosomes (or roughly every 30Kb, 
assuming an average nucleosome repeat length of 200bp). Given the size of the genome 
of a diploid human cell (roughly 6x109 bp), there are approximately 2x105 K56-acetylated 
H3 molecules per cell. Despite the absence of turnover, some of these molecules may 
occur at specific chromosomal loci where H3K56ac could play an important function, 
such as the regulation of gene expression proposed from studies of H3K56ac in 
embryonic stem cells [47]. Overall, our findings demonstrate the importance of 
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quantitative MS to determine the stoichiometry of specific protein modifications under a 
variety of physiological conditions, and subsequently use this information to formulate 
hypotheses regarding the plausible function(s) of these modifications.  
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6.1 Conclusion and Final Thesis Overview  
 
Histones play a vital role in the biology of the cell. Their role includes that of 
DNA packaging “agents”, and their PTMs help regulate important cellular processes (i.e., 
transcription, damage repair). The deregulation of these PTMs can directly affect and 
sustain diseases such as cancer. Hence, characterizing, analyzing, and quantifying the 
extent of these PTMs is important in understanding how they are implicated in disease, as 
well as to how to exploit them therapeutically. The main objective of this Ph.D. project 
was to develop analytical MS-based strategies to analyze histones to further understand 
their involvement in cell biology. This objective was successfully completed and 
documented in the preceding chapters of this thesis. 
 
The first step was to develop a rugged and reproducible workflow that could be 
applied to any sample set. An in-depth literature search revealed that most, if not all, 
research groups used a generic proteomics approach to analyze histones; the few that 
developed more specialized workflows provided no statistical analysis to validate their 
results and findings. This lack of analytically tested and verified results in many 
published papers prompted us to develop an analytically sound strategy for histone 
analysis, and became the basis for the first publication presented in this thesis (chapter 
three).  
 
Our approach was a dual, two-pronged strategy. Histones extracted from cells 
were profiled by high resolution mass spectrometry to generate a molecular weight 
profile. Using histones from wild type and mutant yeasts strains (asf1Δ and rtt109Δ) as a 
biological model, we profiled and examined closely each core intact histone from the 
three different sources. These two mutants were chosen because the deletion of the two 
genes encoding the ASF1 histone chaperone and RTT109 acetyltransferase is known to 
catalyze the acetylation of H3K56 [1]. The results obtained were consistent with our 
expectations. Core histones H2A, H2B, and H4 did not demonstrate any significant 
changes in their intact mass profiles, while histone H3 had obvious changes in the 
abundance and mass shifting between wild type and mutants. This rapid MS profiling 
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demonstrated the utility of performing such an experiment; instead of spending time on 
analyzing histones that showed no significant changes, we channeled our research efforts 
to analyze and determine the changes occurring in histone H3 between wild-type and 
mutants. Histone H3 became the primary candidate for the next step of our dual strategy, 
i.e., bottom-up sequencing. Since this was our first report and major study involving 
histones, we decided to analyze all core histones to demonstrate proof of concept. 
 
Sample preparation for histones was the next aspect to be investigated and 
developed. Since a cellular extract contains a great number of proteins besides histones, 
some type of fractionation step was necessary to remove unwanted proteins, and isolate 
individual histones. Two methods were available for this purpose: SDS-PAGE and 
HPLC. Separation of histones by gels and subsequent staining was not chosen because of 
limited loading and resolution, and the possibility of creating chemical artifacts [2, 3]. 
Using both narrow and standard bore HPLC with conventional reversed-phase C18 
media, we were able to separate core histones from co-extracted proteins, as well as from 
each other. 
 
The protein digestion method posed a serious challenge. It was evident that a 
generic tryptic digestion procedure would not suffice for histone proteins. Endoproteinase 
Arg-C was initially used to perform the digestion to limit proteolysis only to arginine 
residues. However, the use of this enzyme also resulted in non-specific cleavage at lysine 
residues, and was not very reproducible between each digestion. Our preference was to 
use trypsin based protocols due to its efficiency and reproducibility. After an extensive 
literature search, the only technique found that was customized for preparing histones for 
bottom-up sequencing was Hunt’s method using chemical derivatization with propionic 
anhydride [4]. One initial concern about using this method was the possibility that the 
addition of a propionyl group could also occur in-vivo, as shown recently by Liu in 
histone H3 at lysine 23 in mammalian cells [5], albeit at low abundance. We decided to 
search for this PTM in our preliminary experiments. In-vivo propionylation was never 
detected at any significant level. Our initial experiments using this method resulted in a 
high extent of side reactions, i.e., amidation and esterification.  Modifications to the 
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original method resulted in the elimination of carboxylic acid esters being formed, and 
minimizing amidation of the same functional group. Our optimized method resulted in 
almost complete chemically derivatization of all lysine residues. Validation experiments 
using HPLC fractionation, chemical labeling, tryptic digestion and MS analysis resulted 
in only a 15% CV for the intensity measurements of all ions detected from histone H3 
extracts. Spiking experiments using different ratios of H3K56ac demonstrated excellent 
correlation between the observed and calculated fold-changes (r2 = 0.995).  Using the 
H3K56ac peptide, we were able to detect changes over a two orders of magnitude with a 
high degree of confidence (< 10% CV for all spiking levels). These figures of merit 
provided us the analytical confidence in our workflow to detect and quantify changes in 
histone PTM from complex matrices. 
 
LC-MS/MS analysis was performed on extracts derived from all four core 
histones. The raw data was rapidly processed by the bioinformatics mining procedure 
outlined in section 2.4. Scatter plots displaying peptide intensities from wild type and 
mutant yeast strains were constructed from the data exported into Microsoft Excel. These 
graphical representations allow a researcher to make a rapid assessment of the differential 
PTM expression. Peptides from histones H2A, H2B, and H4 exhibited little change 
between wild type and either asf1Δ or rtt109Δ. Only one data point stood out, and tandem 
MS revealed this to be H3K56ac. The results reinforced our expectations that the 
observations detected were real, and we could accurately attribute a quantifiable value to 
these changes.  
 
The application of MRM to quantify histone PTM in this study is one of the very 
first reported in the literature.  MRM was used to determine the stoichiometry of 
H3K56ac in wild type vs. rtt109Δ mutant yeast strain with higher precision. When 
comparing histones derived from wild type and mutant strains, H3K56ac was not present 
genome-wide, but in a sub-population (17%) of all nucleosomes in wild type cells; this 
PTM was drastically reduced to 0.4% in the mutant strain upon deletion of the gene 
encoding the RTT109 acetyltransferase. S. cerevisiae was the first species in which we 
were able to detect this modification. This PTM is present in significant abundance in 
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yeast histones, whose appearance is cell-cycle dependant, and plays a crucial role in the 
DNA damage response [6]. The same sample preparation protocol and MRM method was 
used in a collaborative project to assess the stoichiometry of H3K56ac in a similar but 
pathogenic organism, i.e., Candida albicans [7]. This was the second organism in which 
we were able to detect H3K56ac with a relatively high stoichiometry (20 to 27%). We 
were able to assess the stoichiometry of H3K56ac in different experimental conditions 
with a high degree of precision (CV < 5% over triplicate injections). A more profound 
understanding of this PTM led to its exploitation by our collaborators as a therapeutic and 
anti-infective target. Inhibition of the Sirtuin HDAC Hst3p enzyme by nicotinamide 
treatment lead to an increase in H3K56ac, and inhibited the growth of C. albicans. The 
virulence of this organism was reduced by selectively modulating H3K56ac expression in 
a mouse in vivo infection model.  
 
The development of MS analytical strategies for histone profiling continued on 
the AB Sciex 4000 Q-trap, and become the basis for the second publication presented in 
this thesis (chapter four).  The potential of doing charge separation is an attractive and 
beneficial attribute that can aid in the detection of analytes present in complex biological 
matrices. Techniques such as high field asymmetric wave form ion mobility spectrometry 
(FAIMS) [8] and T-wave ion mobility [9] have been incorporated into various 
instrumental platforms, providing an added dimension of separation. The application of 
the EMC scan for smaller analytes such as peptides had already been reported by 
Hopfgartner [10].  Hence, we decided to apply the same scan mode to enhance the 
detection of a more challenging class of analytes, i.e., intact proteins.  Our initial LC-MS 
experiments went beyond the limits of the instrument and failed. The successful 
implementation of EMC required modifications to be made to the method table that 
controlled various voltages along the ion path and within the LIT, transferring a limited 
range of ions into the linear trap in a sequential fashion, and applying the charge 
separation (MCS) voltage to selectively remove singly charged species. This modified or 
targeted EMC scan not only reduced space charge effects, but also resulted in a 4-fold 
increase in signal-to-noise, as well as a 5-fold increase in resolution. The targeted EMC 
(tEMC) mode provided added resolution approaching that of TOF instruments in the 
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intact histone profiles generated. LC-MS analysis using tEMC of DT40 histones derived 
from wild type and DOT1L mutant helped in the discrimination of closely spaced peaks 
and many histone isoforms. DOT1L is a methyltransferase that modifies predominantly 
lysine 79 in histone H3. Thus, in DOT1L deficient cells, a reduction of lysine 79 
methylation was to be expected. Intact histone H3 profiles between wild type and mutant 
showed subtle changes in the abundance of isoforms peaks, indicating a difference was 
present between the two strains. A true top down strategy was attempted, whereby whole 
protein ions were introduced into the LIT and fragmented by either multistage activation, 
or EPI scan, similar to Meluzzi’s work on an LTQ instrument [11]. However, we were 
not able to induce and detect any fragments from intact histones using the 4000 Q-trap. 
As an alternative, we applied our bottom-up strategy and protocol with MRM detection 
on the same platform. Once again, MRM proved to be very versatile and useful; the 
change in methylation was localized at H3K79, whose mono-methylation was down-
regulated by 240-fold in DOT1L deficient cells. This study was a good example of how 
software manipulation can increase the analytical potential of a mass spectrometer, 
enabling both intact profiling and peptide detection on the same instrumental platform. 
 
HDAC inhibitors have proven to be a promising epigenetic drug strategy for 
cancer therapy. Upon exposure to these molecules, histones become hyperacetylated, and 
silenced tumor suppressor genes reactivated. We applied the methodology developed in 
chapter three to study the effects of two clinically relevant HDAC inhibitors in both 
normal and cancer cells. This study became the basis for the third publication presented 
in this thesis (chapter five). Intact histone profiling proved to be once again very useful. 
In K562 cancer cells treated with either SAHA or MS-275, significant differences in the 
mass profiles were shown for both histone H3 and H4 when compared to non-treated 
K562 cells. The same effects were not observed in WI-38 or IMR90 normal cells treated 
with SAHA. This result was very surprising, and is one of the few demonstrations of the 
effects of HDACi in normal cells reported in the literature. These inhibitors can 
selectively affect cancerous cells and induce hyperacetylated states, without perturbing 
the functions of normal cells. This is in contrast to older therapies, such as 
oxazaphosphorine-based drugs and alkylating agents (e.g. cyclosphosphamide) which 
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have inherent toxicity in cancer chemotherapy [12]. This apparent selective effect of 
HDACi is very desirable in drug design, and can be exploited by medicinal chemists in 
the discovery of next generation HDACi with less side effects and toxicity. 
 
Only histones H3 and H4 in K562 cells were selected for the bottom-up strategy, 
since these histones were the only two to demonstrate significant changes. The 
instrumental advantages of the LTQ-Orbitrap XL mass spectrometer equipped with both 
CID and ETD capability were used to probe deeper into the histone proteome. Our 
analytical protocol enabled the high sequence coverage for both histones H3 and H4 
(63% and 75%, respectively).  Peptide sequencing for histone H3 revealed nine unique 
peptides, in multiply modified forms, both on the N-terminus and globular domain. Only 
a handful of the modified peptides exhibited a significant fold-change. These included 
known acetylation sites at lysine 9, 14, 18, and 23. Both SAHA and MS-275 inhibited 
HDAC enzymes that catalyzed these acetylation “hotspots” primarily on the N-terminus. 
Interestingly, histone H3 methylation was also affected by exposure to both HDACi’s, 
but to a lesser extent. Most notably was the dimethylation present concurrently at both 
lysine 27 and 36. Again, this is one of the first reports of histone methylation being 
upregulated in cells exposed to HDACi. The overexpression of this peptide was observed  
in several instances after exposure to both SAHA and MS-275, with a similar fold-
change. It is perplexing why such modifications would be upregulated simultaneously on 
the same peptide, since H3 lysine 27 methylation is a mark of transcriptionally silent 
chromatin [13], while H3 lysine 36 methylation is a mark of active chromatin [14]. The 
function (if any) of this over-expressed dual modification remains to be explored and 
understood.  
 
Peptide sequencing for histone H4 revealed seven unique peptides in multiply 
modified forms. Similar effects were observed for histone H4 in response to HDACi 
treatment. The acetylation of four different sites on the H4 N-terminus was up-regulated 
at different extents upon exposure to either SAHA or MS-275. The concurrent 
hyperacetylation of the tetra-acetylated H4 N-terminus at lysines 5, 8, 12, and 16 
indicated that HDACi inhibit several enzymes at the same time that catalyze this 
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modification at these sites. The challenge in HDACi drug design remains in selectively 
inhibiting specific deacetylases that target removal of acetyl groups, rather than inhibiting 
several HDACs at the same time. This challenge is further compounded by many of these 
enzymes being structurally homologous and are inhibited by the same mechanism [15]. 
 
A number of publications have reported the presence of H3K56ac in human cells. 
Up to this point, in our experiments using higher organisms (mouse, fruitfly, chicken, 
human stem cells), we had no success in detecting this modification. Unlike yeast 
histones, H3K56ac in mammalian cells is present in very low abundance. Based on 
extrapolation from our analytical determinations using MRM, the stoichiometry of this 
PTM was well below 0.1% compared to the unmodified (free K56) peptide. It is difficult 
to speculate the real function of this PTM at such a low stoichiometry in mammalian 
cells. Furthermore, some research groups have made claims about this modification based 
on immunoblotting data, with no MS data to confirm and support their findings. For 
example, Jackson reported the down-regulation of H3K56ac in response to DNA damage 
[16], while Yuan argued that the modification plays a crucial role in genomic stability 
and the DNA damage response in mammals [17]. Our experiments using similar 
antibodies that were supposedly specific against H3K56ac demonstrated cross reactivity 
with other up-regulated acetylations sites; hence, this showed the inherent risk of drawing 
erroneous conclusions using only data generated from immunoblots.  Using our sample 
preparation and MRM techniques, we screened for this PTM in human cells from a 
variety of sources including K562 and HeLa. Our analytically rugged and proven MS 
methodology was able to detect and quantitate this low abundant PTM in human cells at 
stoichiometric levels below 0.1%. Using high resolution MS combined with absolute 
quantitation with an isotopically labeled internal standard, we determined the amounts of 
this PTM to be at the attomole level in mammalian cells, and did not change significantly 
after HDACi treatment. With this information, it is unlikely that the same PTM in both 
yeast and mammalian cells has the same function. It is difficult to conclude what is the 
real purpose of this PTM in mammalian cells; this question remains to be answered. 
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6.2 Future Perspectives 
 
Research into histone biology is a dynamic and perpetually changing field. New 
methods, sample preparation, and instrumental techniques are in constant development to 
learn more insight about how these proteins and their modifications affect cell biology 
and disease. One such trend is the use of an alternative enzyme (e.g. Asp-N) to generate 
larger peptides, and the use of ETD to sequence and localize PTM, as reported by Coon 
in the large scale analysis of histone H4 from human stem cells [18]. This “middle down” 
strategy could be used in parallel with our approach to not only detect more PTM, but 
also gain insight in the connectivity and cross-talk of the modifications.  
 
Gaseous phase sample introduction devices such as FAIMS have been shown to 
possess great analytical benefits. This technique can be an orthogonal alternative to 
detecting hydrophilic peptides that would not retain on conventional C18 phases using 
conventional nano-flow HPLC. Instead of developing new separation conditions on 
different stationary phases (e.g. HILIC and ion exchange sorbents) which take a 
considerable amount of time, ion mobility separations can be developed and performed 
quite rapidly to characterize poorly retained peptides. In a collaborative study, we were 
able to use FAIMS to detect, quantify, and sequence a small hydrophilic histone H4 
tetrapeptide (K20VLR) that failed to be retained on our C18 trapping and analytical 
columns [19]. Hence, we believe that the use of FAIMS and other ion mobility 
techniques will also become another important tool in the MS detection of histone 
peptides.  
 
Targeted proteomic strategies using MRM pioneered by Aebersold’s group will 
be adopted by more groups, as the benefits of MRM technologies become more apparent 
and recognized.  The ability to monitor hundreds of MRM transitions in a single HPLC 
run will provide histone researchers a powerful means to detect and quantity many 
differently modified peptides accurately, rapidly, with high sensitivity. Peptides 
demonstrating a high up-regulation between a control and test condition (i.e. HDACi 
treatment) can serve as biomarkers and monitored routinely in a rapid MRM assay. This 
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MS-driven analysis has several advantages over classical antibody-based assays. Some of 
these advantages include a non-biased approach for profiling modified peptides, precise 
site localization and quantitative capability, and highly accurate stoichiometric 
assessments. With emerging tools and new ones to be discovered, a researcher is only 
limited by his dedication and imagination. 
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Table A.1: Histone H3 volcano plot intensity data CTL vs. SAHA 6h Rx 
 
Peptide m/z Peptide mass Charge Uniprot ID Protein desciption Sequence PTM/Chemical Modification  CTL-1 CTL-2 CTL-3 SAHA 6h-1 SAHA 6h-2 SAHA 6h-3 Avg CTL Avg SAHA fold change CTL/SAHA fold change SAHA/CTL
380.7196 759.4236 2 P68431/P84243 Histone H3.1/H3.3 TKQTAR K4pr 192735 263714 300090 297881 344462 292742 252180 311695 0.81 1.24
387.7283 773.4409 2 P68431/P84243 Histone H3.1/H3.3 TKQTAR K4pr+me1 4792703 5684494 6785001 7912475 8144964 10629199 5754066 8895546 0.65 1.55
507.2910 1012.5663 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+K14pr 23700420 27640555 30296523 16315685 16984009 18063249 27212499 17120981 1.59 0.63
514.2999 1026.5841 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+me1+K14pr 11507683 14361273 16159885 6847960 7426358 8543901 14009614 7606073 1.84 0.54
493.2925 984.5694 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me2+K14pr 7133480 6262590 10366055 1773399 6892073 8689263 7920708 7790668 1.02 0.98
500.3002 998.5848 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me3+K14pr 650159 579439 1032156 121397 796166 1173713 753918 697092 1.08 0.92
500.2832 998.5508 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+K14ac 15983285 19084819 21146942 25161247 30253902 32053440 18738349 29156196 0.64 1.56
493.2749 984.5342 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9ac+K14ac 636572 847846 1090938 7187669 7895249 10432328 858452 8505082 0.10 9.91
507.2901 1012.5646 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me1+K14ac 179952 228089 325360 588777 798111 866959 244467 751282 0.33 3.07
540.2837 1078.5517 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me3+S10phos+K14pr 231268 187582 220375 129014 196383 207261 213075 177553 1.20 0.83
549.8357 1097.6557 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+K23pr 96618395 96664152 100853698 71223467 76629021 82335957 98045415 76729482 1.28 0.78
542.8275 1083.6394 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+K23ac 41196100 47703971 48074084 61817919 65985992 69476600 45658052 65760170 0.69 1.44
556.8430 1111.6704 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+me1+K23pr 444104 359782 421224 262885 327452 330743 408370 307027 1.33 0.75
535.8195 1069.6233 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18ac+K23ac 3520626 3900144 4596917 20591760 20161430 20844000 4005896 20532397 0.20 5.13
516.8015 1031.5874 2 P68431/P84243 Histone H3.1/H3.3 YRPGTVALR none 1353574 1372508 1317450 1278659 1242896 1221855 1347844 1247803 1.08 0.93
653.8736 1305.7316 2 P68431/P84243 Histone H3.1/H3.3 YQKSTELLIR K56pr 80770721 74555581 64099017 80293262 73075908 68201479 73141773 73856883 0.99 1.01
422.7577 843.4998 2 P68431/P84243 Histone H3.1/H3.3 KLPFQR K64pr 59519868 50061343 42624602 49877241 50008556 49237441 50735271 49707746 1.02 0.98
696.3619 1390.7082 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79pr 85202197 80486516 74650782 87750254 79019707 75428111 80113165 80732690 0.99 1.01
703.3710 1404.7264 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79pr+me1 354743 400964 386305 440185 393732 437320 380671 423746 0.90 1.11
682.3646 1362.7136 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79me2 573092 497089 419574 471790 549250 561100 496585 527380 0.94 1.06
720.9172 1439.8188 2 P68431/P84243 Histone H3.1/H3.3 VTIMPKDIQLAR K122pr 59685861 56665423 44875998 54989012 45874233 40403891 53742427 47089045 1.14 0.88
728.9145 1455.8133 2 P68431/P84243 Histone H3.1/H3.3 VTIMPKDIQLAR M120ox + K122pr 89300550 83054880 82094630 90663720 86884010 88378560 84816687 88642097 0.96 1.05
801.4611 1600.9066 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+K36pr+K37pr 935406 1009471 994296 1293741 1380662 1507974 979724 1394126 0.70 1.42
808.4690 1614.9223 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+K37pr 2083318 1463196 1796979 1464506 1628806 1713104 1781164 1602139 1.11 0.90
539.3156 1614.9234 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+K37pr 13204758 12078743 13336185 11375332 13596138 14090210 12873229 13020560 0.99 1.01
787.4642 1572.9127 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36pr+K37pr 1288890 1471089 1752451 1677169 1526114 1627701 1504143 1610328 0.93 1.07
794.4714 1586.9272 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3+K36pr+K37pr 527600 387889 587641 581436 690253 577068 501043 616253 0.81 1.23
529.9815 1586.9211 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3+K36pr+K37pr 7828952 10274631 11283457 10889302 12024530 11422445 9795680 11445426 0.86 1.17
515.9797 1544.9158 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me2+K37pr 691731 1017532 1721796 1326207 2007111 1712807 1143686 1682042 0.68 1.47
387.2379 1544.9204 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me2+K37pr 89642 202333 345846 450379 619266 568162 212607 545936 0.39 2.57
815.4775 1628.9394 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+me1+K37pr 272541 226104 242785 142647 234960 187389 247144 188332 1.31 0.76
543.9866 1628.9364 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+me1+K37pr 1954278 2079490 1744268 1149368 1678902 1781018 1926012 1536429 1.25 0.80
794.4709 1586.9261 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36me2+K37pr 2210028 3162552 3574318 2818872 3101063 3687072 2982299 3202336 0.93 1.07
397.7394 1586.9261 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36me2+K37pr 308837 632602 612579 486179 528326 583414 518006 532640 0.97 1.03
794.4716 1586.9275 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2 + K36me1 + K37pr 224580 231079 309051 236265 267773 313249 254904 272429 0.94 1.07
534.6534 1600.9369 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3 + K36me1 + K37pr 665578 1434768 1471778 1129548 1546011 1889856 1190708 1521805 0.78 1.28
401.2434 1600.9421 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27me1 + K36me3 +K37pr 179991 272334 351079 234456 301306 420628 267802 318797 0.84 1.19
809.4569 1616.8981 2 P84243 Histone H3.3 KSAPSTGGVKKPHR K27pr+K36pr+K37pr 203400 135196 145585 145785 130530 167237 161393 147851 1.09 0.92
816.4657 1630.9158 2 P84243 Histone H3.3 KSAPSTGGVKKPHR K27pr+me1+K36pr+K37pr 185520 108634 126750 123758 106303 137260 140301 122441 1.15 0.87
535.3149 1602.9214 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me2 + K37pr 415023 445586 389926 251899 274846 243643 416845 256796 1.62 0.62
539.9850 1616.9315 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me3 +K37pr 309899 447661 428555 401394 538517 565512 395371 501808 0.79 1.27
549.3166 1644.9263 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me1 + K37pr 410604 412196 360048 245683 313975 322021 394282 293893 1.34 0.75
535.3129 1602.9153 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me3 + K36pr+ K37pr 499713 716374 1002578 773060 1082451 1143635 739555 999715 0.74 1.35
530.6413 1588.9004 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me2 + K36pr+ K37pr 384185 769925 859174 636745 827252 784661 671095 749553 0.90 1.12
pr= propionyl group 
added by chemical
reaction
ac = invivo acetylation
me1= invivo monomethyl.
me2= invivo dimethyl.
me3= invivo trimethyl.
phos= phosphorylation
ox= oxidation
bold values= significant 
differential expression
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Table A.2: Histone H3 volcano plot intensity data CTL vs. SAHA 24h Rx 
 
 
Peptide m/z Peptide mass Charge Uniprot ID Protein desciption Sequence PTM/Chemical Modification CTL-1 CTL-2 CTL-3 SAHA 24h-1 SAHA 24h-2 SAHA 24h-3 Avg CTL Avg SAHA fold change CTL/SAHA fold change SAHA/CTL
380.7196 759.4236 2 P68431/P84243 Histone H3.1/H3.3 TKQTAR K4pr 239490 307771 349890 195266 198523 171374 299050 188388 1.59 0.63
387.7283 773.4409 2 P68431/P84243 Histone H3.1/H3.3 TKQTAR K4pr+me1 5955350 6634160 7910983 12306839 14189708 16882630 6833498 14459725 0.47 2.12
507.2910 1012.5663 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+K14pr 29449833 32258257 35324282 26742922 27567830 28841180 32344124 27717310 1.17 0.86
514.2999 1026.5841 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+me1+K14pr 14299296 16760504 18841645 11985932 14741342 16011139 16633815 14246138 1.17 0.86
493.2925 984.5694 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me2+K14pr 8863969 7308834 12086318 7063150 9909281 9827620 9419707 8933350 1.05 0.95
500.3002 998.5848 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me3+K14pr 797358 676242 1165882 566893 688057 879845 879827 711598 1.24 0.81
500.2832 998.5508 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+K14ac 19860622 22273178 24656312 36691113 39119636 40694440 22263370 38835063 0.57 1.74
493.2749 984.5342 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9ac+K14ac 790996 989489 1271981 8424484 8989578 11167978 1017489 9527347 0.11 9.36
507.2901 1012.5646 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me1+K14ac 1491352 1834893 2239743 3135539 3734626 3687388 1855329 3519184 0.53 1.90
540.2837 1078.5517 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me3+S10phos+K14pr 287370 218920 256946 213502 253124 255776 254412 240801 1.06 0.95
549.8357 1097.6557 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+K23pr 131719500 120278400 118115800 78189300 88326000 88529800 123371233 85015033 1.45 0.69
542.8275 1083.6394 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+K23ac 56679300 55673518 56052058 73142160 82611399 83182243 56134959 79645267 0.70 1.42
556.8430 1111.6704 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+me1+K23pr 551838 419888 491127 296001 383850 422753 487618 367535 1.33 0.75
535.8195 1069.6233 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18ac+K23ac 4374684 4528128 5359783 21429660 24478920 25096980 4754198 23668520 0.20 4.98
516.8015 1031.5874 2 P68431/P84243 Histone H3.1/H3.3 YRPGTVALR none 1681933 1601803 1536083 1770120 1608937 1478215 1606606 1619090 0.99 1.01
653.8736 1305.7316 2 P68431/P84243 Histone H3.1/H3.3 YQKSTELLIR K56pr 100364645 87011027 74736355 80385114 76096931 78262273 87370676 78248106 1.12 0.90
422.7577 843.4998 2 P68431/P84243 Histone H3.1/H3.3 KLPFQR K64pr 73958612 58424719 49698226 56316160 56699484 57754619 60693852 56923421 1.07 0.94
696.3619 1390.7082 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79pr 105871140 93932799 87039203 87398222 85720090 88937485 95614381 87351933 1.09 0.91
703.3710 1404.7264 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79pr+me1 440799 467950 450413 949959 856861 828974 453054 878598 0.52 1.94
682.3646 1362.7136 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79me2 712117 580133 489203 727823 729341 754011 593818 737058 0.81 1.24
720.9172 1439.8188 2 P68431/P84243 Histone H3.1/H3.3 VTIMPKDIQLAR K122pr 74164874 66132093 52323245 54628582 52088130 50900356 64206737 52539023 1.22 0.82
728.9145 1455.8133 2 P68431/P84243 Histone H3.1/H3.3 VTIMPKDIQLAR M120ox + K122pr 110963700 96930240 95718370 100942800 101785200 107210400 101204103 103312800 0.98 1.02
801.4611 1600.9066 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+K36pr+K37pr 1162323 1178116 1159301 1406580 1236564 1551302 1166580 1398149 0.83 1.20
808.4690 1614.9223 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+K37pr 2588703 1707641 2095190 2571383 3101198 3026899 2130512 2899827 0.73 1.36
539.3156 1614.9234 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+K37pr 16408060 14096649 12208500 18729716 23794722 26148693 14237736 22891044 0.62 1.61
787.4642 1572.9127 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36pr+K37pr 2654528 1987621 1998410 3551710 3484515 2703077 2213520 3246434 0.68 1.47
794.4714 1586.9272 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3+K36pr+K37pr 655590 452690 685161 970860 1129663 1043543 597813 1048022 0.57 1.75
529.9815 1586.9211 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3+K36pr+K37pr 9728154 12381600 13148740 13321140 15493773 15837900 11752831 14884271 0.79 1.27
515.9797 1544.9158 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me2+K37pr 859536 1187524 2007531 2581764 3409437 2796969 1351530 2929390 0.46 2.17
387.2379 1544.9204 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me2+K37pr 111388 236135 361877 772620 1133445 1399607 236467 1101891 0.21 4.66
815.4775 1628.9394 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+me1+K37pr 338656 263878 283076 237969 403821 326939 295203 322910 0.91 1.09
543.9866 1628.9364 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+me1+K37pr 2428360 2426895 2033732 1850940 3255798 3015601 2296329 2707446 0.85 1.18
794.4709 1586.9261 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36me2+K37pr 2746152 3690896 4167482 4054260 4778016 4840712 3534843 4557663 0.78 1.29
397.7394 1586.9261 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36me2+K37pr 383757 738287 714237 772744 933491 852086 612094 852774 0.72 1.39
794.4716 1586.9275 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me1+K37pr 279060 269684 360339 401348 426499 421702 303028 416516 0.73 1.37
801.4790 1600.9424 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3 + K36me1 + K37pr 166046 101421 102919 122267 136022 229883 123462 162724 0.76 1.32
534.6534 1600.9369 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3 + K36me1 + K37pr 827039 1674464 1716022 2002308 3019908 3273166 1405842 2765127 0.51 1.97
520.6379 1558.8904 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36ac+K37pr 363110 337565 590571 967071 1174955 1298904 430415 1146977 0.38 2.66
401.2434 1600.9421 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27me1 + K36me3 +K37pr 223655 317831 409341 531566 590834 599586 316942 573996 0.55 1.81
809.4569 1616.8981 2 P84243 Histone H3.3 KSAPSTGGVKKPHR K27pr+K36pr+K37pr 252742 157782 169745 273759 257107 259055 193423 263307 0.73 1.36
816.4657 1630.9158 2 P84243 Histone H3.3 KSAPSTGGVKKPHR K27pr+me1+K36pr+K37pr 230525 126783 147784 190635 209579 223310 168364 207841 0.81 1.23
535.3149 1602.9214 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me2 + K37pr 515702 520027 454634 612276 464342 518996 496788 531871 0.93 1.07
539.9850 1616.9315 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me3 +K37pr 385076 522448 499674 560102 696120 701301 469066 652508 0.72 1.39
549.3166 1644.9263 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me1 + K37pr 510211 481058 419798 356213 658246 576091 470356 530183 0.89 1.13
535.3129 1602.9153 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me3 + K36pr + K37pr 620937 825189 1168958 1489320 1816992 1924914 871694 1743742 0.50 2.00
530.6413 1588.9004 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me2 + K36pr + K37pr 477383 898550 1001756 431075 757080 764280 792563 650812 1.22 0.82
pr= propionyl group 
added by chemical
reaction
ac = invivo acetylation
me1= invivo monomethyl.
me2= invivo dimethyl.
me3= invivo trimethyl.
phos= phosphorylation
ox= oxidation
bold values= significant 
differential expression
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Table A.3: Histone H3 volcano plot intensity data CTL vs. MS-275 6h Rx 
 
Peptide m/z Peptide mass Charge Uniprot ID Protein desciption Sequence PTM/Chemical Modification CTL-1 CTL-2 CTL-3 MS275 6h-1 MS275 6h-2 MS275 6h-3 Avg CTL Avg MS275 fold change CTL/MS275 fold change MS275/CTL
380.7196 759.4236 2 P68431/P84243 Histone H3.1/H3.3 TKQTAR K4pr 246705 297932 363983 344734 279094 242167 302873 288665 1.05 0.95
387.7283 773.4409 2 P68431/P84243 Histone H3.1/H3.3 TKQTAR K4pr+me1 6134764 6422061 8203483 7635133 9892976 10860314 6920102 9462808 0.73 1.37
507.2910 1012.5663 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+K14pr 30337054 31226933 36630358 25766030 26961508 29063597 32731448 27263712 1.20 0.83
514.2999 1026.5841 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+me1+K14pr 14730085 16224657 19538294 12322463 14503890 16090604 16831012 14305652 1.18 0.85
493.2925 984.5694 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me2+K14pr 9131009 7075164 12533197 5285923 8816525 9129434 9579790 7743961 1.24 0.81
500.3002 998.5848 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me3+K14pr 821380 654622 738001 443978 695544 581955 738001 573825 1.29 0.78
500.2832 998.5508 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+K14ac 20458953 21561086 25567952 27253429 34241414 36634189 22529330 32709677 0.69 1.45
493.2749 984.5342 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9ac+K14ac 814825 957854 1319011 3955053 5670499 5558367 1030564 5061306 0.20 4.91
507.2901 1012.5646 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me1+K14ac 230342 257683 393381 503230 600315 685210 293802 596252 0.49 2.03
540.2837 1078.5517 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me3+S10phos+K14pr 296028 211921 266447 249202 361665 443274 258132 351381 0.73 1.36
549.8357 1097.6557 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+K23pr 136345630 115932658 122483000 82117758 82284728 96355100 124920429 86919195 1.44 0.70
542.8275 1083.6394 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+K23ac 53290823 53893589 58124520 69032962 69582311 79579530 55102977 72731601 0.76 1.32
556.8430 1111.6704 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+me1+K23pr 568463 406464 509285 603231 529180 654526 494737 595646 0.83 1.20
535.8195 1069.6233 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18ac+K23ac 4506478 4406190 5557955 10995110 11826000 13643200 4823541 12154770 0.40 2.52
516.8015 1031.5874 2 P68431/P84243 Histone H3.1/H3.3 YRPGTVALR none 1732604 1550592 1592878 1951439 1650280 1925532 1625358 1842417 0.88 1.13
653.8736 1305.7316 2 P68431/P84243 Histone H3.1/H3.3 YQKSTELLIR K56pr 103388283 84229212 77499648 84320741 80920663 81356932 88372381 82199446 1.08 0.93
422.7577 843.4998 2 P68431/P84243 Histone H3.1/H3.3 KLPFQR K64pr 76186728 56556832 51535762 52520783 49473292 55874798 61426441 52622958 1.17 0.86
696.3619 1390.7082 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79pr 109060669 90929689 90257381 89129497 85664018 91460854 96749246 88751456 1.09 0.92
703.3710 1404.7264 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79pr+me1 454079 452989 467067 730247 486729 612113 458045 609696 0.75 1.33
682.3646 1362.7136 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79me2 733571 561586 507291 849166 830057 938467 600816 872563 0.69 1.45
720.9172 1439.8188 2 P68431/P84243 Histone H3.1/H3.3 VTIMPKDIQLAR K122pr 76399203 64017795 54257838 62138204 56688943 54165319 64891612 57664155 1.13 0.89
728.9145 1455.8133 2 P68431/P84243 Histone H3.1/H3.3 VTIMPKDIQLAR M120ox + K122pr 114306650 93831300 99257450 95897200 92242800 97207800 102465133 95115933 1.08 0.93
801.4611 1600.9066 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+K36pr+K37pr 1197340 1140451 1202165 1407133 1633114 1954827 1179985 1665024 0.71 1.41
808.4690 1614.9223 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+K37pr 2666692 1653046 2172658 2155343 2629962 2724405 2164132 2503237 0.86 1.16
539.3156 1614.9234 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+K37pr 16902378 13645967 16124266 15823064 19743576 22549147 15557537 19371929 0.80 1.25
787.4642 1572.9127 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36pr+K37pr 1649807 1661964 2118821 1810812 2202572 2229587 1810197 2080990 0.87 1.15
794.4714 1586.9272 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3+K36pr+K37pr 675340 438217 710494 639890 935024 924178 608017 833031 0.73 1.37
529.9815 1586.9211 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3+K36pr+K37pr 10021229 11607771 13634900 11821810 13323960 14775819 11754633 13307196 0.88 1.13
515.9797 1544.9158 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me2+K37pr 885431 1149558 1801607 2324029 2234410 3063074 1278865 2540504 0.50 1.99
387.2379 1544.9204 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me2+K37pr 114744 205470 361877 638158 606280 1117037 227364 787158 0.29 3.46
815.4775 1628.9394 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+me1+K37pr 348859 255441 293542 359562 341592 354712 299281 351955 0.85 1.18
543.9866 1628.9364 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+me1+K37pr 2501518 2349305 2108927 3234439 2857558 3312047 2319917 3134681 0.74 1.35
794.4709 1586.9261 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36me2+K37pr 2828884 3572895 4321570 4381510 4083912 5372010 3574450 4612477 0.77 1.29
397.7394 1586.9261 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36me2+K37pr 395318 714683 740645 968097 786148 841704 616882 865316 0.71 1.40
794.4716 1586.9275 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me1+K37pr 287467 261062 373662 376164 440122 470886 307397 429057 0.72 1.40
801.4790 1600.9424 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3 + K36me1 + K37pr 92121 98178 106724 121768 158041 172775 99008 150861 0.66 1.52
534.6534 1600.9369 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3 + K36me1 + K37pr 851955 1620930 1779470 2099818 2459808 3231733 1417452 2597120 0.55 1.83
401.2434 1600.9421 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27me1 + K36me3 + K37pr 230393 307670 424476 423751 333162 565760 320846 440891 0.73 1.37
809.4569 1616.8981 2 P84243 Histone H3.3 KSAPSTGGVKKPHR K27pr+K36pr+K37pr 260356 152737 176021 163656 188836 228369 196371 193620 1.01 0.99
816.4657 1630.9158 2 P84243 Histone H3.3 KSAPSTGGVKKPHR K27pr+me1+K36pr+K37pr 237470 122730 153248 190395 224213 201930 171149 205513 0.83 1.20
535.3149 1602.9214 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me2 + K37pr 366750 303718 287817 259986 306698 434750 319428 333811 0.96 1.05
539.9850 1616.9315 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me3 +K37pr 406756 505745 518149 554354 621618 681658 476883 619210 0.77 1.30
549.3166 1644.9263 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me1 + K37pr 525582 465678 435320 662376 615167 673496 475527 650346 0.73 1.37
535.3129 1602.9153 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me3 + K36pr+ K37pr 639644 798807 1212178 1264851 1687176 1773616 883543 1575214 0.56 1.78
530.6413 1588.9004 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me2 +K36pr + K37pr 491765 869823 1038795 677894 827820 1236415 800128 914043 0.88 1.14
pr= propionyl group 
added by chemical
reaction
ac = invivo acetylation
me1= invivo monomethyl.
me2= invivo dimethyl.
me3= invivo trimethyl.
phos= phosphorylation
ox= oxidation
bold values= significant 
differential expression
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Table A.4: Histone H3 volcano plot intensity data CTL vs. MS-275 24h Rx 
 
Peptide m/z Peptide mass Charge Uniprot ID Protein desciption Sequence PTM/Chemical Modification CTL-1 CTL-2 CTL-3 MS275 24h-1 MS275 24h-2 MS275 24h-3 Avg CTL Avg MS275 Fold change CTL/MS275 Fold change MS275/CTL
380.7196 759.4236 2 P68431/P84243 Histone H3.1/H3.3 TKQTAR K4pr 191490 246254 302539 292672 296019 272724 246761 287138 0.86 1.16
387.7283 773.4409 2 P68431/P84243 Histone H3.1/H3.3 TKQTAR K4pr+me1 4761744 5308116 6840377 9440935 12173809 11697055 5636745 11103933 0.51 1.97
507.2910 1012.5663 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+K14pr 23547324 25810435 30543790 16687406 19750678 22446737 26633850 19628274 1.36 0.74
514.2999 1026.5841 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+me1+K14pr 11433347 13410393 16291775 6315883 7180687 9039319 13711838 7511963 1.83 0.55
493.2925 984.5694 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me2+K14pr 7087400 5847935 10450658 1314537 4952659 2481888 7795331 2916361 2.67 0.37
500.3002 998.5848 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me3+K14pr 1447746 1810007 1910760 1062851 1547351 1885224 1722838 1498475 1.15 0.87
500.2832 998.5508 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9pr+K14ac 15880038 17821187 21319534 26581038 28963322 33483560 18340253 29675974 0.62 1.62
493.2749 984.5342 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9ac+K14ac 632460 791709 1099842 11589838 15927932 14310088 841337 13942619 0.06 16.57
507.2901 1012.5646 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me1+K14ac 178789 212987 328016 550872 758224 647090 239931 652062 0.37 2.72
540.2837 1078.5517 2 P68431/P84243 Histone H3.1/H3.3 KSTGGKAPR K9me3+S10phos+K14pr 229774 175162 222173 139738 183749 274692 209036 199393 1.05 0.95
549.8357 1097.6557 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+K23pr 103298663 95823445 101676822 58222100 62805160 64121971 100266310 61716410 1.62 0.62
542.8275 1083.6394 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+K23ac 44781877 44545424 48466443 75050364 78552075 79507305 45931248 77703248 0.59 1.69
556.8430 1111.6704 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18pr+me1+K23pr 441235 335961 424662 270985 257580 315891 400619 281485 1.42 0.70
535.8195 1069.6233 2 P68431/P84243 Histone H3.1/H3.3 KQLATKAAR K18ac+K23ac 3497884 3641910 4634435 28966470 28933470 31926440 3924743 29942127 0.13 7.63
516.8015 1031.5874 2 P68431/P84243 Histone H3.1/H3.3 YRPGTVALR none 1344830 1281632 1328202 1379116 1337485 1227076 1318222 1314559 1.00 1.00
653.8736 1305.7316 2 P68431/P84243 Histone H3.1/H3.3 YQKSTELLIR K56pr 80248970 69619152 64622165 89449109 82967357 83627927 71496762 85348131 0.84 1.19
422.7577 843.4998 2 P68431/P84243 Histone H3.1/H3.3 KLPFQR K64pr 59135390 46746711 42972485 53402861 42399202 31615240 49618196 42472434 1.17 0.86
696.3619 1390.7082 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79pr 84651821 75157391 75260049 91075345 85056969 85806044 78356420 87312786 0.90 1.11
703.3710 1404.7264 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79pr+me1 352451 374416 389458 457327 359803 378706 372108 398612 0.93 1.07
682.3646 1362.7136 2 P68431/P84243 Histone H3.1/H3.3 EIAQDFKTDLR K79me2 569390 464176 422999 568734 633156 577853 485522 593248 0.82 1.22
720.9172 1439.8188 2 P68431/P84243 Histone H3.1/H3.3 VTIMPKDIQLAR K122pr 59300312 52913526 45242256 50429594 42118248 40282254 52485365 44276699 1.19 0.84
728.9145 1455.8133 2 P68431/P84243 Histone H3.1/H3.3 VTIMPKDIQLAR M120ox + K122pr 88723700 77555700 82764650 103236900 101219400 96803200 83014683 100419833 0.83 1.21
801.4611 1600.9066 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+K36pr+K37pr 929364 942633 1002411 1410557 1846133 1998266 958136 1751652 0.55 1.83
808.4690 1614.9223 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+K37pr 2069860 1366315 1811645 2037439 1865210 2104843 1749273 2002498 0.87 1.14
539.3156 1614.9234 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+K37pr 13119460 11278992 13681700 14684893 15739556 16858458 12693384 15760969 0.81 1.24
787.4642 1572.9127 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36pr+K37pr 1280564 1373686 1766754 1443312 1690173 1694056 1473668 1609180 0.92 1.09
794.4714 1586.9272 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3+K36pr+K37pr 409015 364077 399636 666178 609217 714476 390909 663290 0.59 1.70
529.9815 1586.9211 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3+K36pr+K37pr 7778380 9594334 11369300 11827140 13177620 12751960 9580671 12585573 0.76 1.31
515.9797 1544.9158 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me2+K37pr 687263 950160 1735848 2274047 2243506 3244070 1124424 2587208 0.43 2.30
387.2379 1544.9204 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me2+K37pr 89063 188936 348668 682921 780654 1073692 208889 845755 0.25 4.05
815.4775 1628.9394 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+me1+K37pr 270781 211134 244767 190829 233770 284944 242227 236514 1.02 0.98
543.9866 1628.9364 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36pr+me1+K37pr 1941654 1941804 1758504 1807379 1770828 2078945 1880654 1885717 1.00 1.00
794.4709 1586.9261 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36me2+K37pr 2115643 3679100 4404412 4360005 4698108 5501028 3399718 4853047 0.70 1.43
397.7394 1586.9261 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27pr+me1+K36me2+K37pr 306842 590717 617578 499648 588896 622270 505046 570271 0.89 1.13
794.4716 1586.9275 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me2+K36me1+K37pr 223129 215779 311574 254493 277593 243195 250161 258427 0.97 1.03
801.4790 1600.9424 2 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3 + K36me1 + K37pr 101723 106626 222558 112976 132999 235810 143636 160595 0.89 1.12
534.6534 1600.9369 3 P68431 Histone H3.1 KSAPATGGVKKPHR K27me3 + K36me1 + K37pr 661279 1339770 1483790 1563588 1986192 2336308 1161613 1962029 0.59 1.69
401.2434 1600.9421 4 P68431 Histone H3.1 KSAPATGGVKKPHR K27me1 + K36me3 +K37pr 178829 254302 353945 268341 308288 366166 262359 314265 0.83 1.20
809.4569 1616.8981 2 P84243 Histone H3.3 KSAPSTGGVKKPHR K27pr+K36pr+K37pr 202086 126244 146773 182503 205282 246076 158368 211287 0.75 1.33
816.4657 1630.9158 2 P84243 Histone H3.3 KSAPSTGGVKKPHR K27pr+me1+K36pr+K37pr 184322 101441 127784 161398 164063 245643 137849 190368 0.72 1.38
535.3149 1602.9214 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me2 + K37pr 327485 254653 281412 435447 387188 385279 287850 402638 0.71 1.40
539.9850 1616.9315 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me3 +K37pr 315720 418021 432053 396918 503342 478777 388598 459679 0.85 1.18
549.3166 1644.9263 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me1 + K36me1 + K37pr 407952 384904 362986 303417 412371 375185 385280 363658 1.06 0.94
535.3129 1602.9153 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me3 + K36pr + K37pr 496485 660249 1010761 1057770 1170740 1235273 722498 1154594 0.63 1.60
530.6413 1588.9004 3 P84243 Histone H3.3 KSAPSTGGVKKPHR K27me2 + K36pr + K37pr 381703 718947 866187 821886 1050390 1787136 655612 1219804 0.54 1.86
pr= propionyl group 
added by chemical
reaction
ac = invivo acetylation
me1= invivo monomethyl.
me2= invivo dimethyl.
me3= invivo trimethyl.
phos= phosphorylation
ox= oxidation
bold values= significant 
differential expression
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Table A.5: Histone H4 volcano plot intensity data CTL vs. SAHA 6h Rx 
 
Peptide m/z Peptide mass Charge Uniprot ID Protein desciption Sequence PTM/Chemical modification  CTL-1 CTL-2 CTL-3 SAHA 6h-1 SAHA 6h-2 SAHA 6h-3 Avg CTL Avg SAHA fold change CTL/SAHA fold change SAHA/CTL
747.9414 1493.8672 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R K5pr-K8pr-K12pr-K16pr 46181593 56557915 48164281 29397382 28735108 24910804 50301263 27681098 1.82 0.55
494.2913 1479.8504 3 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Mono-acetyl: K16ac or K12ac 9161871 8024100 7091263 10293531 10450402 9892890 8092411 10212274 0.79 1.26
733.9251 1465.8345 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Di-acetyl: K8ac,K12ac or K12ac,K16ac 6624350 6405618 6982682 20710501 19819755 18212158 6670883 19580805 0.34 2.94
489.6194 1465.8348 3 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Di-acetyl:  K8ac,K16ac 1823874 1730691 1837160 6251017 6207279 6005672 1797242 6154656 0.29 3.42
726.9175 1451.8193 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Tri-acetyl: K5pr-K8ac-K12ac-K16ac 1579110 1464774 1334279 11490814 9316265 10893965 1459388 10567015 0.14 7.24
719.9112 1437.8067 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Tetra-acetyl: K5ac-K8ac-K12ac-K16ac 452345 454885 517277 9358078 7114344 7952371 474836 8141598 0.06 17.15
650.0613 1947.1604 3 P62805 Histone H4 KVLRDNIQGITKPAIR K20pr+me1 + K31pr 142167 141956 113679 106872 106729 97859 132601 103820 1.28 0.78
636.0575 1905.1490 3 P62805 Histone H4 KVLRDNIQGITKPAIR K20me2 + K31pr 414647 438809 466277 422895 455532 539637 439911 472688 0.93 1.07
691.3959 1380.7762 2 P62805 Histone H4 DNIQGITKPAIR K31pr 52743600 52808644 54296981 58676800 52958880 60475800 53283075 57370493 0.93 1.08
698.4020 1394.7883 2 P62805 Histone H4 DNIQGITKPAIR K31pr+me1 16090 16442 14157 15298 13613 21594 15563 16835 0.92 1.08
590.8152 1179.6147 2 P62805 Histone H4 ISGLIYEETR none 5264101 5302053 6349053 7188693 7641365 9111473 5638402 7980510 0.71 1.42
721.9421 1441.8685 2 P62805 Histone H4 GVLKVFLENVIR K59pr 7584565 10108180 12290338 10793492 12015959 15586549 9994361 12798667 0.78 1.28
673.8383 1345.6609 2 P62805 Histone H4 DAVTYTEHAKR K77pr 1075113 1095700 1209936 1194584 1157469 1385552 1126916 1245868 0.90 1.11
853.9816 1705.9476 2 P62805 Histone H4 KTVTAMDVVYALKR K79pr + K91pr 5919022 7592056 7105709 6053409 8806120 5835337 6872262 6898289 1.00 1.00
861.9783 1721.9409 2 P62805 Histone H4 KTVTAMDVVYALKR K79pr + M84ox + K91pr 1941660 3394112 2870491 1930656 3070080 4657422 2735421 3219386 0.85 1.18
pr= propionyl group 
added by chemical
reaction
ac = invivo acetylation
me1= invivo monomethyl.
me2= invivo dimethyl.
ox= oxidation
bold values= significant 
differential expression
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Table A.6: Histone H4 volcano plot intensity data CTL vs. SAHA 24h Rx 
 
Peptide m/z Peptide mass Charge Uniprot ID Protein desciption Sequence PTM/Chemical modification  CTL-1 CTL-2 CTL-3 SAHA 24h-1 SAHA 24h-2 SAHA 24h-3 Avg CTL Avg SAHA fold change CTL/SAHA fold change SAHA/CTL
747.9414 1493.8672 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R K5pr-K8pr-K12pr-K16pr 51430805 58421865 53196155 36149473 40448140 32417064 54349608 36338226 1.50 0.67
494.2913 1479.8504 3 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Mono-acetyl: K16ac or K12ac 10203252 8288546 7615769 11325566 16230922 12843358 8702522 13466615 0.65 1.55
733.9251 1465.8345 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Di-acetyl: K8ac,K12ac or K12ac,K16ac 7377304 6616724 6982682 20001538 20241807 17118279 6992237 19120541 0.37 2.73
489.6194 1465.8348 3 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Di-acetyl:  K8ac,K16ac 2031184 1787729 1837160 5948596 6577134 4854373 1885358 5793367 0.33 3.07
726.9175 1451.8193 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Tri-acetyl: K5pr-K8ac-K12ac-K16ac 1758598 1513048 1432969 9875552 8592513 8275090 1568205 8914385 0.18 5.68
719.9112 1437.8067 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Tetra-acetyl: K5ac-K8ac-K12ac-K16ac 503761 469876 594787 4556669 3540912 3339763 522808 3812448 0.14 7.29
650.0613 1947.1604 3 P62805 Histone H4 KVLRDNIQGITKPAIR K20pr+me1 + K31pr 158327 146635 130713 176004 151632 234000 145225 187212 0.78 1.29
636.0575 1905.1490 3 P62805 Histone H4 KVLRDNIQGITKPAIR K20me2 + K31pr 461777 453271 439746 758075 549850 994249 451598 767391 0.59 1.70
691.3959 1380.7762 2 P62805 Histone H4 DNIQGITKPAIR K31pr 58738680 54549031 53298010 57744480 64356630 62789580 55528574 61630230 0.90 1.11
698.4020 1394.7883 2 P62805 Histone H4 DNIQGITKPAIR K31pr+me1 18100 17900 14970 16200 12300 19700 16990 16067 1.06 0.95
590.8152 1179.6147 2 P62805 Histone H4 ISGLIYEETR none 5862443 5476790 5565559 8957828 8200006 9252943 5634931 8803592 0.64 1.56
721.9421 1441.8685 2 P62805 Histone H4 GVLKVFLENVIR K59pr 8446662 10441310 14131948 12174065 7761776 13170150 11006640 11035330 1.00 1.00
673.8383 1345.6609 2 P62805 Histone H4 DAVTYTEHAKR K77pr 1197315 1131810 1209936 1607943 1322178 1527075 1179687 1485732 0.79 1.26
853.9816 1705.9476 2 P62805 Histone H4 KTVTAMDVVYALKR K79pr + K91pr 6591805 7842263 6059672 7114824 7508762 8241676 6831247 7621754 0.90 1.12
861.9783 1721.9409 2 P62805 Histone H4 KTVTAMDVVYALKR K79pr + M84ox + K91pr 1583618 3575018 2690912 3401052 3296829 2633400 2616516 3110427 0.84 1.19
pr= propionyl group 
added by chemical
reaction
ac = invivo acetylation
me1= invivo monomethyl.
me2= invivo dimethyl.
ox= oxidation
bold values= significant 
differential expression
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Table A.7: Histone H4 volcano plot intensity data CTL vs. MS-275 6h Rx 
 
Peptide m/z Peptide mass Charge Uniprot ID Protein desciption Sequence PTM/Chemical Modification  CTL-1 CTL-2 CTL-3 MS275 6h-1 MS275 6h-2 MS275 6h-3 Avg CTL Avg MS275 fold change CTL/MS275 fold change MS275/CTL
747.9414 1493.8672 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R K5pr-K8pr-K12pr-K16pr 53935894 71783190 72860495 52508994 42901600 41278330 66193193 45562975 1.45 0.69
494.2913 1479.8504 3 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Mono-acetyl: K16ac or K12ac 9279381 9571888 8635725 13909229 9451856 8850030 9162331 10737038 0.85 1.17
733.9251 1465.8345 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Di-acetyl: K8ac,K12ac or K12ac,K16ac 7736637 8129997 8148473 22489078 23454278 24623564 8005036 23522307 0.34 2.94
489.6194 1465.8348 3 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Di-acetyl:  K8ac,K16ac 1888068 1845874 1837160 6516784 6304362 6321439 1857034 6380862 0.29 3.44
726.9175 1451.8193 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Tri-acetyl: K5pr-K8ac-K12ac-K16ac 1634689 1562259 1624882 9276528 7238000 9575091 1607277 8696540 0.18 5.41
719.9112 1437.8067 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Tetra-acetyl: K5ac-K8ac-K12ac-K16ac 528298 577339 620732 4560635 3554682 3772251 575456 3962522 0.15 6.89
650.0613 1947.1604 3 P62805 Histone H4 KVLRDNIQGITKPAIR K20pr+me1 + K31pr 166038 180171 136415 98732 102732 90592 160875 97352 1.65 0.61
636.0575 1905.1490 3 P62805 Histone H4 KVLRDNIQGITKPAIR K20me2 + K31pr 484270 556935 499532 304043 353230 329639 513579 328970 1.56 0.64
691.3959 1380.7762 2 P62805 Histone H4 DNIQGITKPAIR K31pr 59770276 67024622 63345772 57370484 49501029 56467619 63380224 54446377 1.16 0.86
698.4020 1394.7883 2 P62805 Histone H4 DNIQGITKPAIR K31pr+me1 18791 20868 14157 20142 21841 19472 17939 20485 0.88 1.14
590.8152 1179.6147 2 P62805 Histone H4 ISGLIYEETR none 6147991 6729355 6721095 8558475 8370813 8558457 6532813 8495915 0.77 1.30
721.9421 1441.8685 2 P62805 Histone H4 GVLKVFLENVIR K59pr 8858081 12829282 14748406 12289069 10398827 11570115 12145256 11419337 1.06 0.94
673.8383 1345.6609 2 P62805 Histone H4 DAVTYTEHAKR K77pr 16650923 15863487 13810812 24367105 20009098 20563493 15441741 21646565 0.71 1.40
853.9816 1705.9476 2 P62805 Histone H4 KTVTAMDVVYALKR K79pr + K91pr 6912879 9635822 7023766 10138527 11476050 13880282 7857489 11831620 0.66 1.51
861.9783 1721.9409 2 P62805 Histone H4 KTVTAMDVVYALKR K79pr + M84ox + K91pr 2267682 4307800 3415300 3020693 2277431 3773484 3330261 3023869 1.10 0.91
pr= propionyl group 
added by chemical
reaction
ac = invivo acetylation
me1= invivo monomethyl.
me2= invivo dimethyl.
ox= oxidation
bold values= significant 
differential expression
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Table A.8: Histone H4 volcano plot intensity data CTL vs. MS-275 24h Rx 
 
Peptide m/z Peptide mass Charge Uniprot ID Protein desciption Sequence PTM/Chemical Modification  CTL-1 CTL-2 CTL-3 MS275 24h-1 MS275 24h-2 MS275 24h-3 Avg CTL Avg MS275 fold change CTL/MS275 fold change MS275/CTL
747.9414 1493.8672 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R K5pr-K8pr-K12pr-K16pr 53701639 57263682 57496681 16550297 28196324 22168488 56154001 22305036 2.52 0.40
494.2913 1479.8504 3 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Mono-acetyl: K16ac or K12ac 8224943 8558127 7450371 12460425 10071015 12268297 8077814 11599912 0.70 1.44
733.9251 1465.8345 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Di-acetyl: K8ac,K12ac or K12ac,K16ac 7703035 6485551 7285189 28250788 25209874 32313104 7157925 28591255 0.25 3.99
489.6194 1465.8348 3 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Di-acetyl:  K8ac,K16ac 1888068 1845874 1837160 8648348 6755281 8447779 1857034 7950469 0.23 4.28
726.9175 1451.8193 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Tri-acetyl: K5pr-K8ac-K12ac-K16ac 1634689 1562259 1452735 19353376 16774806 22183310 1549894 19437164 0.08 12.54
719.9112 1437.8067 2 P62805 Histone H4 GK5GGK8GLGK12GGAK16R Tetra-acetyl: K5ac-K8ac-K12ac-K16ac 526003 460561 614144 10612387 13935881 13076695 533569 12541654 0.04 23.51
650.0613 1947.1604 3 P62805 Histone H4 KVLRDNIQGITKPAIR K20pr+me1 +K31pr 165317 143728 134967 35369 21793 48924 148004 35362 4.19 0.24
636.0575 1905.1490 3 P62805 Histone H4 KVLRDNIQGITKPAIR K20me2 429241 468013 475140 281543 231728 356938 457465 290070 1.58 0.63
691.3959 1380.7762 2 P62805 Histone H4 DNIQGITKPAIR K31pr 61332180 53467625 59483519 49640932 57757032 65911948 58094441 57769971 1.01 0.99
698.4020 1394.7883 2 P62805 Histone H4 DNIQGITKPAIR K31pr+me1 19096 16992 14211 14968 15969 18448 16767 16462 1.02 0.98
590.8152 1179.6147 2 P62805 Histone H4 ISGLIYEETR none 6121289 5368216 5744752 7418526 8797575 8645263 5744752 8287121 0.69 1.44
721.9421 1441.8685 2 P62805 Histone H4 GVLKVFLENVIR K59pr 8819609 10234317 14591866 11945549 9632478 13154548 11215264 11577525 0.97 1.03
673.8383 1345.6609 2 P62805 Histone H4 DAVTYTEHAKR K77pr 1250180 1109373 1209936 1112630 1840743 1889780 1189830 1614384 0.74 1.36
853.9816 1705.9476 2 P62805 Histone H4 KTVTAMDVVYALKR K79pr + K91pr 6127352 8097329 6059672 9754685 9803245 12660134 6761451 10739355 0.63 1.59
861.9783 1721.9409 2 P62805 Histone H4 KTVTAMDVVYALKR K79pr + M84ox + K91pr 2257833 3436466 2724491 3530059 4052780 5437646 2806263 4340162 0.65 1.55
pr= propionyl group 
added by chemical
reaction
ac = invivo acetylation
me1= invivo monomethyl.
me2= invivo dimethyl.
ox= oxidation
bold values= significant 
differential expression
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Table A.9: Histone H3 Peptide MS/MS Identifications 
 
H3 peptide ID list
Residue start Residue end Experimental m/z Theoretical m/z Experimental mass Theoretical mass Charge ppm Sequence PTM/Chemical Modification Mascot score (CID Hi/Low) Expectation (CID Hi/Low) Mascot Score (ETD Hi/Low) Expectation (ETD Hi/Low)
3 8 380.7196 380.7192 759.4236 759.4239 2 0.4 TKQTAR K4pr 45 4.30E-05
3 8 387.7283 387.7270 773.4409 773.4395 2 -1.8 TKQTAR K4pr+me1 46 7.00E-05
9 17 507.2910 507.2905 1012.5663 1012.5665 2 0.2 KSTGGKAPR K9pr+K14pr 57 8.30E-06
9 17 514.2999 514.2984 1026.5841 1026.5822 2 -1.9 KSTGGKAPR K9pr+me1+K14pr 62 3.50E-06
9 17 493.2925 493.2931 984.5694 984.5716 2 2.3 KSTGGKAPR K9me2+K14pr 52 3.80E-05
9 17 500.3002 500.3009 998.5848 998.5872 2 2.5 KSTGGKAPR K9me3+K14pr 54 4.20E-05
9 17 500.2832 500.2827 998.5508 998.5509 2 0.04 KSTGGKAPR K9pr+K14ac 46 7.00E-05
9 17 493.2749 493.2749 984.5342 984.5352 2 1.0 KSTGGKAPR K9ac+K14ac 69 1.20E-07
9 17 507.2901 507.2905 1012.5646 1012.5665 2 1.9 KSTGGKAPR K9me1+K14ac 58 7.30E-06
9 17 540.2837 540.2841 1078.5517 1078.5536 2 1.7 KSTGGKAPR K9me3+S10phos+K14pr 38 0.00088
18 26 549.8357 549.8351 1097.6557 1097.6557 2 -0.1 KQLATKAAR K18pr+K23pr 82 1.20E-07
18 26 542.8275 542.8273 1083.6394 1083.6400 2 0.6 KQLATKAAR K18pr+K23ac 67 2.50E-06
18 26 556.8430 556.8429 1111.6704 1111.6713 2 0.8 KQLATKAAR K18pr+me1+K23pr 51 0.00015
18 26 535.8195 535.8195 1069.6233 1069.6244 2 1.0 KQLATKAAR K18ac+K23ac 72 8.00E-07
41 49 516.8015 516.8011 1031.5874 1031.5876 2 0.2 YRPGTVALR none 37 0.00032
54 63 653.8736 653.8719 1305.7316 1305.7292 2 -1.8 YQKSTELLIR K56pr 75 4.00E-07
64 69 422.7577 422.7556 843.4998 843.4966 2 -3.7 KLPFQR K64pr 32 0.0024
73 83 696.3619 696.3619 1390.7082 1390.7092 2 0.7 EIAQDFKTDLR K79pr 82 4.90E-08
73 83 703.3710 703.3697 1404.7264 1404.7249 2 -1.1 EIAQDFKTDLR K79pr+me1 59 1.10E-05
73 83 682.3646 682.3644 1362.7136 1362.7143 2 0.5 EIAQDFKTDLR K79me2 34 0.0041
117 128 720.9172 720.9158 1439.8188 1439.8170 2 -1.3 VTIMPKDIQLAR K122pr 70 7.70E-07
117 128 728.9145 728.9132 1455.8133 1455.8119 2 -1.0 VTIMPKDIQLAR M120ox + K122pr 78 9.80E-08
H3.1 specific peptides
27 40 801.4611 801.4597 1600.9066 1600.9049 2 -1.1 KSAPATGGVKKPHR K27pr+K36pr+K37pr 112 8.80E-11
27 40 808.4690 808.4675 1614.9223 1614.9205 2 -1.1 KSAPATGGVKKPHR K27pr+me1+K36pr+K37pr 92 9.80E-09
27 40 539.3156 539.3141 1614.9234 1614.9205 3 -1.8 KSAPATGGVKKPHR K27pr+me1+K36pr+K37pr 58 4.00E-05
27 40 787.4642 787.4623 1572.9127 1572.9100 2 -1.7 KSAPATGGVKKPHR K27me2+K36pr+K37pr 92 7.00E-09
27 40 794.4714 794.4701 1586.9272 1586.9256 2 -1.0 KSAPATGGVKKPHR K27me3+K36pr+K37pr 62 7.80E-06
27 40 529.9815 529.9825 1586.9211 1586.9256 3 2.9 KSAPATGGVKKPHR K27me3+K36pr+K37pr 74 7.50E-07
27 40 515.9797 515.9790 1544.9158 1544.9151 3 -0.5 KSAPATGGVKKPHR K27me2+K36me2+K37pr 83 5.10E-08
27 40 387.2379 387.2360 1544.9204 1544.9151 4 -3.5 KSAPATGGVKKPHR K27me2+K36me2+K37pr 63 4.40E-06
27 40 815.4775 815.4754 1628.9394 1628.9362 2 -2.0 KSAPATGGVKKPHR K27pr+me1+K36pr+me1+K37pr 72 1.10E-06
27 40 543.9866 543.9860 1628.9364 1628.9362 3 -0.2 KSAPATGGVKKPHR K27pr+me1+K36pr+me1+K37pr 47 0.00059
27 40 794.4709 794.4701 1586.9261 1586.9256 2 -0.3 KSAPATGGVKKPHR K27pr+me1+K36me2+K37pr 65 3.50E-06
27 40 397.7394 397.7387 1586.9261 1586.9256 4 -0.3 KSAPATGGVKKPHR K27pr+me1+K36me2+K37pr 51 9.80E-05
27 40 794.4716 794.4701 1586.9275 1586.9256 2 -1.2 KSAPATGGVKKPHR K27me2+K36me1+K37pr 55 4.50E-05
27 40 801.4790 801.4779 1600.9424 1600.9413 2 -0.7 KSAPATGGVKKPHR K27me3 + K36me1 +K37pr 54 5.40E-05
27 40 534.6534 534.6544 1600.9369 1600.9413 3 2.8 KSAPATGGVKKPHR K27me3 + K36me1 +K37pr 69 2.00E-06
27 40 520.6379 520.6387 1558.8904 1558.8943 3 2.5 KSAPATGGVKKPHR K27me2 + K36ac + K37pr 49 0.00015
27 40 401.2434 401.2426 1600.9421 1600.9413 4 -0.5 KSAPATGGVKKPHR K27me1 + K36me3 +K37pr 52 9.00E-05
H3.3 specific peptides
27 40 809.4569 809.4572 1616.8981 1616.8998 2 1.1 KSAPSTGGVKKPHR K27pr+K36pr+K37pr 71 1.30E-06
27 40 816.4657 816.4650 1630.9158 1630.9154 2 -0.2 KSAPSTGGVKKPHR K27pr+me1+K36pr+K37pr 76 3.20E-07
27 40 535.3149 535.3141 1602.9214 1602.9205 3 -0.5 KSAPSTGGVKKPHR K27me1 + K36me2 + K37pr 33 0.0058
27 40 539.9850 539.9860 1616.9315 1616.9362 3 2.9 KSAPSTGGVKKPHR K27me1 + K36me3 +K37pr 49 0.00014
27 40 549.3166 549.3176 1644.9263 1644.9311 3 2.9 KSAPSTGGVKKPHR K27me1 + K36me1 + K37pr 50 0.00012
27 40 535.3129 535.3141 1602.9153 1602.9205 3 3.2 KSAPSTGGVKKPHR K27me3 + K36pr + K37pr 94 5.20E-09
27 40 530.6413 530.6422 1588.9004 1588.9049 3 2.8 KSAPSTGGVKKPHR K27me2 + K36pr + K37pr 58 2.50E-05
H3.1 Unique peptides: 9
H3.3 Unique peptides: 9
Sequence coverage: 63%
pr= propionyl group 
added by chemical
reaction
ac = invivo acetylation
me1= invivo monomethyl.
me2= invivo dimethyl.
me3= invivo trimethyl.
phos= phosphorylation
ox= oxidation  
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Table A.10: Histone H4 Peptide MS/MS Identifications 
 
H4 peptide ID list
Residue start Residue end Experimental m/z Theoretical m/z Experimental mass Theoretical mass Charge ppm Sequence PTM/Chemical Modification Mascot score (CID Hi/Low) Expectation (CID Hi/Low)
4 17 747.9414 747.9412 1493.8672 1493.8678 2 0.4 GKGGKGLGKGGAKR K5pr-K8pr-K12pr-K16pr 79 1.50E-07
4 17 494.2913 494.2913 1479.8504 1479.8521 3 1.2 GKGGKGLGKGGAKR K5pr-K8pr-K12pr-K16ac 65 3.00E-06
4 17 494.2918 494.2913 1479.8518 1479.8521 3 0.2 GKGGKGLGKGGAKR K5pr-K8pr-K12ac-K16pr 73 5.90E-07
4 17 733.9251 733.9255 1465.8345 1465.8365 2 1.4 GKGGKGLGKGGAKR K5pr-K8ac-K12ac-K16pr 89 1.30E-08
4 17 489.6194 489.6194 1465.8348 1465.8365 3 1.1 GKGGKGLGKGGAKR K5pr-K8ac-K12pr-K16ac 37 0.0016
4 17 733.9254 733.9255 1465.8352 1465.8365 2 0.9 GKGGKGLGKGGAKR K5pr-K8pr-K12ac-K16ac 25 0.033
4 17 726.9175 726.9177 1451.8193 1451.8208 2 1.0 GKGGKGLGKGGAKR K5pr-K8ac-K12ac-K16ac 92 4.90E-09
4 17 719.9112 719.9099 1437.8067 1437.8052 2 -1.1 GKGGKGLGKGGAKR K5ac-K8ac-K12ac-K16ac 94 2.10E-09
20 35 650.0613 650.0616 1947.1604 1947.1629 3 1.3 KVLRDNIQGITKPAIR K20pr+me1 +K31pr 52 0.00038
20 35 636.0575 636.0580 1905.1490 1905.1523 3 1.7 KVLRDNIQGITKPAIR K20me2 + K31pr 56 9.90E-05
24 35 691.3959 691.3935 1380.7762 1380.7725 2 -2.7 DNIQGITKPAIR K31pr 68 1.70E-06
24 35 698.4020 698.4013 1394.7883 1394.7881 2 -0.1 DNIQGITKPAIR K31pr+me1 32 0.0067
46 55 590.8152 590.8140 1179.6147 1179.6135 2 -1.0 ISGLIYEETR none 76 1.40E-07
56 67 721.9421 721.9401 1441.8685 1441.8656 2 -2.0 GVLKVFLENVIR K59pr 87 1.50E-08
68 78 673.8383 673.8386 1345.6609 1345.6626 2 1.3 DAVTYTEHAKR K77pr 74 1.70E-07
79 92 853.9816 853.9791 1705.9476 1705.9436 2 -2.3 KTVTAMDVVYALKR K79pr + K91pr 108 1.40E-10
79 92 861.9783 861.9765 1721.9409 1721.9385 2 -1.4 KTVTAMDVVYALKR K79pr + M84ox + K91pr 90 6.90E-09
H4 Unique peptides: 6
Sequence coverage: 75%
pr= propionyl group 
added by chemical
reaction
ac = invivo acetylation
me1= invivo monomethyl.
me2= invivo dimethyl.
ox= oxidation
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Table A.11:  Histone H3K56 peptide MRM transitions 
 
 
   1- H3K56pr 
   Sequence: YQK(pr)STELLIR 
   Precursor ion (m/z): 653.87+2 
 
 
MRM transitions:   653.9+2 Æ 1015.6+1     y8 fragment 
          653.9+2 Æ 831.5+1      y7 fragment 
          653.9+2 Æ 744.5+1      y6 fragment 
          653.9+2 Æ 476.3+1      b3 fragment 
 
 
2- H3K56ac (light form) 
   Sequence: YQK(ac)STELLIR 
   Precursor ion (m/z): 646.86+2  
 
MRM transitions:   646.9+2 Æ 1001.6+1     y8 fragment 
          646.9+2 Æ 831.5+1      y7 fragment 
          646.9+2 Æ 744.5+1      y6 fragment 
          646.9+2 Æ 462.2+1      b3 fragment 
 
 
3- H3K56ac (heavy form, internal standard) 
   Sequence: YQK(ac)STELL*IR 
   Precursor ion (m/z): 650.36+2 
 
MRM transitions:   650.4+2 Æ 1008.6+1     y8 fragment 
          650.4+2 Æ 838.5+1      y7 fragment 
          650.4+2 Æ 751.5+1      y6 fragment 
          650.4+2 Æ 462.2+1      b3 fragment 
 
 
4- YRPGTVALR (normalization peptide) 
   Precursor ion (m/z): 516.80+2  
 
MRM transitions:   516.8+2 Æ 713.4+1     y7 fragment 
          516.8+2 Æ 616.4+1    y6 fragment 
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Table A.12:  Histone H4K91 peptide MRM transitions 
 
 
1- H4K91pr 
 
Sequence: KprTVTAMDVVYALKprR 
 
Precursor ions (m/z):  853.98+2 and 569.66+3 
 
 
MRM transitions:   854.0+2 Æ 543.4+1       y4 fragment 
          854.0+2 Æ 706.4+1      y5 fragment 
          854.0+2 Æ 805.5+1      y6 fragment 
          854.0+2 Æ 1019.6+1    y8 fragment 
          854.0+2 Æ 359.2+1      y2 fragment 
 
 
 
MRM transitions:   569.7+3 Æ 543.4+1       y4 fragment 
          569.7+3 Æ 706.4+1      y5 fragment 
          569.7+3 Æ 805.5+1      y6 fragment 
          569.7+3 Æ 1019.6+1    y8 fragment 
          569.7+3 Æ 359.2+1      y2 fragment 
 
 
5- H4K91ac 
 
Sequence: KprTVTAMDVVYALKacR 
 
Precursor ions (m/z):  846.97+2 and 564.98+3 
 
 
MRM transitions:   847.0+2 Æ 529.4+1       y4 fragment 
          847.0+2 Æ 692.4+1      y5 fragment 
          847.0+2 Æ 791.5+1      y6 fragment 
          847.0+2 Æ 1005.6+1    y8 fragment 
          847.0+2 Æ 345.2+1      y2 fragment 
 
 
MRM transitions:   565.0+3 Æ 529.4+1       y4 fragment 
          565.0+3 Æ 692.4+        y5 fragment 
          565.0+3 Æ 791.5+1      y6 fragment 
          565.0+3 Æ 1005.6+1    y8 fragment 
          565.0+3 Æ 345.2+1      y2 fragment 
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Figure A.1: Total ion chromatogram (TIC) from the LC-MS analysis of intact histones 
derived from untreated (control) K562 cells. Histone proteins are annotated in the TIC, 
and eluted between 50 and 65 minutes. Gradient conditions are specified in the main text 
(see section 5.3.6) 
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Figure A.2: Reversed-phase C18 fractionation of core histones derived from K562 
untreated (control) cells. Histone proteins are annotated in the chromatogram. Gradient 
conditions are specified in the main text (see section 5.3.5) 
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Figure A.3: Targeted MRM analyses of H4K91 peptides in histones derived from K562 
cells treated with SAHA for a 24h period. MRM ion transition chromatograms for the 
free (propionylated) K91 residue are shown above, for both the doubly (a) and triply (b) 
charged states. 
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Figure A.4: Targeted MRM analyses of H4K91 peptides in histones derived from K562 
cells treated with SAHA for a 24h period. MRM ion transition chromatograms for the 
acetylated K91 residue are shown above, for both the doubly (a) and triply (b) charged 
states. 
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